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| Abstract 
Calcitonin gene-related peptide (CGRP) is a 37 amino acid neuropeptide that is predominantly 
synthesised and secreted by small, thinly-myelinated and unmyelinated sensory neurons that richly 
innervate the vasculature. It is perhaps best known for its ability to act as a potent dilator of the 
microvasculature and its role as a vasculoprotectant is gradually being discovered within a range of 
cardiovascular disease models. However, the role of CGRP in the ageing cardiovascular system and 
current information regarding CGRP and the ageing process in general is unknown. This study is 
particularly relevant as ageing is the single biggest independent risk factor for the development of 
future cardiovascular complications. 
We hypothesised that CGRP may have a beneficial role in protecting the cardiovascular system 
against age-associated cardiovascular disease, such as hypertension, and related vascular 
inflammatory processes mediated by aberrant inflammatory cell activity. We initially characterised 
the vascular phenotype of ageing (15 months) αCGRP wild type (WT) and knockout (KO) mice, in 
comparison to respective juveniles (3 months). We found that aged animals had comparable blood 
pressures to juvenile animals and KO mice did not differ significantly from WTs at either timepoint. 
Furthermore, markers of leukocytic vascular inflammation were significantly raised within the aortae 
of ageing mice but the genetic deletion of αCGRP had no bearing on this process.  
To study direct influences of CGRP on inflammatory processes driven by leukocytes, we employed a 
reductive approach and studied leukocyte-endothelial cell interactions in vitro, under physiological 
flow conditions. Here, we showed that treatment of endothelial cells with CGRP for six hours is 
sufficient to attenuate the adhesion of monocytic cells to tumour necrosis factor alpha (TNFα)-
activated HUVEC (HUVEC) by around 50%. The mechanisms regulating this phenomenon did not 
appear to be related to alterations in the whole-cell expression of classical cell adhesion molecules, 
including vascular cell adhesion molecule-1(VCAM-1). Furthermore, microarray analysis of HUVEC 
transcriptome revealed that CGRP did not influence gene expression induced by TNFα in these cells. 
We finally sought to establish a novel geriatric pathology model in mice that may be more relevant 
to the human disease condition. To do this, we infused aged αCGRP WT and KO mice with 1.1 
mg/kg/day angiotensin II (ATII) for 14 days to induce hypertension and vascular inflammation. 
However, despite some level of pharmacological activity by ATII, we did not witness the induction of 
hypertension and we observed no clear vascular inflammatory phenotype. 
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This thesis provides evidence that ageing in mice is sufficient to induce vascular inflammation in the 
absence of an overt maladaptive cardiovascular phenotype, where the deletion of αCGRP appears to 
have minimal effect. However, we have uncovered novel evidence to suggest that CGRP might be 
protective against leukocytic inflammation by virtue of its ability to attenuate leukocyte-endothelial 
cell interactions under physiological flow conditions. 
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1. | Chapter One: Introduction 
Advances in modern medicine, thanks to breakthrough discoveries in biomedical research, 
have undoubtedly shaped the lives of those privileged enough to have access to it for the 
better. However, in ensuring that we are far less susceptible to falling ill than we once were, 
another problem has been created. We are now living much longer than ever before, and 
this presents a different set of problems related to how we care for the elderly. In order to 
understand how we might treat the geriatric population, efforts must be made to 
understand the basic biology of ageing. The aetiology of ageing is heterogeneous in nature 
and some interventions (both pharmacological or lifestyle-oriented) have shown promise 
with respect to extension of lifespan and, more critically, extension of healthspan (i.e. the 
proportion of time spent at the end of life in good health) (Kolovou et al., 2014). 
Calcitonin gene-related peptide (CGRP) is the most potent microvascular vasodilator known 
to date (Brain et al., 1985) and possesses diverse activity throughout the cardiovascular and 
other body systems (Russell et al., 2014). It is widely expressed throughout the central and 
peripheral nervous systems, with a particularly rich expression within small-diameter thinly 
myelinated and amyelinated sensory Aδ/C neuronal fibres. These fibres densely innervate 
the cardiovascular system, in particular the arteriolar side of the vascular tree. CGRP is a 37 
amino acid peptide, discovered in 1982 (Amara et al., 1982) and is a member of the 
calcitonin family of peptides, which also comprises calcitonin, amylin, adrenomedullin (AM) 
and intermedin/adrenomedullin 2. CGRP is thought to possess a protective role in a wide 
range of pathologies, including those relevant to the cardiovascular system. Indeed, many 
have shown cardioprotective (Covino and C Spadaccio, 2011) roles of CGRP and also 
vasculoprotective roles, especially within the context of systemic hypertension (Smillie and 
Brain, 2011). However, little is known of how CGRP influences the pathophysiological 
processes of ageing. 
The introduction to this thesis will begin by introducing both the phenomenon of ageing 
with respect to its socioeconomic burden, how it came to be through an evolutionary 
biological perspective, and also discussing several of the classical mechanisms that drive 
such a heterogeneous phenotype, with particular emphasis on those impinging upon the 
cardiovascular system. The introduction will then present a review of the literature 
concerning CGRP, including its basic biology, effects on organ systems and how it mediates 
these effects though specific receptor systems. The central hypotheses and aims of this 
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1.1.1 The Ageing Epidemic 
The United Kingdom (UK) is facing a looming epidemic with respect to its ageing population. 
In a 2008 population census, roughly 10 million people aged 65 years or older were living in 
the UK. This is projected to reach around 15 million by 2033 and by 2050 this population 
demographic is set to double to around 19 million people. While one-in-six of the population 
are currently aged 65 and over, by 2050, one-in-four will be. Figure 1 illustrates the spread 
of the UK population in 2008 versus predicted population growth by 2033. It is quite clear 
from these projections that the population that is set to grow the most is that of the over 
65s, with substantial increases in the number of nonagenarians and even those living as long 














Figure 1: Graph depicting 2008 population demographics and 2033 population projections, divided into five-




The prospect of an ageing population brings with it real socioeconomic concern. Of great 
importance is the cost this will impose on the National Health Service (NHS). Currently, the 
average NHS spending for retired households is nearly double that for non-retired 
households: in 2007/08, the average cost of NHS services for retired households was £5,200, 
compared with £2,800 for non-retired. This cost further increases the older one gets, where 
NHS services are thought to cost around three times as much for someone aged 85 years 
and older, versus those aged between 65 to 74 years. Thus, there is a real need to 
understand what sort of health problems the older generation is likely to face and how we 
can begin to tackle these problems. 
According to the UK Office for National Statistics, a 2012 consensus revealed that 
cardiovascular disease was the leading cause of death in England and Wales for men and 
women combined. This finding is also reflected throughout the European Union and the 
United States. The main forms of CVD are coronary heart disease, heart attack and stroke. A 
common feature of these diseases is the development of atherosclerotic plaques within the 
walls of blood vessels, which can lead to vessel obstruction either by arterial stenosis, or the 
formation of a thrombus, which can dislodge to obstruct distal vessels. As one ages, the risk 
of developing some form of CVD substantially increases and, in fact, the single biggest 
independent risk factor for the development of CVD is getting older. To put this into context, 
the Framingham score for the risk of coronary heart disease allocates seven points to men 
between the ages of 70-74, compared with only three for men with high cholesterol and 
high blood pressure and only two points for those who are smokers or are diabetic (Wilson 
et al., 1998). Not only does the advancement of age significantly increase the risk of 
developing CVD, many other age-associated degenerative diseases such as dementia have 
been shown to have a substantial vascular component in their aetiology. With these factors 
in mind, there is a clear need to understand the basic biological mechanisms of ageing with 
reference to the cardiovascular system, in order to be able to develop new therapeutics that 
can either extend lifespan or, more importantly, compress end of life morbidity. 
Ageing is almost always not an ‘isolated’ condition and high blood pressure, or hypertension, 
is very often comorbid with advancing age. Hypertension is diagnosed in the UK as a 
persistently high blood pressure of 140/90 mmHg and is broadly classified as two distinct 
types, depending on its aetiology. These are referred to as primary (or ‘essential’) and 
secondary hypertension. Secondary hypertension is much less common than essential 
hypertension, affecting around 5% of hypertensive patients and its genesis is dependent on 
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another known medical condition that drives the increase in blood pressure. This may be as 
a result of endocrine dysfunction, cardiac and renal diseases or certain tumours, such as 
phaeochromocytomas. Therefore, the treatment of secondary hypertension must be first 
targeted to the underlying condition in order to bring about a reduction in blood 
pressure(Rimoldi et al., 2014). In contrast to this, essential hypertension is largely idiopathic, 
having no obvious underlying cause. Despite this, there are various risk factors that can 
contribute to increased likelihood of developing primary hypertension. These include 
genetic factors, hyperactivity of the sympathetic nervous system and hyperactivity of the 
renin-angiotensin-aldosterone axis. Lifestyle factors such as high alcohol intake, smoking, 
high salt intake, little or no exercise and stress can also significantly increase one’s risk of 
developing the disease. However, the single biggest independent risk factor for the 
development of essential hypertension (and other CVDs as a result) is increased age 
(Carretero and Oparil, 2000). 
As previously discussed, in the UK, stroke and coronary heart disease are the major causes 
of death in people aged 65 years and older. The most common treatable risk factor for these 
is hypertension. Advancing age as a risk factor for hypertension has been known for some 
time. Data obtained from the Framingham Heart Study demonstrated that systolic blood 
pressure shows a continuous increase from the age of 34 onwards, until death(Fleg and 
Strait, 2011). Diastolic blood pressure, on the other hand, is much more variable, increasing 
until the fifth decade and slowly decreasing from around the age of 60 to at least 84 years of 
age. This divergence in systolic versus diastolic pressure leads to a substantially increased 
pulse pressure with age, which is thought to be a powerful predictor of future adverse 
events. 
Whilst hypertension is clearly definedby pathophysiological elevations in blood pressure, it is 
also associated with widespread vascular inflammation and remodelling. The inflammation 
associated with hypertension overlaps greatly with that associated with the ageing process, 
albeit to an exaggerated extent and this will be discussed in subsequent sections. 
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1.1.2 Evolutionary Theories of Ageing 
Ageing is arguably the most familiar yet least well-understood aspect of human biology. It is 
broadly defined as the time-dependent functional decline in the capacity of the body to 
maintain proper homeostasis. To ask how or even why ageing occurs requires an 
understanding of the evolutionary biology of ageing and the question remains as to why 
such an apparently disadvantageous trait is allowed to be perpetuated in the face of the 
widely-accepted Darwinian theory of natural selection. 
The most common hypotheses for the evolution of ageing processes work at the level of 
group selection, stating that age-related decline leading to death prevents population 
overcrowding and facilitates the progression of further evolution by ensuring proper 
population turnover. These hypotheses echo Weissmann, who is noted to have said “Worn 
out individuals are not only valueless to the species, but they are even harmful, for they take 
the place of those which are sound.”(Weissmann, 1891). Thus, ageing in this manner is said 
to be “programmed”, largely for utilitarian purposes. There are many reasons as to why this 
idea is flawed. Firstly, data obtained from organisms living in the wild show that many 
individuals rarely survive to ages where age-associated deterioration actually becomes 
apparent; most organisms succumb to extrinsic mortality (such as predation or 
environmental challenges such as cold or starvation) before senescence becomes a factor. 
This means that there is no pressure for ageing to “weed out” older individuals. Secondly, 
there’d be little opportunity for evolution to select genes specifically ‘for’ ageing, given 
natural selection would not normally see them in action. In addition, these hypotheses 
stress that ageing benefits the group rather than the individual and this is flawed. Traits that 
benefit the good of the group are open to the problem of individuals being dishonest. For 
example, individuals possessing mutations that inactivate or lengthen the ageing 
programme would be favoured over those who succumb to death earlier and this phenotype 
would be expected to spread throughout the group, thus diminishing the original effect of 
ageing itself(Kirkwood, 2002). Even though the argument of programmed ageing seems 
compelling, further research performed in C. elegans has shown that no single gene 
mutation or combination of mutations has produced a phenotype that completely abolishes 
ageing altogether, despite being able to extend longevity. This suggests that programmed 
ageing either does not exist or is incredibly robust. Thus the question remains, if ageing is 
not programmed, how has it evolved? There are three main evolutionary theories of ageing 
and these shall now be discussed in turn. 
 33 
1.1.2.1 Mutation Accumulation 
Peter Medawar put forward one of the first modern explanations as to why ageing occurs in 
a 1952 lecture at University College London, entitled “An Unsolved Problem of Biology”. In 
this, he suggested that the force of natural selection tended to wane the longer an individual 
lived. For instance, if an individual possessed a trait as a result of random germline mutation 
that made it likely for it to die before it reached reproductive age, this trait was likely to be 
subjected to a very large negative selection pressure as the ‘fatal gene’ would be unlikely to 
be passed on to subsequent generations. If, however, an individual possessed a lethal trait 
that only manifested itself after the individual was likely to have reproduced, then it could 
conceivably be selected for, provided the individual looked after its progeny well. An 
example of this model would be human sufferers of Huntingdon’s disease – such an 
apparently disadvantageous disease (with respect to survival, at least) can be propagated 
throughout the gene pool because its lethal phenotype strikes individuals aged between 35-
44 years of age, when most individuals will have already reproduced and have passed the 
faulty gene on. Medawar postulated that such late-acting alleles might accumulate over 
time as natural selection is weak to act against them and such mutations may facilitate 
negative phenotypes. Thus, any individual fortunate enough to escape extrinsic mortality 
would feel the full force of these mutations as “ageing” (Medawar, 1952). 
1.1.2.2 Antagonistic Pleiotropy 
In keeping with Medawar’s theory of mutation accumulation is that of antagonistic 
pleiotropy, proposed by George Williams in a 1957 paper entitled “Pleiotropy, Natural 
Selection, and the Evolution of Senescence” (Williams, 1957). Genetic pleiotropy refers to the 
ability of a gene to exert different effects at different stages of an individual’s lifespan. 
Williams proposed that ageing was caused by genetic pleiotropy, where genes ‘for’ ageing 
were selected due to their ability to produce a beneficial effect from youth until 
reproductive age was reached, in spite of their ability to produce deleterious effects in old 
age, when selection pressures are negligible. To illustrate, one can imagine a gene that 
enhances calcification processes to be beneficial in youth as the skeletal system develops, 
thus enhancing fitness. However, once the skeleton is fully developed, such a gene may 
become deleterious in as much as it may promote aberrant calcification of other tissues, 
such as those of the cardiovascular system, which is unwanted and would subsequently 
lower fitness. However, such a gene would evade negative selection due to its beneficial 
nature in early life.  
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1.1.2.3 Disposable Soma Theory 
Whilst the ideas of Medawar and Williams detail most of the current thinking about the 
genetic evolutionary theories of ageing, there is a severe lack of empirical evidence to back 
these up. A more testable theory of ageing was proposed by Thomas Kirkwood in 1977 
(Kirkwood, 1977), in which he put forward the idea of the ‘disposable soma’. In this, he 
envisioned an energetic “trade-off” between germline and somatic cells, where the 
individual should optimally allocate its resources between maintenance of the body (the 
soma) to ensure fitness of the individual, increasing chances of reaching reproductive age, 
and the germline to ensure protection of the gametes and thus increasing their fitness. As 
metabolic resources are finite, clearly spending resources on one reduces the amount one 
can spend on the other and thus a trade-off is established. The idea of the disposable soma 
is certainly very relevant when we examine some of the molecular mechanisms that are 
associated with the ageing process. 
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1.1.3 The Ageing Vasculature 
The physiology of the ageing process is incredibly complex: a multitude of factors can 
contribute and interact to produce the phenotype and not all of these factors need be 
involved to produce the end result. Thus, the phenotype of the ageing vasculature can be 
quite heterogenous depending on a variety of factors, particularly in humans where the total 
combinations of environmental interactions one may encounter over time to influence 
vascular health can be numerous. However, whilst complex, there is a broad group of 
hallmarks that appear to be well conserved throughout this process and these will be 
discussed in turn below. These hallmarks can largely be grouped under the single idea of a 
type of low-grade, sterile injury known as “inflammaging”, first coined by Franceschi in a 
2003 paper investigating the biological characteristics of centenarians (Franceschi and 
Bonafè, 2003). In humans, the effect of ageing on the arterial tree is very heterogeneous, 
depending on which vascular bed is studied. Macroscopically, however, the effects of age on 
the larger elastic arteries appear to include increased collagen retention, covalent cross-
linking of collagen fibres, elastin fibre fragmentation and calcification and reduction in 
elastin content. There are also significant changes to endothelial function, wall thickness 
media to lumen ratio, and arterial stiffness. The smaller resistance arteries experience 
similar changes, though less emphasis is placed on changes to the proteins of the 
extracellular matrix, given their low expression and relevance within these vascular 
networks. Endothelial dysfunction, however, is a key problem within the microvasculature as 
the organism ages. As previously mentioned, the ageing vascular phenotype can be quite 
multifaceted. With this in mind, the following section will discuss common molecular 
mechanisms that appear to drive the ageing phenotype, with special reference to those that 
are related to the theory of “inflammaging”. 
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1.1.4 Molecular Mechanisms of Vascular Ageing 
1.1.4.1 Circulating Cells and Soluble Factors 
Moving from the luminal compartment of the vessel through the vascular wall, it is possible 
to identify several hallmark changes that occur with advancing age in both humans and 
animal models. Accumulating evidence suggests that a type of circulating stem cell, the 
endothelial progenitor cell (EPC), can contribute to vascular repair and re-endothelialisation. 
In settings of vascular damage, such as ischaemia, EPCs are mobilised from the bone marrow 
into the circulation, whereby they can migrate to regions of damage to initiate the repair 
process. Reductions in circulating EPC counts have been identified as an independent 
predictor of future cardiovascular events (Werner et al., 2005). In normal, ‘healthy’ ageing, a 
reduction in circulating EPC populations has not been identified. Rather, EPCs isolated from 
‘old’ patients (mean age 61 years) were less functional than those isolated from ‘young’ 
patients (mean age 25 years). For example, the old EPCs were less capable of proliferation, 
migration and survival (Heiss et al., 2005). Interestingly, it has been shown that 
transplantation of EPCs from young, non-atherosclerotic apolipoprotein E (ApoE) KOmice 
into elderly ApoEKOrecipients maintained on a high cholesterol diet was sufficient to reduce 
atherosclerotic plaque size in these animals (Rauscher, 2003). Such a reduction in 
functionality with age may be partially ascribed to telomere attrition (described in more 
detail in a subsequent section), leading to initiation of cell cycle arrest – EPCs harvested from 
older males have been shown to have telomeres around 20% shorter than those taken from 
younger adults (Kushner et al., 2009). Further to this, EPCs from older patients have been 
shown to have a significant reduction in telomerase activity resulting in a proapoptotic EPC 
phenotype (Kushner et al., 2011). Whilst young EPCs naturally appear to have quite high 
expression of antioxidant defense enzymes, He et al have shown that aged EPCs are less 
capable of tolerating oxidative damage through a reduction in expression and activity of the 
enzyme glutathione peroxidase-1 (GPx-1) (He et al., 2009). This, coupled with an increase in 
proinflammatory circulating factors with age, such as angiotensin II (ATII), which are known 
to stimulate reactive oxygen species (ROS) production in EPCs means that EPCs in the ageing 
organism may be more susceptible to oxidative damage. Indeed, blockade of AT1Rs in 
coronary artery disease patients has been shown to significantly increase the number of 
circulating EPCs available (Endtmann et al., 2011). Therefore, EPCs derived from older 
patients may be less capable of mediating endothelial repair and maintaining vascular 
health, as they are more likely to succumb to cellular senescence.  
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Ageing is also associated with an increased bioavailability of advanced glycation endproducts 
(AGEs), which are detectable in plasma. AGEs are formed by the irreversible post-
translational modification of proteins, lipids and nucleic acids by glucose via a chain of 
spontaneous, non-enzymatic chemical reactions, known as the Maillard reaction. These 
species are perhaps best known for their role in driving the pathogenesis of diabetes, 
secondary to the hyperglycaemia that is characteristic of diabetic patients(Simm, 2013). 
However, owing to the spontaneous nature of AGE formation, time is a critical element in 
their formation and over a person’s lifespan, AGE bioavailability has been seen to increase, 
either by increased rate of formation or by increased stability of glycated macromolecules 
(Farmer and Kennedy, 2009).  Common examples of AGE-modified proteins are those that 
comprise the extracellular matrix and also plasma albumins, having the longest half-life of all 
circulating proteins andtherefore are consequently ripe targets for glycation(Garlick and 
Mazer, 1983). At first glance, it may appear that the formation of AGEs is largely random, 
leading to the formation of swathes of modified moieties, each with very different structural 
characteristics. However, it has since been discovered that there is areceptor that recognises 
AGEs, known as the receptor for advanced glycation endproducts, or rAGE. rAGE is a 
multiligand receptor of the immunoglobulin superfamily of cell-surface molecules and is 
expressed widely throughout the vascular system, including on endothelial cells (EC), 
vascular smooth muscle cells (VSMC) and leukocytes(Farmer and Kennedy, 2009). Activation 
of rAGE by its ligands is classically considered to be proinflammatory through several distinct 
mechanisms. Commonly, rAGE activation has been shown to reduce nitric oxide (NO) 
bioavailability within ECs either through direct quenching (Bucala et al., 1991) or through 
deactivation/lowering of expression of NO synthases (Rojas et al., 2000). Furthermore, AGEs 
have been demonstrated to induce oxidative stress via increased NADPH oxidase (NOX) 
activity (Coughlan et al., 2009), which in turn may activate pro-inflammatory transcription 
factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
through ROS production(Bierhaus et al., 2001).  
Circulating autacoids may also markedly influence the ageing process. Two of the most 
influential circulating factors in driving the vascular ageing phenotype are ATII and 
endothelin (ET). Local, bioactive concentrations of ATII have consistently been shown to be 
elevated in both ageing humans and laboratory animals (Wang et al., 2013). This is as a 
result of increased transcription, translation and activity of the angiotensin converting 
enzyme (ACE), which is responsible for the cleavage of angiotensin I to the bioactive product 
ATII. (Michel et al., 1994; Wang et al., 2003; 2007a). In tandem with increased bioavailability 
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of the ligand ATII in aged subjects, there is also increased expression of the so-called 
“inflammatory” angiotensin receptor subtype, AT1R (Wang et al., 2013). Furthermore, 
messenger RNA (mRNA) expression of the vasoconstrictor peptide precursor, pro-ET and its 
activating protein, endothelin-converting enzyme-1 (ECE-1) has been shown to be elevated 
in the aged aorta (Goel et al., 2010). This was associated with an increased level of 
exocytosis of ET from the EC. Furthermore, increased ET receptor mRNA expression has 
been documented in ageing animals, in conjunction with an increase in the total binding 
capacity of the ligand to its receptor, as determined by radioligand binding (Ishihata and 
Katano, 2006). In summary, it is evident that the bioavailability and activity of both ATII and 
ET are elevated with age. Whilst acutely this may promote vasoconstriction, the effects of 
long-term elevation of these peptides may have more serious repercussions, owing to the 
signalling pathways both molecules converge upon. These pathways can promote the 
induction of endothelial dysfunction by aberrant ROS generation, for example, or can 
promote vascular remodelling through their effects onVSMC activity, causing them to 
proliferate and migrate in a pathophysiological manner(Savoia et al., 2011). 
Cytokines are another group of circulating factors that are differentially regulated as part of 
the ageing process. Of these, those that have consistently been shown to change and 
contribute to age-associated pathologies and increased risk of mortality in humans are 
members of the acute phase protein family, TNFα.  A study examining a large cohort of 
mixed-gender centenarians showed that soluble TNFα plasma concentrations more than 
doubled from 1.4 pg/ml in 18-30 year-old healthy controls to 3.7 pg/ml in 
centenarians(Bruunsgaard et al., 1999). Whilst statistically significant, this is a reasonably 
modest increase that is far from that associated with inflammation seen in acute infection, 
reflecting the widely held tenet that ageing is associated with chronic low-grade 
inflammation. Plasma levels of TNFα also correlated positively with increased levels of 
interleukin-6 (IL), the soluble TNFα receptor sTNFR-II and C-reactive protein (CRP). sTNFR is 
an endogenous inhibitor of TNFα activity, yet rises in circulating levels of this inhibitory 
protein appeared to have no effect on the association between high TNFα plasma 
concentrations and increased risk of dementia and/or atherosclerosis in the centenarian 
group (Bruunsgaard et al., 1999). In vitro, peripheral blood mononuclear cells (PBMC) 
isolated from elderly donors had increased TNFα secretion under basal conditions versus 
younger donors (Myśliwska et al., 1999) and following viral stimulation (Saurwein-Teissl et 
al., 2000). In a mouse model of neuroinflammation following intracerebroventricular 
injection of lipopolysaccharide (LPS), there was an age-dependent increase in mortality that 
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was associated with increased brain and plasma concentrations of TNFα over time and 
increased cerebral microglial/macrophage activation (Kalehua et al., 2000).  
Increased bioavailability of TNFα within the circulation may increase the likelihood of it 
binding to one of two cognate receptors: TNFR1 (CD120a) and TNFR2 (CD120b), both 
expressed by ECs – one of the first cell types to ‘sample’ circulating cytokines. Signalling 
from these receptors is initiated by ligand binding and subsequent recruitment of a wide 
array of intracellular adaptor proteins to the activated receptor. These adaptor proteins 
have been linked to two common signalling convergence points, namely activation of the 
transcription factors activator protein-1 (AP-1) and NF-κB(Sedger and McDermott, 2014). 
NF-κB is often thought of as being the ‘master regulator’ of inflammation. It has been 
identified as the transcription factor most associated with mammalian aging, based on 
patterns of gene expression(Adler et al., 2007). In quiescent cells, NF-κB transcriptional 
activity is usually low, owing to the inhibitory sequestering effect on the complex by 
cytosolic inhibitors of κB (IκB). Following activation of the EC by TNFα, IκB proteins become 
phosphorylated at critical serine residues that allows for polyubiquitination of the protein 
and subsequent targeting for proteosomal degradation, thus releasing the suppressor effect 
it has on NF-κB(Csiszar et al., 2008). This process can happen in HUVEC as rapidly as 15 
minutes following TNFα stimulation and NFκB activity in HUVEC following stimulation by this 
ligand is maximal at 15-60 minutes and is sustained for >20h. Once IκB proteins are 
degraded, NFκB is free to translocate to the nuclear compartment where it can initiate gene 
transcription. Binding of the transcription factor to DNA response elements drives pro-
inflammatory gene expression and typically promotes long-term cell surface expression of 
cell adhesion molecules, such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular cell adhesion molecule-1 (ICAM-1)(Johnson et al., 1996; Spiecker et al., 2000). 
Other cytokines that are thought to be found at increased levels in the plasma and 
contribute to increased risk of frailty are IL-6 and CRP(Harris et al., 1999; Alley et al., 2007). 
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1.1.4.2 Vascular Cells, Telomere Attrition and Cellular Senescence 
The 2009 Nobel Prize in Physiology or Medicine was awarded to three eminent scientists: 
Elizabeth Blackburn, Carol Greider and Jack Szostak for their seminal work examining how 
DNA can be faithfully copied during cell division without loss of information – addressing the 
so-called ‘end replication problem’. The end replication problem refers to how the 5’ ends of 
DNA strands cannot be replicated during mitosis, meaning that with each cell division, the 
length of each daughter chromosome is shortened, which should result in progressive loss of 
genomic information. However, in most cases this is shown not to occur. The reason this 
does not occur is due to extended repeat regions of nucleotide sequences (GGGTTA in 
vertebrates) at the end of each chromosome, known as telomeres, which are highly 
conserved throughout the tree of life(Zhao et al., 2014). As an analogy, the telomeres are 
often thought of as the protective capping at the end of a shoelace to prevent damage to 
the lace itself. With each round of mitosis, the telomeres shorten and cells can tolerate this 
attrition to an extent. However, when telomeres shorten to a certain threshold, this signals 
the arrest of cellular division and cells become senescent. This event helps explain a well-
known event known as the Hayflick phenomenon, first described by Hayflick and Moorhead 
in 1961 (Hayflick and Moorhead, 1961). When cells are isolated and serially subcultured in 
vitro, they can only undertake a certain number of cell divisions before they stop dividing, a 
point known as the ‘Hayflick limit’ or ‘Hayflick number’. This happens to most cells in culture 
and many cells in vivo and can be attributed to excessive telomere shortening. As this 
shortening can be described as a time-dependent effect, where ‘older’ cells are more likely 
to have shortened telomeres, there is a case to be made for telomere attrition being an 
important contributing factor to the ageing process.  
What is interesting, however, is that some cells in vivo are virtually exempt from telomere 
shortening and associated cellular senescence. Of particular note are germline cells, which 
actively express a family of genes that encode proteins required to form a reverse 
transcriptase enzyme complex known as telomerase, which works to actively extend the 
length of the telomere and replace eroded nucleotide repeats(Zhao et al., 2014). The fact 
that germline cells are given this senescence-avoiding advantage and yet somatic cells are 
exempt from it is a strong supporter of the disposable soma theory of ageing – preferentially 
maintaining a healthy germline in order to pass on one’s genes to the next generation. 
Whilst somatic cells might seem to be hindered by lacking expression of this enzyme and 
thus risking falling into senescence, this might be somewhat advantageous. Uncontrolled 
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and unlimited cellular division could result ultimately in the excision of all telomere 
sequences from the daughter DNA strand and eventual excision of important genomic 
information from the ends of each chromosome. This could result in an abnormal cellular 
phenotype that senescence actively protects against, namely oncogenesis. However, it has 
become evident that not all cell types fall into senescence, for example cardiomyocytes, as 
these cells are largely mitotically-inactive. Whilst telomere attrition is a significant 
contributory factor the initiation of cellular senescence, it is worth noting that other stimuli 
can induce this phenotypic switch in the absence of shortened telomeres. Factors that 
contribute to genomic instability (for example direct damage to nucleotide bases or 
formation of double-strand breaks or interstrand crosslinking, for instance) can also induce 
telomere-independent senescence. Most factors that contribute to the initiation of cellular 
senescence mediate this process via engagement of p53/p21 or p16/retinoblastoma protein 
tumour suppressor pathways as the final effectors of this senescence programme(Zhao et 
al., 2014).Despite being beneficial in protecting against tumorigenesis, cellular senescence 
does not come without its costs, highlighting an antagonistically pleiotropic role for this 
mechanism.  An increased ratio of senescent to non-senescent cells with ageing can be 
detrimental, owing to the so-called ‘senescence-associated secretory phenotype’ or ‘SASP’ 
(Kuilman et al., 2010). This will be discussed in subsequent sections. 
Both of the major cell types resident to the vascular wall have been shown to be capable of 
falling into senescence both in vitro and in vivo. Human studies have shown that shorter 
telomeres have been shown to correlate strongly with the lifespan of vascular cells and, as 
an extension, those with short telomeres are more likely to develop coronary artery disease 
and also have stiffer arteries, as measured by higher pulse pressures and pulse wave 
velocities (Benetos et al., 2001). Even in healthy middle-aged individuals with no apparent 
overt risk of CVD, shorter telomeres correlated with increased circulating inflammatory 
markers, such as CRP and IL-6 (Bekaert et al., 2007). In hypertensive patients, short 
telomeres are associated with increased prevalence of carotid artery atheromas (Benetos et 
al., 2004). Additonally, normotensive and hypertensive patients who were found to have an 
increased renin to aldosterone ratio (indicative of increased renin-angiotensin-aldosterone 
activity) were shown to have shorter telomeres (Vasan et al., 2008), hinting that ATII can be 
a potent inducer of telomere attrition even in the absence of elevated blood pressures. 
In patients with atherosclerosis (a disease highly comorbid with increased age), populations 
of senescent cells have been shown to be elevated in the affected vasculature compared to 
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other vessels obtained from the same individual. This staining is largely restricted to cells of 
the tunica intima, indicating the presence of senescent ECs (Minamino et al., 2002). In this 
study, senescent aortic ECs were shown to have a reduction in endothelial nitric oxide 
synthase (eNOS) expression and activity (potential markers of endothelial dysfunction, 
discussed below), which led to an increase in cellular ICAM-1 expression, a key molecule 
involved in leukocyte (specifically, monocyte) firm adhesion. This phenotype was rescued by 
introducing telomerase enzyme into the cells, which presumably had a positive effect on 
telomere length (Minamino et al., 2002).  A number of studies have shown that many of the 
changes in senescent vascular cell behaviour are consistent with known changes seen in age-
related vascular diseases, suggesting a critical role of cellular senescence in driving age-
associated vascular pathophysiology. For instance, NO bioavailability is markedly reduced in 
senescent ECs, which may lead to endothelial dysfunction (discussed in a later section). This 
occurs both in relation to basal NO production (Sato et al., 1993) and shear-induced NO 
production (Matsushita et al., 2001) and the mechanism behind this is thought to be related 
to an overall reduction in eNOS protein expression in conjunction with a decrease in Akt-
mediated phosphorylation of critical serine residues within eNOS that positively regulate its 
activity (Hoffmann et al., 2001). Senescent ECs also decrease prostacyclin production 
(Nakajima et al., 1997) and increase plasminogen activator inhibitor-1 expression (Comi et 
al., 1995) as they become senescent, promoting a vasoconstrictor and prothrombogenic 
environment. Further to this, interactions between monocytes and ECs are significantly 
enhanced when ECs become senescent (Maier et al., 1993). 
It is clear that senescent ECs are present within arteries affected by atherosclerosis. 
Senescent VSMCs have also been identified within the intimal but not medial layers of the 
vessel (migrating VSMCs are a common feature of atheroma) (Minamino et al., 2003). 
Senescent VSMCs synthesise and secrete an array of pro-inflammatory factors, which 
together comprise the so-called ‘SASP’, mentioned previously. Such releasable factors may 
include cytokines and cell adhesion molecules, such as IL-1, IL-6, IL-8 and monocyte 
chemoattractant protein-1 (MCP-1). The SASP phenotype in these cells has been shown to 
be dependent on increased extracellular signal-related kinase (ERK) activity (Minamino et al., 
2003). 
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1.1.4.3 Endothelial Dysfunction 
It was once thought that the endothelial monolayer served only as a structural barrier, 
separating the cells of the blood compartment from those located within the vascular wall. 
With time, we have come to appreciate that the endothelium is in fact a key regulator of 
vascular tone, structure and function as well as being a barrier. This polymodal function is 
controlled by a host of endothelial-derived autacoids, including prostacyclin and endothelial-
derived hyperpolarising factor but is perhaps best ascribed to the activity of NO. Seminal 
experiments in the 1980s by Furchgott and Zawadzki highlighted the obligatory role of the 
endothelium in the generation of VSMC relaxation in response to acetylcholine: rabbit 
aortae with intact endothelia produced a dose-dependent relaxation to acetylcholine, whilst 
those vessels with the endothelium mechanically or chemically removed lost this vasodilator 
response (Furchgott and Zawadzki, 1980). However, it wasn’t until 1987 that the identity of 
this “endothelium-derived relaxing factor” was identified as being NO (Ignarro et al., 1987; 
Palmer et al., 1987). Within the EC, NO is produced mainly by eNOS via the metabolism of L-
arginine to L-citrulline, producing NO as a by-product. eNOS activity can be influenced by the 
action of various agonists that mobilise intracellular calcium (such as acetylcholine), leading 
to the binding of calcium to calmodulin, increasing the affinity of this molecule for the 
enzyme. However, eNOS can also be activated by stimuli independent of long-term elevation 
in intracellular calcium and one such stimulus important for vascular homeostasis is laminar 
shear stress(Förstermann and Sessa, 2012). Continuous flow of blood parallel to the vessel 
wall is an important stimulus of eNOS phosphorylation at a critical residue for its activation: 
Ser1177. Phosphorylation of this amino acid residue increases the activity of eNOS severalfold 
(Fleming and Busse, 2003). The constant release of NO from the endothelium promotes a 
vascular environment that is vasodilatory, anti-coagulative, anti-proliferative and anti-
inflammatory (Förstermann and Sessa, 2012). Any negative alteration in NO bioavailability 
can severely impair vascular function by shifting its phenotype to that of a vasoconstrictor, 
pro-coagulative, proliferative and pro-inflammatory system. Such a decrease in NO 
bioavailability is often described as “endothelial dysfunction”, which is diagnosed in humans 
by a reduced ability of the peripheral arteries to produce an endothelial-dependent 
dilatation (EDD) in response to chemical or mechanical stimuli(Seals et al., 2011). 
Endothelial dysfunction is a phenomenon that increases in prevalence and severity with age, 
as characterised by EDD (Seals et al., 2011). Reduction in EDD does not appear to be 
mediated by a reduction in sensitivity of vascular smooth muscle to NO, as vasodilator 
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responses to NO donors are unchanged (Taddei et al., 1995). Data suggest that age-
associated endothelial dysfunction is mediated by a decrease in NO bioavailability. This may 
be due to a decrease in NO synthesis or an increase in its removal, or both. However, the 
exact contributions of altered NO production compared with its removal during endothelial 
dysfunction are yet unknown and, indeed, they may vary considerably between individuals. 
Despite consistent observation that NO bioavailability is reduced with advancing age, data in 
animal models are inconsistent when examining arterial eNOS protein expression and 
“active” eNOS expression using phospho-specific antibodies to Serine1177 – reports have 
shown increased, decreased and unchanged levels of expression and activity (Cernadas et 
al., 1998b; Yang et al., 2009; Rippe et al., 2010). Such discrepancies might be attributable to 
species and strain differences, making results difficult to interpret. Furthermore, differences 
in age of animals used are likely to have a major impact on results. In healthy humans 
however, studies in the brachial artery have shown increased eNOS expression and activity 
in ECs of older versus younger patients, accompanied by the hallmark reduction in EDD 
(Donato et al., 2009). Therefore, this increase in eNOS activity might be a compensatory 
response to diminished levels of total NO. 
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1.1.4.4 Oxidative Stress 
Another important factor that may contribute to a reduction in NO bioavailability in the 
ageing vasculature is that of an increased production of ROS. The evolution of aerobic 
respiration in eukaryotic cells was clearly critical for the development of complex, multi-
cellular organisms. However, oxygen metabolism comes at a price, owing to its capacity to 
be transformed into toxic metabolites such as superoxide (O2
-), hydroxyl anion (OH-) and 
hydrogen peroxide (H2O2). Cells constantly produce ROS as a result of oxidative 
phosphorylative processes to generate ATP within the mitochondria and, as a result, they 
have evolved multiple mechanisms to defend themselves against the deleterious effects of 
aberrant ROS production(Puca et al., 2013). This balance between ROS production and 
defense is often described as the redox state of the cell. Vascular cells are capable of 
producing ROS from sources other than the mitochondria, such as from cytochrome P450, 
xanthine oxidase, the NOXes and also from uncoupled NO synthase (Bachschmid et al., 
2012). NO synthase enzymes can become uncoupled under reduced availability of the 
substrate, L-arginine, or its essential co-factor tetrahydrobiopterin (Landmesser et al., 2003). 
Uncoupling of the enzyme leads to a switch from NO production to superoxide production. 
This direct suppression of NO formation is accompanied by an ability of superoxide to react 
rapidly with remaining NO to form the highly reactive nitrogen species, peroxynitrite (ONOO-
), thus further driving down NO bioavailability by a quenching mechanism. Generation of 
ROS can further feedback onto the NOS enzyme by oxidising tetrahydrobiopterin, thereby 
causing it to be uncoupled from the enzyme and initiating a positive feedback circuit of 
dysregulated ROS formation. 
In tandem with a propensity to develop endothelial dysfunction with increasing age is an 
increased incidence of oxidative stress. Almost a century ago it was noted that animals with 
high metabolic rates had shorter lifespan, though the reason for this was unknown. In the 
mid-1950s, however, Denham Harman proposed a “free-radical theory” of ageing that 
stands today as one of the most convincing arguments to explain which mechanisms govern 
the ageing process. Harman hypothesised that cells had the capacity to generate 
endogenous oxygen radicals whose action resulted in a pattern of cumulative damage to 
cellular components (Harman, 1956). As discussed previously, ROS are generated as a by-
product of mitochondrial oxidative phosphorylative processes that govern ATP synthesis. 
Movement of electrons down the mitochondrial electron transport chain can result in the 
donation of electrons to molecular oxygen to form superoxide radical. As the production of 
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superoxide is non-enzymatic, the rate of its formation from the mitochondria is directly 
related to metabolic rate (Hou et al., 2011; Dai et al., 2012). As superoxide is relatively 
incapable of crossing plasma membranes, mitochondrial-derived superoxide is often 
retained within this compartment and is therefore allowed to react with mitochondrial 
proteins and DNA, leading to mitochondrial dysfunction. Mitochondrial dysfunction can 
promote malfunction of the respiratory chain and an even greater production of superoxide 
(Xin et al., 2003). As already mentioned, other sources of ROS exist throughout the cell but 
perhaps the most interesting source of free radicals emanates from the NOX family of 
enzymes. The NADPH oxidase was first described in phagocytic cells, where it plays a pivotal 
role in regulating the innate immune response to pathogen via the generation of a large 
burst of superoxide (the “oxidative burst”) during the process of phagocytosis(Cave et al., 
2006). It has since been discovered that other NOX isoforms exist within cells of the 
cardiovascular system and indeed it is thought that they represent the largest source of free 
radicals in the vasculature. This is an intriguing discovery, given that the apparent sole 
function of the enzyme family is to generate ROS – indicating that generation of free radicals 
from this source is likely to have some form of evolutionary benefit and therefore may play 
an important physiological role (Cave et al., 2006). Several members of the NOX family of 
enzymes have been detected in vascular cells. NOX1 is expressed in smooth muscle cells, 
and to a lesser extent in ECs. NOX2 is found in ECs and adventitial fibroblasts, whilst NOX4 is 
far more ubiquitously expressed throughout all levels of the vascular wall (Takac et al., 
2012). It has been shown that old rats have an increased capacity to generate NOX-derived 
superoxide anion when compared with young rats and this increase in activity is 
accompanied by an elevation in protein expression of NOX subunits (Oudot et al., 2006). 
Furthermore, certain NOX isoforms (particularly NOX2) can be stimulated by pro-
inflammatory cytokines, such as TNF , which are known to be upregulated with advancing 
age (Bruunsgaard et al., 2000). However, others hypothesise that the xanthine oxidase 
enzyme is a more important source of ROS in the ageing cardiovascular system (Vida et al., 
2011). 
Together with an increased likelihood of ROS formation within vascular cells to induce a pro-
oxidant environment with age, there is also an increased likelihood for these cells to have an 
impaired oxidant handling system. The major removal mechanism for superoxide anion is by 
the superoxide dismutase (SOD) family of enzymes, of which there are three distinct 
isoforms: the cytosolic copper-zinc SOD (Cu/ZnSOD, SOD-1), mitochondrial manganese 
(MnSOD, SOD-2) and extracellular SOD (ecSOD, SOD-3). These enzymes function to convert 
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superoxide to hydrogen peroxide and molecular oxygen (Faraci and Didion, 2004). Despite 
considerable effort, it is not at this stage clear how the expression of these three SOD 
isoforms are regulated as part of the ageing process. Other antioxidants include the 
enzymatic antioxidants catalase, haem oxygenase-1 (HO-1) and glutathione peroxidase 
(GPx). Non-enzymatic ROS scavengers also exist and include glutathione, urate and some 
vitamins (van der Loo et al., 2009). 
Transcriptional regulators of the oxidative stress response can also be dysregulated as a 
function of age. The nuclear factor erythroid-2-related factor-2 (Nrf2) is an evolutionarily 
highly conserved redox-sensitive transcription factor that can be activated by ROS 
production within the vasculature. Activation of Nrf2 induces the transcription of multiple 
genes that are involved in ROS detoxification processes or those that have direct antioxidant 
properties(Baird and Dinkova-Kostova, 2011). Despite increases in vascular superoxide 
production, ageing rats have been shown to have a dampened Nrf2 response, as assayed by 
measurement of Nrf2-dependent gene transcription and protein production (including 
NADPH quinone oxidoreductase-1 (NQO1), ϒ-glutamylcystein synthase and HO-1. The 
reduction in Nrf2-dependent gene transcription was observed in parallel with an 
upregulation of NFκB-dependent gene targets (Mármol et al., 2007). Similar results were 
observed in vascular tissues obtained from the nonhuman primate, Macaca mulatta 
(Ungvari et al., 2011). Further studies investigating the biology of the naked mole rat bolster 
this hypothesis. The naked mole rat is extremely long-lived in comparison to other rodents, 
despite having a similar degree of ROS production and a similar intracellular oxidative 
environment (Lewis et al., 2010). However, the key to this organism’s longevity and healthy 
longevity appears to be a consistent high level of Nrf2 activity, even into old age. This animal 
is more resistant to oxidant-induced apoptosis of vascular cells and also DNA fragmentation 
(Labinskyy et al., 2006). Therefore, maintenance of Nrf2 activity could represent a viable 
target in preventing the onset of age-associated vascular inflammation secondary to 
dysregulated redox balance. All things considered, it is widely accepted that as an organism 
ages, its ability to handle oxidative stress declines and this translates to an inflammatory 
phenotype as a result. Figure 2 illustrates common signalling pathways that occur in the EC 


























Figure 2: Signalling schematic denoting typical pro- and anti-oxidant pathways important in mediating age-
associated endothelial dysfunction. ROS: reactive oxygen species; O2
-
: superoxide; H2O2: hydrogen peroxide; 
NO: nitric oxide; HO-1: haem oxygenase-1; NQO1: NAD(P)H dehydrogenase quninone-1; GPx: glutathione 
peroxidase; SOD: superoxide dismutase; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; 
AP-1: activator protein-1. 
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1.1.4.5 Vascular Smooth Muscle Cells 
The predominant cell type to populate the medial layer of the vascular wall is the VSMC. The 
impaired generation and maintenance of the EC combined with an increased capacity of the 
vascular smooth muscle to proliferate and migrate significantly influence vessel remodeling 
with age. Traditionally, VSMCs have either been classed as one of two extremes: ‘contractile’ 
or ‘synthetic’. However, the current paradigm recognises that VSMCs exist on a spectrum, 
and can adopt properties of both cellular phenotypes. Contractile smooth muscle cells are 
largely quiescent and are responsible for maintaining an appropriate level of vascular tone 
and respond to a range of vasoactive stimuli in order to do so. The phenotype of the VSMC 
can change, however, in response to environmental cues, whereby the cell moves from a 
contractile to a synthetic state. As their name suggests, synthetic VSMCs are capable of 
synthesising and secreting an array of factors including adhesion molecules, matrix 
metalloproteases, pro-fibrotic molecules and chemokines. Their synthesis and release can 
substantially contribute towards the formation of vascular inflammation mediated by the 
VSMC(Davis-Dusenbery et al., 2011). Within the aged arterial wall, these factors can impinge 
upon signalling pathways that may lead to arterial inflammation, stiffening and fibrosis. This 
may produce arteries that are overall less distensible. Thus, VSMCs at the level of the 
resistance arteries are less capable of regulating peripheral resistance and therefore blood 
pressure. Additionally, less distensible VSMCs that comprise the medial wall of the large 
resistance arteries may contribute to lowered compliance, meaning pressure waves 
emanating from the heart are more likely to be reflected backwards rather than propagated 
forwards, leading to increased systolic pressures(Zhu et al., 2012). A significant factor in 
mediating VSMC dysfunction with age is the increased propensity for cells to cease 
proliferating and to enter a senescent state, which can significantly alter the phenotype of 
the cell. 
 
With these factors in mind, aspects of the ageing vasculature and the role of inflammation in 
driving age-associated cardiovascular pathology will be investigated. This will primarily be 
investigated within the context of CGRP biology, which will be introduced in the next section 
of this thesis. 
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1.2 Calcitonin gene-related peptide 
1.2.1 Brief History 
Calcitonin gene-related peptide is a 37 amino acid peptide that is primarily expressed by 
peripheral sensory neurons. Specifically, it is expressed by  the small-diameter, 
unmyelinated and small-diameter, thinly-myelinated C and Aδ nociceptive fibres. These 
nerves have their cell bodies in the dorsal root ganglia (DRG) and project afferent fibres to 
the dorsal horn of the spinal cord to transmit nociceptive signals to the central nervous 
system. They also possess efferent fibres, which innervate throughout the body, with a rich 
degree of innervation to the cardiovascular system, particularly at the perivascular level. 
CGRP is also to a lesser extent expressed non-neuronally, although much less is known about 
these sources of the peptide(Russell et al., 2014). 
Evolutionarily, CGRP is fairly well conserved and appears to have an ancient origin among 
species of the metazoan era, existing before the emergence of deuterostomes, including 
modern vertebrates. The emergence of the related calcitonin gene did not happen until 
later, indicating that CGRP might actually be the precursor gene to calcitonin and not vice-
versa (Lafont et al., 2007). Despite being relatively ancient, the existence of CGRP was first 
discovered by humans in 1982 following the observation that rat medullary thyroid cells 
decreased the production of mRNA encoding the calcium-regulating hormone, calcitonin, in 
favour of another distinct RNA transcript, which was then christened as CGRP. This initial 
finding also hinted at the differential expression pattern of calcitonin and CGRP mRNAs. 
Amara et al showed that calcitonin was produced mainly by the parafollicular cells of the 
thyroid gland, whilst CGRP production was predominant within the hypothalamus (Amara et 
al., 1982). Until 1984, the production of CGRP had only been observed in rats and it was 
unclear whether this was a peptide that was synthesised also by humans. Using an antibody 
raised against a fragment of rat CGRP, Morris et al detected a cross-reacting peptide in 
human medullary thyroid carcinoma biopsies. The isolated peptide was sequenced by mass 
spectrometry and was found to differ to the rat peptide by four amino acid residues, 
resulting in an 89% homology between both species (Morris et al., 1984). Shortly after the 
discovery of human CGRP, an additional CGRP-encoding gene was identified, that was 
shown to contain sequences highly homologous to exons 3, 5 and 6 of the CALC I gene 
(CGRP-encoding) but not to exon 4 of the same gene (calcitonin-encoding). The gene was 
found to be located nearby on the same chromosome of CALC I (chromosome 11 in humans; 
7 in mice) but only facilitated the transcription of mRNA for a CGRP-like product, as opposed 
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to both calcitonin and CGRP (Höppener et al., 1985; Steenbergh et al., 1985). The product of 
this gene is now recognised as an alternative isoform of CGRP: βCGRP. Thus, CGRP is now 
known to exist as two distinct isoforms: alpha and beta. Given its similarity and proximity to 
the CALC I gene, it is likely that the CALC II gene arose through duplication. The structure of 
the CALC I gene is depicted in Figure 3. CGRP belongs to a much wider family of related 
peptide hormones that includes calcitonin, CGRP, AM, AM2 (or intermedin) and 
amylin(Russell et al., 2014). Whilst expressed by very different cell types, these peptides 
share similarities in their structure and also in the receptor molecules they bind to in order 





















Figure 3: Illustration of the CALC I gene and exons required to encode mRNA for calcitonin and αCGRP, 
including peptide processing mechanisms. Adapted from (Russell et al., 2014). 
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1.2.2 Synthesis, structure and release 
The regulation of CGRP synthesis is still poorly understood. CGRP synthesis is known to be 
upregulated in models of nerve damage, such as peripheral axotomy, and it is thought that 
synthesis of the peptide is enhanced in tissues that are undergoing an inflammatory 
response (Donnerer and Stein, 1992). This may be linked to local release of nerve growth 
factor (NGF) from cells such as macrophages and keratinocytes. NGF is vitally important for 
the growth of sensory nerves and for the maintenance of function of mature nerves 
(Terenghi, 1999). After depletion of sensory neuropeptides from nerve terminals following 
treatment with the pungent chilli pepper extract and transient receptor potential vanilloid 1 
(TRPV1) agonist capsaicin, NGF is required for the synthesis of new peptide (Donnerer et al., 
1992). Interestingly, NGF has been linked to the upregulation of CGRP production within the 
DRG and promotion of CGRP expression in the spontaneously hypertensive rat 
(SHR)(Supowit et al., 2001). 
As previously discussed, CGRP exists in two distinct isoforms, encoded for by two distinct 
genes located on the same chromosome (although the chromosome where these genes are 
located differs between mice and humans). Each isoform shares >90% sequence homology 
with the other, differing by three amino acid residues in the human (Morris et al., 1984; 
Amara et al., 1985; Steenbergh et al., 1986). Human αCGRP is comprised of four principal 
domains (Conner et al., 2002) that have been deduced mainly through nuclear magnetic 
resonance spectroscopic and other physical techniques. The N-terminus of the peptide is 
constrained within a ring-like structure owing to a disulphide bond existing between amino 
acid residues 2 and 7. Removal of the N-terminus of the molecule ablates its activity as an 
agonist at the CGRP receptor and instead produces a competitive, reversible antagonist at 
the same receptor. The second domain appears to form an alpha helix in hydrophobic 
solvents between residues 8 and 18 (Hubbard et al., 1991; Mimeault et al., 1992). The third 
domain appears to be a little less well-structured, comprising a hinge region that may adopt 
the form of a β or Υ twist (Conner et al., 2002). Residues 28-37 constitute the final domain, 
which appears to be important in generating an overall high-affinity conformation of the 
peptide for its cognate receptor, with two critical bends in the peptide structure occurring at 
residues 29 and 34. Human βCGRP peptide appears to adopt a largely similar molecular 
topology (Morris et al., 1984). The primary sequences of human, mouse and rat αCGRP and 
βCGRP are denoted in Figure 4. 
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After synthesis, CGRP is stored in large, dense-core vesicles within the sensory nerve 
terminal (Matteoli et al., 1988). Following neuronal depolarization, CGRP is released from 
the terminal via calcium-dependent exocytosis mediated by classical exocytotic pathways 
that involve members of the SNARE (Soluble NSF Attachment Protein Receptor) family of 
proteins (Meng et al., 2007). The release of CGRP from sensory neurons was first 
demonstrated using capsaicin, which selectively activates sensory neurons (Diez Guerra et 
al., 1988). However, as capsaicin is an exogenous compound, it is unlikely that the release of 
CGRP is regulated via this mechanism alone. The main pharmacological target of capsaicin is 
TRPV1, an ion channel that is also activated by noxious heat (>43 C) and is sensitised by low 
pH (Caterina et al., 1997). It therefore seems more likely that these sorts of stimuli are more 
relevant in terms of TRPV1 activation and subsequent CGRP release in vivo, especially in 
areas of inflammation that are likely to have raised local temperature and increased proton 
concentrations. More recently, it has been shown that mediators of the endocannabinoid 
system, such as anandamide, are endogenously produced by the body and are capable of 
binding and activating TRPV1(Fernandes et al., 2012). Aside from TRPV1, other members of 
the TRP family have been shown to release CGRP following stimulation, such as thetransient 
receptor potential ankyrin 1 (TRPA1) channel. TRPA1 is often coexpressed alongside TRPV1 
in certain populations of sensory neurons. Indeed, it is estimated that 50% of TRPV1-
expressing neurons also express TRPA1 (Bodkin and Brain, 2011). The release of CGRP from 
novel, non-neuronal cells has also been linked to the activation of TRPV1 (Luo et al., 2008a). 
Undoubtedly, other mechanisms and receptors will be linked to the release of CGRP from 









Figure 4: Primary sequences of human, rat and mouse αCGRP and βCGRP. Residues highlighted in blue indicate 
where residues differ from human αCGRP. Adapted from (Russell et al., 2014).  
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1.2.3 Metabolism and Removal 
Several aspects concerning the regulation of CGRP activity are well understood but it is still 
unclear as to how the peptide is metabolised following release from the cell. Initial studies 
investigating the capacity of the neuropeptide substance P (SP) to elicit neurogenic 
inflammation showed that low concentrations of CGRP were able to potentiate plasma 
extravasation induced by SP in rat abdominal skin (Gamse and Saria, 1985). Undoubtedly, 
this result may have been as a result of many different pharmacological effects but it was 
later suggested that CGRP was capable of inhibiting SP degradation and therefore 
augmenting its bioactivity by competing for degradation by the same endopeptidase, though 
the identity of this molecule was not determined (Le Grevès et al., 1985; 1989). The lack of 
an identified candidate for this effect may be attributed to a false interpretation of data 
from these groups. Indeed, it is perhaps more likely that the potentiation of oedema 
formation in this model was due to the potent vasodilator activity of CGRP working in 
synergy with the potent endothelial junction destabilisation activity of SP (Brain and 
Williams, 1985). In order to provide some more information as to the type of protease 
involved in breaking down both CGRP and SP, experiments were performed using purified 
mast cell tryptase from human lung samples. This study showed that whilst the tachykinins 
tested were not metabolised by mast cell tryptase, CGRP was hydrolysed by this system with 
favourable kinetic parameters (Brain and Williams, 1989). Subsequent to this study, the 
identity of a shared removal enzyme common to both SP and CGRP had been identified as 
neutral endopeptidase (Katayama et al., 1991). More recently, a proteomic approach has 
been used to identify novel CGRP fragments in mouse tissue and to reveal the endogenous 
cleavage sites within the primary sequence of the peptide. Mass spectrometry revealed the 
presence of 10 endogeously-produced peptide fragments in murine spinal cord 
homogenates that highlighted two primary cleavage sites in vivo: Serine17-Arginine18 and 
Asparagine26-Phenylalanine27. Subsequent biochemical assays identified a role for a 
metalloprotease in the regulation of CGRP proteolysis, of which insulin-degrading enzyme 
(IDE) was found to be particular important in processing of the peptide at the 
aforementioned cleavage sites (Kim et al., 2012). Another enzyme, ECE-1 has also been 
implicated in the degradation of CGRP and this has been suggested to be of functional 
importance in murine pulmonary fibrosis (Hartopo et al., 2013).  
An alternative mechanism has been proposed to regulate CGRP removal. In the mouse vas 
deferens, application of the TRPV1 agonist capsaicin was shown to attenuate electrically-
induced twitch responses, an effect that was attributable to the release of CGRP from the 
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sensory nerve terminal. However, following a second exposure to capsaicin, its ability to 
blunt muscle twitch was markedly reduced, suggesting sensory afferents had depleted their 
stores of CGRP following the first stimulation. This effect was rescued by pre-incubating the 
preparation for a short time with exogenous CGRP. The authors suggest that this restoration 
of function is attributable to reuptake of CGRP into the neuron by an active transport system 
(Sams-Nielsen et al., 2001; Sheykhzade et al., 2011) Indeed, this aspect of reuptake is similar 
to the reuptake process in sympathetic nerves (Mandela and Ordway, 2006). Similar results 
for CGRP have been shown in the guinea pig basilar artery and in rat dura mater encephali, 
where reuptake may prove to be an important mechanism by which CGRPergic signalling is 
regulated in conditions such as migraine (Gupta et al., 2010). In summary, a wide range of 
removal mechanisms have been proposed to be important in the removal or breakdown of 
CGRP following its release from nerves or vascular cells. Specific targeting of each of these 
mechanisms may yield a novel means by which to augment or suppress CGRP bioactivity for 
therapeutic gain. 
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1.2.4 Distribution of CGRP 
1.2.4.1 Sensory neurons 
CGRP is widely distributed throughout the central and peripheral nervous systems. In the 
periphery, it is most commonly found within sensory neurons: it has long been known that 
the small, unmyelinated C-fibres and the larger, myelinated A  fibres contain CGRP. These 
fibres do not express CGRP alone and have been shown to differentially express other co-
transmitters, depending on anatomical location and tissue innervation. Common co-
transmitters include SP and the neurokinins (Bell and McDermott, 1996). These sensory 
neurons have nerve terminals located within a wide range of tissues and organ systems, 
including those of the cardiovascular system. Intriguingly, peripheral neuronal somata have 
recently been identified within the adventitial layers of rat mesenteric arteries and these 
neurons are thought to express the beta isoform of CGRP (Somasundaram et al., 2006; 
2012). This direct neuronal source of CGRP stemming from the DRG within the vascular wall 
makes a significant contribution to CGRP within the vasculature and remains the biggest 
source of bioactive CGRP within the vessel wall.  
Sensory neurons richly innervate multiple tissues throughout the body and the 
cardiovascular system is no exception. It has been known for some time that the 
cardiovascular system received peptidergic innervation, with particular reference to SP-
positive neurons. Following the discovery of CGRP in 1982, much work was done to 
characterise the distribution of this peptide throughout the peripheral nervous system and 
its target tissues. An initial, chiefly immunohistochemical study performed by Mulderry et al 
in 1985 in the rat showed that CGRP-positive nerve fibres had a widespread and close 
association around the vasculature, in a manner that was largely similar to the localisation of 
SP-positive nerves. Innervation of cardiac tissue was minimal but within the limit of 
detection (Mulderry et al., 1985). The following year, a similar yet more comprehensive 
study was performed in guinea pig that showed again that the large vessels, such as the 
carotid and thoracic aorta, received a rich innervation of CGRP-immunoreactive fibres and 
innervation appeared to decrease as one descended into the microvascular 
network(Lundberg et al., 1985; Dhall et al., 1986). Generally, the arteriolar side of the 
circulation appeared to receive a higher degree of innervation than that of the venous side. 
These nerve fibres extended to the tunica adventitia of the vessel and sometimes as far as 
the adventitial-medial border. The heart, once again, was demonstrated to receive sensory 
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innervation but more at the level of the epi- and endo-cardium, with little innervation in the 
myocardium itself (Uddman et al., 1986). 
Aside from neuronal sources of the peptide, however, a recent body of evidence has 
emerged to suggest that the production of CGRP is not strictly limited to sensory neurons 
and might in fact be directly synthesised by some cells of the blood and vasculature, as 
discussed in the subsequent section of this thesis. 
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1.2.4.2 Endothelial Cells 
There is accumulating evidence for expression of CGRP by the ECs that form the innermost 
layer of cells within blood vessels. This was first reported in 1992 by Cai et al who used 
immunogold labelling techniques to demonstrate that CGRP was expressed by around 10% 
of HUVECin situ (Cai et al., 1993). This finding was later confirmed in the rat carotid body 
using a similar detection technique, except that further evidence now pointed to the 
localisation of CGRP within the Weibel-Palade bodies of the EC, which might indicate a 
potential storage site for the peptide within the endothelium (Ozaka et al., 1997). Building 
upon this, CGRP was again shown to be localised to the Weibel-Palade bodies (and rough 
endoplasmic reticulum) of ECs obtained from conduit and resistance arteries of rats (Doi et 
al., 2001). 
However, expression of CGRP by the EC does not mean that it acts in a functionally relevant 
manner in this cell type. Since the identification of CGRP in the endothelium, it has been 
shown that acute heat stress (42°C) is capable of releasing CGRP from HUVEC, secondary to 
endothelial TRPV1 activation, an effect that was recapitulated in vivo(Ye et al., 2007). This 
source of CGRP was found to be beneficial in protecting the endothelium against damage 
induced by lysophosphatidylcholine. A subsequent paper also examining the effects of heat 
stress on the EC showed both alpha and beta CGRP mRNA expression by HUVEC that 
decreased with subsequent passaging of the cells. This was also released by TRPV1 
stimulation and protected the cells from damage by improving their overall viability (Luo et 
al., 2008a). Further to this, the α2-adrenoceptor agonist, clonidine, has been shown to 
induce gene transcription of both isoforms of CGRP and the release of CGRP from cultured 
ECs in a NO-dependent manner (Zhang et al., 2009). In summary, evidence for expression of 
CGRP by ECs is not as robust as that of sensory nerves, but certainly warrants further 
research in order to confirm existing findings and expand upon the role of local sources of 
CGRP within the vessel wall. 
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1.2.4.3 Endothelial Progenitor Cells 
EPCs have been of great interest of late to cardiovascular researchers, given their ability to 
repair damaged regions of endothelium and their contribution to neovascularisation 
processes. Early publications investigating links between CGRP and EPCs actually took 
advantage of CGRP’s potential vascular protection and stably transfected EPCs with CGRP 
DNA in an attempt to ameliorate pulmonary hypertension and associated pathology (Zhao et 
al., 2007). However, this study did not show endogenous expression of CGRP in this cell 
type. 
This issue has since been addressed. In 2010, Zhou et al showed that EPCs derived from 
human patients did indeed express αCGRP mRNA and this level was decreased significantly 
in EPCs derived from hypertensive patients (Zhou et al., 2010b). A similar phenotype was 
seen in EPCs derived from SHRs, where further mechanistic insight could be gleaned. Rats 
administered with a reported phytoalkaloid TRPV1 agonist, rutaecarpine(derived from the 
plant Evodia rutaecarpa), had dose-dependent increases in EPC αCGRP transcript that 
correlated with a reduction in EPC senescence (Zhou et al., 2010b). In a related study from 
the same group, human EPCs were maintained in culture for a period of up to 21 days, 
where it was shown that αCGRP mRNA expression increased up to day 10, where levels then 
declined. These cells also expressed mRNA for CGRP receptor genes. Once again, 
rutaecarpine was shown to inhibit EPC senescence induced by ATIIvia upregulation of the 
“anti-aging” hormone klotho and subsequent reduction in ROS-producing enzymes (Zhou et 
al., 2010a). Others have also confirmed expression and release of CGRP by EPCs (Fang et al., 
2011). Indeed, whilst it seems as though EPCs both synthesise and release CGRP following 
stimulation, the relevance of this source of the peptide is still unclear and, as such, EPCs 
represent an exciting new research avenue for CGRP. 
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1.2.4.4 Cells and Tissues of the Immune System 
Little is known about the endogenous expression of the peptide by the cells of the immune 
system. However, what is perhaps better established is the existence of a sensory nerve-
immune system synapse. Early histochemical studies performed in this field identified CGRP-
positive sensory nerve fibres infiltrating non-inflamed primary and secondary lymphoid 
tissues, including the thymus, bone marrow and many peripheral lymph nodes (Weihe et al., 
1991). Many of these fibres were found to be in close association with the vasculature 
feeding the tissue but perhaps more interestingly, some were found to innervate the tissue 
directly, unassociated with blood vessels. Within the lymph nodes themselves, non-vascular 
associated CGRP-positive fibres tend to be found within the paracortical T-cell regions of the 
lymph node. Other studies have highlighted a more intense interaction between the sensory 
nervous system and individual immune cells. Interactions have been documented with cell 
types including macrophages and epidermal Langerhans cells (Hosoi et al., 1993). More 
convincingly, there is a larger body of evidence to support direct interactions between 
sensory neurons containing CGRP and tissue mast cells (Stead et al., 1987; Weihe et al., 
1989; Naukkarinen and Jaervikallio, 1996). Given mast cell degranulation can lead to the 
release of a variety of substances that can sensitise and activate sensory nerves to lead to 
the perception of pain, this interaction is perhaps not so surprising (Steinhoff et al., 2000).  
However, despite interactions between CGRP-positive neurons and cells of the immune 
system, less is known about the endogenous expression of the peptide by these types of 
cells. Subsets of cells from both the adaptive and innate immune systems appear to express 
CGRP following stimulation. For instance, both B cells and T cells produce CGRP following 
mitogen/cytokine stimulation (Holzmann, 2011) and in some cases following stimulation by 
the endocannabinoid, anandamide (Li et al., 2009; Shi et al., 2012). Further to this, human 
monocytes have been shown to upregulate the expression of CGRP following stimulation by 
NGF or LPS.Additionally, upregulation of CGRP following LPS challenge could be attenuated 
with the coincubation of an anti-NGF antibody (Bracci-Laudiero et al., 2005). It was unclear, 
however, which isoform of CGRP these cells were expressing. In summary, our knowledge of 
the expression of CGRP by immune cells is quite weak, but there exists a level of interaction 
between the sensory nervous system and regions that are highly-populated with immune 
cells, indicating a possible regulatory role of sensory-derived neuropeptides in immune cell 
function. 
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1.2.5 Biological Activity 
1.2.5.1 Vascular 
CGRP is perhaps best known for its ability to act as a potent microvascular vasodilator. This 
effect was first characterised by Brain et al in 1985. This seminal study showed that CGRP 
was capable of dose-dependently relaxing strips of rabbit aorta within the picomolar to 
nanomolar range via a mechanism that appeared to be largely dependent on the presence 
of endothelial-dependent NO activity. Furthermore, femtomolar and picomolar injections of 
CGRP into the human volar skin of the forearm elicited a marked reddening of the injection 
site that lasted for several hours. This effect was attributable to increased microvascular 
vasodilatation and increased blood flow as a result (Brain et al., 1985). Early studies 
examining the effect of CGRP in human dermal blood flow showed similar results, whereby 
picomolar concentrations of peptide injected intradermally into the human forearm 
produced an erythema that was slow in onset but persisted up to 10-12 hours post-injection 
(Brain et al., 1986). CGRP’s ability to act as a potent microvascular vasodilator has been 
reproducibly demonstrated in a wide range of vascular beds (ranging from skin 
microvasculature(Brain et al., 1985) and gastric mucosa (Whittle et al., 1992)) from a wide 
range of model organisms and also humans(Russell et al., 2014). Shortly after the discovery 
of the vasodilator properties of CGRP, it was discovered that the peptide was able to 
increase the production of the second messenger cAMP in rat VSMCs via adenylate cyclase, 
whilst having no effect on the generation of cGMP in the same preparation (Kubota et al., 
1985). A more mechanistic insight into CGRP-induced arteriolar dilatation showed that the 
K+ATP channel blocker, glibenclamide, was capable of attenuating the CGRP relaxation 
response in mesenteric arteries obtained from the rabbit. In single cell preparations, CGRP 
was shown to hyperpolarise VSMC obtained from the same vessel type and that 
glibenclamide could also reverse this hyperpolarization (Nelson et al., 1990). The current 
thinking remains that conduit vessel vasodilatation mediated by CGRP is largely dependent 
on endothelial-derived NO production whilst the smaller resistance vessels are more 
dependent on the activity of K+ATP channels present within the VSMC(Russell et al., 2014). 
In keeping with the ability of CGRP to relax blood vessels in vitro and also at a local level in 
vivo, CGRP produces a hypotensive response when given intravenously. Integrated in vivo 
responses to CGRP were shown initially in guinea pigs, where intravenous injection of the 
peptide in anaesthetised animals produced hypotension and reflex tachycardia that 
mimicked the response to capsaicin infusion, providing an early hint at the link between 
 62 
TRPV1 activation and CGRP release (Lundberg et al., 1985). Subsequent experiments in rats 
further characterised the effects of in vivo CGRP infusion by measuring responses in 
conscious animals, where a similar response of vasodilatation coupled with increased heart 
rate was shown (Sirén and Feuerstein, 1988). Early experiments in man showed that i.v. 
infusion of 100μg CGRP produced a drop in blood pressure of around 20 mmHg that 
recovered after roughly two hours post-injection. This hypotensive response was 
accompanied by a reflex tachycardia and elevation of plasma catecholamines (Gennari and 
Fischer, 1985). These results are in contrast to when CGRP is delivered 
intracerebroventricularly, which leads to enhanced sympathetic outflow and, as a result, 
marked hypertension and tachycardia in rats (Amara et al., 1983).  
Given that CGRP acts as a very potent vasodilator, it is certainly plausible that it is capable of 
being released to act as a homeostatic controller of physiological blood pressure. However, 
the current paradigm suggests that CGRP has little role to play in baseline blood pressure 
regulation and appears to become more important as the cardiovascular system is exposed 
to stress, such as during a pre-hypertensive state. Early studies investigating a role for CGRP 
in blood pressure maintenance were mixed, owing to differences in the generation of “CGRP 
knockout” mice. Groups using mice with the sole deletion of CGRP found no change in 
baseline cardiovascular parameters (Lu et al., 1999), whilst other groups using a mixed 
calcitonin/ CGRP model found a dramatic and significant elevation in resting blood pressure 
of around 40 mm Hg (Gangula et al., 2000). As a result of the mixed outcome, however, 
further studies have been performed, taking advantage of other investigative tools. For 
example, administration of CGRP receptor antagonists to anaesthetised rats resulted in no 
change in systemic blood pressure (Arulmani et al., 2004; Lynch et al., 2010) and, further, 
administration of CGRP function-blocking antibodies to conscious rats was shown to have 
little effect on either blood pressure or heart rate (Zeller et al., 2008). Providing more 
convincing evidence still, Petersen et al showed that in a clinical trial for the use of 
BIBN4096BS as an anti-migraine therapy, healthy patients that received the antagonist 
treatment had no detectable change in haemodynamic parameters (Petersen et al., 2005). 
However, it remains to be seen what effect CGRP receptor antagonists will have on 
migraineurs with existing cardiovascular complications. 
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1.2.5.2 Cardiac 
Although the best-characterised effects of CGRP have been studied within the context of the 
vasculature, there is undoubtedly a role for CGRP in maintaining cardiac homeostasis, 
particularly under times of stress. Prior to the functional characterisation of CGRP in 
cardiovascular tissues, it was known that CGRP-containing nerve fibres were present in the 
heart, with a particularly dense innervation of the coronary arteries, papillary muscle and 
also excitatory regions such as the sinoatrial and atrioventricular node (Mulderry et al., 
1985). Other experiments investigating the effect of capsaicin on the spontaneously beating 
guinea pig auricle showed that application of the TRPV1 agonist capsaicin resulted in a 
positive chronotropic and inotropic response from the atrial tissue (Lundberg et al., 1984). 
This was an effect that could not be blocked by antagonists of any classical transmitter, 
including SP and ATP, hinting at the presence of a yet unknown transmitter being released 
from sensory nerves into cardiac tissue. It wasn’t long before the transmitter was identified 
as CGRP (Lundberg et al., 1985). In fact, since the identification of CGRP as a cardiac 
signalling molecule, it has been shown that it is capable of acting as a very potent 
endogenous mediator of preconditioning – the phenomenon whereby pre-exposure of the 
heart to a preconditioning agent can attenuate subsequent damage incurred by an 
ischaemic episode (Li et al., 2000). In the Langendorff-perfused rat heart, exogenous CGRP 
mimics preconditioning induced by transient ischaemia via ligation of the left anterior 
descending coronary artery. Furthermore, application of the small molecule CGRP 
antagonist BIBN4096BS inhibited the preconditioning response from either exogenous CGRP 
or transient ischaemia, indicating that CGRP plays an important role in the physiological 
response to myocardial ischaemia (Chai et al., 2006). The overall clinical weight of CGRP’s 
role in mediating the preconditioning response has still to be evaluated. However, it may be 
especially relevant in myocardial ischaemia suffered by diabetic patients. In experimental 
models of diabetes, the ischaemic preconditioning response is markedly attenuated (Lu et 
al., 2001b), an effect that can be reversed via adenoviral transfection of CGRP gene to 
myocardial tissue (Zheng et al., 2011). In addition, deletion of the TRPV1 gene produces a 
similar loss of preconditioning in the heart, suggesting that the beneficial effects of CGRP are 
secondary to TRPV1 stimulation and neuropeptide release (Zhong and Wang, 2007). The 
ability of CGRP to produce a preconditioning effect also appears to be attenuated with the 
advancement of age (Lu et al., 2001a). Therefore, as both diabetes and ageing are associated 
with sensory nerve degeneration, it is conceivable that a loss of myocardial sensory 
innervation is a key process in increasing susceptibility to myocardial damage following 
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ischaemia. Furthermore, in cellular models of cardiac hypertrophy, CGRP has been shown to 
inhibit norepinephrine-induced apoptosis of cardiomyocytes, suggesting a further level of 
protection aside from increased perfusion (Zhao et al., 2010). 
 65 
1.2.5.3 Immune System 
During inflammatory responses, both local and systemic levels of CGRP rapidly increase in 
vivo. The overall result of this increase appears to be to inhibit the activity of cells of the 
immune system. This anti-inflammatory effect has been shown in a series of in vitro 
experiments. Peritoneal macrophages isolated from mouse were stimulated with LPS to 
encourage cytokine production, among which were IL-10 and IL-1β. Co-stimulation of these 
macrophages with LPS and CGRP facilitated the exacerbated production of IL-10, largely 
considered to be ‘anti-inflammatory’, and decreased the production of IL-1β (considered 
‘pro-inflammatory’) (Torii et al., 1997). This enhanced production of IL-10 by CGRP has also 
been confirmed in isolated human PBMCs (Fox et al., 1997). The elevation in IL-10 
concentration has been suggested by both groups to inhibit antigen presentation by 
professional antigen-presenting cells. However, others argue that this inhibition of 
immunocyte function occurs through an IL-10-independent pathway and instead occurs 
through CGRP receptor-mediated activation of protein kinase A (PKA) and subsequent 
downstream activation of the transcription factor inducible cAMP early repressor (ICER) 
(Harzenetter et al., 2007). However, it should be noted that these studies utilized different 
cell types to analyse CGRP-dependent immune cell suppression and this may partially 
explain discrepancies in the reported results. 
The aforementioned studies were performed in isolated cultures of cells of the innate 
immune system and therefore are not necessarily representative of the integrated immune 
system in vivo. Thus, several studies have been performed in models of infection, in 
particular sepsis, to assess the role of CGRP in modulating the body’s response to systemic 
inflammation. A 2005 study by Gomes et al showed that treating septic mice with CGRP 
improved their survival post-endotoxaemia by limiting peritoneal neutrophil invasion and 
upregulation of pro-inflammatory plasma cytokines such as keratinocyte-derived chemokine 
(KC) and TNFα, whilst encouraging the circulation of anti-inflammatory cytokines IL-6 and IL-
10 (Gomes et al., 2005). In a similar model of endotoxin-induced hepatic dysfunction, CGRP 
was shown to be protective via induction of ICER activity and subsequent reduction in pro-
inflammatory cytokine expression (Kroeger et al., 2009). Whilst difficult to interpret the 
direct role of CGRP, studies performed in receptor activity modifying protein 1 (RAMP1)-
deficient mice (a key molecule related to the CGRP receptor, discussed in a later section) 
have supported the notion that mice lacking this part of the CGRP receptor are more 
susceptible to tissue immune cell infiltration and increases in plasma inflammatory cytokines 
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following endotoxaemia and systemic polymicrobial sepsis (Tsujikawa et al., 2007; Jusek et 
al., 2012). 
Whilst there exists a body of evidence supporting an immunosuppressant role for CGRP in 
vitro and in vivo, it is relatively unclear at this stage how and if this neuropeptide influences 
leukocyte trafficking through the endothelial monolayer and into the surrounding tissue. An 
early study investigating this process by Sung et al showed that stimulation of quiescent 
HUVEC monolayers with CGRP facilitated adhesion of U937 monocytic cells and human 
PBMCs under static conditions (Sung et al., 1992). This pro-adhesive phenotype was 
subsequently confirmed for neutrophils by a separate group in a similar model (Zimmerman 
et al., 1992). In contrast to this, Huang et al showed that HUVEC activated by LPS and co-
stimulated with CGRP resulted in an inhibition of transmigration of neutrophils and 
mononuclear cells through the endothelial monolayer in a chemotaxis assay under similar 
static conditions (Huang et al., 2011). This inhibition of migration was attributable to 
attenuation in the production of pro-inflammatory chemokines CXCL8, CXCL1 and CCL2 via 
stabilization of the transcription factor NFκB in the cytosol, thus preventing its 
transmigration into the nuclear compartment of the cell to promote gene transcription 
(Huang et al., 2011). Additionally, acute stimulation of LPS- and formyl-met-leu-phe-treated 
neutrophils and monocytes with exogenous CGRP lowered CD11b protein expression by 
both cell types (2003). Furthermore, treatment of LPS-activated microglia with CGRP 
resulted in the reduction of their capacity to produce pro-inflammatory cytokines such as IL-
6 and TNFα and chemokines such as MCP-1 (Consonni et al., 2011). These data may point to 
a role of CGRP in regulating leukocyte transmigration on the side of the white blood cell. In 
anin vivo model of peripheral ischaemic preconditioning, CGRP was shown to inhibit 
leukocyte rolling and adhesion in reperfused vessels, to a similar extent to that of 
preconditioned vessels, indicating it may be a key mediator of leukocyte trafficking in this 
setting (Hartmann et al., 2011) and in ethanol-induced preconditioning (Kamada et al., 
2006). Put together, however, there is a general absence of information regarding the role 
of CGRP in the very initial stages of leukocyte adhesion and transmigration and this certainly 
warrants future research in this area. 
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1.2.6 CGRP and Ageing 
The ageing process involves a complex series of interactions between multiple organ 
systems that results in a deterioration of normal physiological function and an inability to 
properly maintain whole-body homeostasis. Sensory neurons are not exempt from the 
gradual deterioration in function and, as such, it is important to consider some of the 
changes that may happen to these cells if we wish to understand how CGRP bioactivity may 
change with advancing age. This is especially pertinent, given that sensory nerves are 
considered to be the biggest source of CGRP within the body. Furthermore, if it is true that 
CGRP is an important mediator of cardiovascular health, any change in bioactivity as part of 
the ageing process could result in a change in cardiovascular phenotype, for better or for 
worse, and as such, CGRP may represent a valid therapeutic target. 
Peripheral neurons in general are negatively affected by the ageing process in terms of their 
ability to conduct action potentials and to sprout collaterals in regenerating fibres (Verdú et 
al., 2000). One of the first studies investigating the developmental changes that occur to 
peptidergic sensory neurons was performed in the ageing guinea pig, where it was 
discovered that density of peptidergic neurons surrounding the mesenteric and carotid 
arteries increased with foetal development, with a peak at birth. CGRP-ergic nerve plexuses 
then declined with age, waning to about half-maximal density once the animal had reached 
around 2 years of age (Dhall et al., 1986). Interestingly, a study investigating peptidergic 
innervation of the ageing rat aorta showed that CGRP-positive neuronal fibres were present 
in animals younger than 6 months, but gradually disappeared to complete absence when 
animals reached one year of age (Connat et al., 2001). Conversely, a separate study has 
indicated no change in DRG αCGRP mRNA expression in rats aged 6 months versus 24 
months (Lu et al., 2002). Therefore, it is still unclear what happens to peptidergic 
perivascular innervation as time progresses. However, some aspects of neuronal physiology 
are compromised as part of ageing. As CGRP is a peptide that is synthesised directly by the 
nucleus (unlike small molecules that require complex metabolic pathways for synthesis, 
often present within the cytosol) but has the majority of its effects when released from the 
nerve terminal, it requires axoplasmic transport from the cell body to the axon terminals by 
means of the neuronal microtubular network. The rate of active transport from nucleus to 
terminal is significantly diminished with age and this may represent a reduction in CGRP 
release as age advances (Fernandez and Hodges-Savola, 1994). 
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In addition to stored CGRP, serum levels of released CGRP have been noted to both increase 
and decrease with advancing age. One possible reason why serum levels of CGRP are seen to 
be increased as age increases may be related to the change in CALC I gene splicing in favour 
of CGRP rather than calcitonin (recall that CGRP was first discovered in the thyroid tissue of 
ageing rats and isolated in elderly humans from thyroid carcinoma cells). Increased 
production of CGRP by a highly-vascularised endocrine gland such as the thyroid would 
presumably explain increases in plasma concentrations (Kendall et al., 1986; Wimalawansa, 
1991). However, as circulating levels of CGRP are so low, it is unlikely that this source of 
peptide has any significant biological effect. It seems more likely that controlled localised 
release of CGRP is more important than this suggested ‘spillover’ and as the local sources 
are more often seen to be reduced than increased as one ages, it is possible that a very 
valuable store of CGRP is being lost as part of the ageing process. 
Functional experiments investigating changes in CGRP bioactivity with age have been 
published, though are often somewhat confounded by other aspects, such as the induction 
of experimental hypertension in laboratory animals. As such, results obtained cannot be 
directly attributed to ageing alone. Nonetheless, some interesting results have been 
uncovered. In aged female rats, circulating levels of CGRP have been shown to decline 
slightly in comparison to younger animals and the content of bioavailable CGRP found within 
the mesenteric vascular bed shows an even more profound drop. This reduction in CGRP 
could be reversed with supplementation of female sex steroid hormones (Gangula et al., 
2009). Several longitudinal studies have also been performed utilising the SHR. In these 
animals, αCGRP mRNA expression within DRG neurons was found to decrease as the animal 
aged whilst no change in expression was found in normotensive rats (Yamaga et al., 2001). 
This decline in CGRP mRNA expression in hypertensive animals appears to be accompanied 
by a measurable decrease in CGRP-positive sensory nerves that innervate the mesenteric 
resistance arteries (Kawasaki et al., 1990a; 1991). This reduction in neuronal density was 
found to result in an overall decrease of releasable CGRP following peripheral nerve 
electrical stimulation (Kawasaki and Takasaki, 1992) and also following capsaicin stimulation 
(resulting in the activation of TRPV1 channels and subsequent exocytosis of CGRP-loaded 
vesicles) (Sun et al., 1998). There has been proposed a strong interaction between the 
angiotensin signalling system and CGRP and its receptors within the SHR model. One 
longitudinal study showed that long-term inhibition of AT1Rs using selective antagonists, 
such as temocapril and losartan, prevented the reduction in perivascular sensory nerve 
innervation in a blood pressure-dependent manner (Hobara et al., 2005). Thus, it is possible 
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that as hypertension becomes more prolonged as one ages, this has a negative effect on 
CGRP-containing nerves and the amount ofbioavailiable CGRP. 
CGRP-containing sensory nerves also appear to be important in governing the cardiac 
preconditioning response to intermittent periods of ischaemia, in order to prepare for an 
impending ischaemic episode that may precede myocardial infarction. It is true that older 
humans are more susceptible to myocardial infarction and isolated heart preparations from 
older laboratory animals appear to lose this preconditioning response (Lu et al., 2001b; Hu 
et al., 2002). This has been attributed to a reduction in release of endogenous stores of 
CGRP found within the heart and, curiously, a reduction in the ability of exogenous CGRP to 
also have a protective effect (Lu et al., 2001a). A similar impairment in CGRP bioactivity with 
increasing age has been demonstrated in vascular preparations from ageing rats. The ability 
of CGRP to relax aortic and caudal artery rings was significantly impaired as the animal grew 
older and intravenous injections of CGRP to older animals resulted in an attenuated 
hypotensive blood pressure response (Chan and Fiscus, 2002). A similar reduction in 
sensitivity to CGRP has been shown in the isolated perfused mesenteric bed in both 
normotensive and hypertensive ageing rats, though this effect was not exclusive to CGRP as 
vasodilatation to other relaxing agents was also impaired (Amerini et al., 1994). 
It is still relatively unclear how the expression, release and bioactivity of CGRP changes with 
advancing age. This lack of clarity mainly arises from the use of tissue derived from different 
species of laboratory animal, differing lengths of longitudinal study employed and the 
majority of information stemming from the use of the SHR. That said, enough information 
has been uncovered to warrant future research into this area, particularly as the current 
consensus appears to be that local stores of CGRP are depleted as age advances and this 
results in a decrease in its bioactivity. If CGRP is indeed an important mediator of 
cardiovascular (and otherwise) health, then it is conceivable that we are losing a very 
important protective mediator and this may present with a viable future therapeutic 
strategy. 
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1.2.7 CGRP and Hypertension 
The majority of our knowledge concerning the role of CGRP as a potential protective 
mediator working within the cardiovascular system comes from preclinical models of 
experimental hypertension. Indeed, our understanding has deepened considerably with the 
development of CGRP knockout mice, which will be discussed further in this section. 
1.2.7.1 Human Studies 
Circulating levels of CGRP are often attributed to overspill from sensory nerves and plasma 
levels are not considered to be a major source of biologically relevant peptide. However, this 
reservoir represents a suitable means to investigate changes in CGRP dynamics under 
different (patho)physiological and experimental settings. With relevance to hypertension, it 
has been shown that a subpopulation of Chinese citizens who possess a single nucleotide 
polymorphism in the CALC I gene (T-692C) were more likely to have essential hypertension 
than those who possessed the normal allele (Luo et al., 2008b). Measurement of plasma 
levels of CGRP in hypertensive patients has provided mixed results, though the majority of 
studies seem to favour a reduction in circulating CGRP from patients with essential 
hypertension versus normotensive controls (Tang et al., 1989; Portaluppi et al., 1992; Wang 
et al., 2007b; Li et al., 2009). One study has shown that CGRP levels tend to correlate 
positively with blood pressure and levels were highest in the case of hypertension secondary 
to primary aldosteronism or phaeochromocytoma. Of the patients suffering from secondary 
hypertension, elevated levels of CGRP could be reversed following adrenalectomy (Masuda 
et al., 1992). In the setting of severe hypertension and pre-eclampsia, levels have been 
shown to be lower than normotensive controls (Edvinsson et al., 1989; Dong et al., 2006). 
Other studies have shown no change in circulating plasma levels of the peptide, though it is 
of note that these studies were carried out in borderline and mildly-hypertensive patients, 
where the role of CGRP in regulating the hypertensive response may not have been fully 
realised (Schifter et al., 1991; Lemne et al., 1994). At the vascular level, reports have shown 
that hypertensive arterioles can either have a significantly blunted response to exogenous 
CGRP application (measured in vivo by laser Doppler flowmetry) (Lindstedt et al., 2006)  or 
an augmented response to the peptide (measured ex vivovia myography) (Lind and 
Edvinsson, 2002). 
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1.2.7.2 Rodent Studies 
Whilst human studies can be enlightening, they often lack mechanistic insight and this is 
where experiments performed in animal models can be of great utility. Certainly, this is the 
case for investigating the role of CGRP within the cardiovascular system, with respect to the 
initiation and progression of pathophysiology associated with hypertension. Investigations 
into circulating levels of CGRP in humans have yielded mixed results, though the general 
consensus seems to point to a decline in plasma levels in hypertensive patients. Using 
animal models, CGRP dynamics can be investigated as part of this disease process, and 
changes in tissue expression measured, which might be a more relevant analysis. Extensive 
work has been carried out in this area and a similar mixed result has emerged, though such 
discrepancies in findings may be attributed to the use of different models, analysis of various 
tissues and examination of different experimental timepoints. As previously stated, the 
majority of studies tend to find a general reduction in CGRP bioavailability or bioactivity, to 
one extent or another. In the SHR, laminae I/II spinal cord expression of CGRP is diminished 
(Westlund et al., 1991), mRNA expression is decreased (Supowit et al., 1993; Kawasaki et al., 
2000; Li et al., 2008) and the density of CGRP-positive sensory neurons innervating the 
vasculature appears to decrease, along with their ability to release peptides into the vascular 
environment (Kawasaki et al., 1990b; 1990a; 1991). Levels of CGRP have been shown to be 
decreased in other models of hypertension, such as hypoxia-induced hypertension (Tjen-A-
Looi et al., 1998), Dahl-salt (Katki et al., 2001) and phenol-induced neurogenic hypertension 
(Deng et al., 2004a). In general, two-kidney-one-clip (2K1C) rats appear to have elevated 
CGRP expression, both at the mRNA level within the DRG and when measured via 
immunoreactivity in the plasma (Deng et al., 2003; Qin et al., 2007). Interestingly, a study 
has been published examining both the 2K1C model of renovascular hypertension and the 
SHR model. This study showed that CGRP plasma concentrations were lowered in the SHR 
versus control WKY but in the 2K1C model, plasma levels were shown to be elevated (Li et 
al., 2009). This study highlights the importance of considering which hypertensive model to 
use in order to investigate CGRP-dependent effects, as changes in CGRP activity may be 
strongly dependent on the nature of the hypertensive stimulus, rather than just general 
hypertension itself. Others have shown no change in CGRP bioavailability throughout 
hypertension in deoxycorticosterone acetate (DOCA)-salt (Supowit et al., 1995), subtotal 
nephrectomy (Supowit et al., 1998) and L-NAME (Gangula et al., 1997) models of 
hypertension. 
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With this in mind, some groups have studied the relative importance of endogenous ATII in 
driving changes in CGRP expression and activity during hypertension. Indeed, it has been 
shown that ATII can directly inhibit the release of CGRP from perivascular sensory neurons 
within the mesenteric circulation, via its action on AT1Rs. This effect was only present within 
SHRs and not in the normotensive controls (Kawasaki et al., 1998). Further to this, long-term 
treatment of SHRs with ACE inhibitors or AT1 receptor blockers was shown to be effective in 
restoring electrically-induced CGRP release and vasodilatation to a normal level (Kawasaki et 
al., 1999), improving CGRP DRG mRNA and circulating plasma expression (Kawasaki et al., 
2003; Shi et al., 2012) and reducing perivascular sensory denervation (Hobara et al., 2005). 
As well as being a potent vasodilator in vivo under normotensive conditions, CGRP can also 
act as a vasodilator during hypertension, first demonstrated in anaesthetised SHRs in 1989 
(Xu et al., 1989). Its potency as a vasodilator initially appeared to be unaltered by systemic 
blood pressure (Ando et al., 1990). However, isolated pial vessels from SHR appear to show 
increased sensitivity to the peptide (Hong et al., 1997) and the in vivo hypotensive response 
to the peptide was also increased in SHRs (Yamada et al., 1998). More recently it has been 
shown that in a subtotal nephrectomy model of hypertension, both the hypotensive and 
vasodilator response in isolated vessels to exogenous CGRP was increased, an effect that 
was attributable to increased vascular receptor component protein (RCP, a CGRP receptor-
associating protein) expression, thus boosting receptor-dependent signalling(Supowit et al., 
2011). One other study has found a similar result in ATII-induced hypertension in rats, where 
the vasodilator response to CGRP was improved in hypertension, owing to an increased 
expression of calcitonin receptor-like receptor (CLR) and RAMP1 (molecules required in 
forming CGRP receptors, see later section for more detail)(Li and Wang, 2005). 
Administration of CGRP receptor antagonists have no effect on the basal blood pressures of 
Sprague-Dawley rats but when these animals are rendered hypertensive via an array of 
techniques including L-NAME (Gangula et al., 1997), deoxycorticosterone-salt delivery 
(Supowit et al., 1997) and subtotal nephrectomy (Supowit et al., 1998), antagonism of the 
CGRP receptor further exacerbates experimental hypertension, strengthening the idea that 
CGRP may become more important as the cardiovascular system becomes stressed. In a 
similar fashion, targeted blockade of CGRP receptor gene expression, CGRP peptide 
immunoneutralisation and CGRP receptor antagonism have been shown to worsen 
pulmonary hypertension (Tjen-A-Looi et al., 1992; Qing and Keith, 2003). Furthermore, 
sensory nerve degeneration induced by neonatal capsaicin treatment has been shown to 
exacerbate experimental hypertension (Tjen-A-Looi et al., 1998; Deng et al., 2003). A handful 
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of investigations have been carried out employing the use of thephytoalkaloid rutaecarpine. 
Rutaecarpine is a reported TRPV1 agonist that can facilitate the release of CGRP to produce 
vasodilatation that is inhibited by TRPV1 antagonism, CGRP receptor antagonism and 
depletion of neuropeptide stores by capsaicin pretreatment (Hu et al., 2003). Chronic 
rutaecarpine treatment to renal phenol injury hypertensive rats reduces blood pressure in 
line with increased CGRP expression and release (Deng et al., 2004b). In addition to its blood 
pressure lowering effect, rutaecarpine has also been shown to prevent adverse arterial 
remodeling following the 2K1C procedure (Qin et al., 2007) and to prevent aberrant platelet 
activation in SHRs (Li et al., 2008), both phenotypes thought to be mediated by CGRP 
activity. 
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1.2.7.3 Transgenic Studies 
The development of genetically engineered mouse models has significantly advanced our 
understanding of the role of CGRP in the cardiovascular system, and otherwise. Owing to the 
complexity of the receptor system and the duplicity of the CGRP genes, there exists many 
potential ways by which one can investigate this system. Most commonly used is the CGRP 
mouse. The first study to publish an investigation into the endogenous cardiovascular 
regulatory role of CGRP was by Lu et al in 1999. This group showed that both blood pressure 
and heart rate were unaffected by CGRP deletion under resting conditions. Following a 
forced swimming exercise, blood pressure was indeed found to be raised but with no 
difference between WT and KO animals. Interestingly, however, there was a small but 
significant decrease in the heart rate of mice lacking CGRP versus WT following exercise, 
though this is a phenomenon yet to be expanded on. In addition, both groups of mice 
appeared to have normal baroreceptor activity (Lu et al., 1999). This study found no level of 
developmental compensation from the related peptide, βCGRP, following αCGRP removal. 
Conversely, a strikingly different result was obtained by Gangula et al, published in the 
Journal of Hypertension mere months after Lu et al. This group showed increased blood 
pressures in both male and female αCGRP-null mice under baseline conditions (systolic 
blood pressure of 120 mm Hg in WT males versus 160 mm Hg in KO males) (Gangula et al., 
2000). The hypertensive phenotype of these mice was shown to be as a result of 
hyperactivation of the renin-angiotensin system, specifically an increase in renin expression 
(Li et al., 2004). Such a stark difference in findings may be attributed to the generation of 
different types of KO mice by each group. For instance, generation of the KO used by Lu et al 
involved the targeted disruption of exon 5 of the CALCI gene with a neomycin resistance 
cassette, in order to remove CGRP but not calcitonin mRNA synthesis. On the other hand, 
the KO mice studied by Gangula et al are deficient in both calcitonin and αCGRP. Therefore, 
it is difficult to interpret studies published by this group using these mice, given any 
phenotype observed could be as a result of calcitonin deletion, αCGRP deletion or, indeed, 
an interaction resulting from deletion of both genes. Others have studied CGRP KO mice 
bred onto genetic backgrounds other than C57BL/6. For example, Oh-Hashi et al (2001) and 
Kurihara et al (2003) have generated αCGRP KO mice bred onto a 129/Sv x C57BL/6 hybrid 
background and these have also been shown to be hypertensive, owing to an increase in 
sympathetic nervous system activity (Oh-hashi et al., 2001; Kurihara et al., 2003). With these 
disparate results in mind, it would be prudent to choose a model similar to that of Lu et al, 
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using a mouse that solely carries αCGRP and not calcitonin deletion, that shows no baseline 
changes in haemodynamic parameters. 
Despite an unlikely role for CGRP in the regulation of cardiovascular parameters under 
resting conditions, there is a rapidly growing body of evidence to suggest that the peptide 
may become more important as the cardiovascular system becomes stressed, particularly 
within the setting of hypertension. As previously discussed, several studies have shown an 
eminent role for CGRP in the pathophysiological response to high blood pressure. However, 
these studies did not take advantage of the CGRP-null mouse. In 2005, Supowit et al utilized 
the CALC I KO to investigate its role in DOCA-salt-induced hypertension. Whilst they 
reproduced initial findings of elevated baseline blood pressure in these mice, they also 
found that αCGRP-deficient animals had higher blood pressures following intervention. This 
was accompanied by histopathological changes to both cardiac and renal tissues, with an 
increase in urinary microalbuminuria, an indicator of renal dysfunction (Supowit et al., 
2005). A follow-up study from this group showed an increase in vascular inflammatory 
markers within the kidneys of CGRP KO in this model (Bowers, 2005). Recently, this group 
has addressed whether the inflammatory phenotype they see in this model is pressure-
dependent or –independent, by normalising elevations in blood pressure using hydralazine. 
Whilst hydralazine delivery did improve blood pressure in the hypertensive animals, it had 
no effect on the renal inflammation seen in the CGRP KO. This was measured in terms of 
macrophage infiltration and quantification of renal cytokine expression (Li et al., 2013a). 
Thus, whilst one must be cautious of the conclusions these studies make, owing to the use 
of the CALC I KO, it is possible that CGRP has an important role in protecting the kidney 
during hypertension. To provide clarity, we have recently shown that in an ATII infusion 
model of experimental hypertension, mice solely lacking αCGRP had exacerbated 
hypertension versus WT. This phenotype was coupled with increased adverse vascular 
remodeling and when hypertension was extended from 14 days to 28 days, we observed a 
loss of vascular eNOS expression, an indicator of endothelial and vascular dysfunction 
(Smillie et al., 2014).  
Others have manipulated RAMP1 expression in mice to determine the relevance of CGRP in 
cardiovascular health. Owing to the ability of AM to bind to RAMP1-CLR receptors, this is not 
an ideal model to use to interrogate CGRP-dependent responses and this must be kept in 
mind, though RAMP1-CLR is typically thought of as the CGRP receptor. The first study to 
examine the role of RAMP1 in cardiovascular regulation was published in 2007, where the 
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RAMP1 gene was deleted in mice. These animals were found to be spontaneously 
hypertensive, similar to the phenotype observed in CALC I KO mice (Tsujikawa et al., 2007). 
Conversely, others have studied the role of RAMP1 via its global overexpression. At baseline, 
the RAMP1 overexpressers were not found to differ in terms of cardiovascular phenotype 
versus WT animals. However, once rendered hypertensive via ATII infusion, the RAMP1 
transgenic animals were dramatically protected from the induction of hypertension, only 
becoming very mildly hypertensive at around 2 weeks of ATII infusion (WTs developed 
hypertension on day 3). This protection could be removed by supplementation of the CGRP 
receptor antagonist, CGRP8-37. Furthermore, RAMP1 overexpressers appeared to have 
improved baroreceptor function and thus were better able to regulate their blood pressure 
in face of a vasopressor stimulus (Sabharwal et al., 2010). In a separate study, control mice 
were found to develop endothelial dysfunction following ATII infusion, measured in terms of 
vasodilatory responses in isolated arteries to acetylcholine. However, RAMP1 transgenic 
mice were not found to have any degree of endothelial dysfunction (Zhang and Russo, 
2010). These results help bolster the key role CGRP may play in hypertension. 
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1.2.8 CGRP Receptors 
1.2.8.1 History of the CGRP receptor 
Early evidence for the existence of a receptor for CGRP was largely accumulated via 
radioligand binding studies in a wide range of tissue preparations. Research at this stage was 
led by evidence showing that CGRP peptide expression was highest in regions of the central 
nervous system. Studies using rat tissue showed moderate expression of “specific” CGRP-
binding substances (bearing in mind current knowledge of CGRP’s affinity for many related 
receptor subtypes), with a notably high binding capacity in the spinal cord and pituitary 
gland (Goltzman and Mitchell, 1985). Binding of CGRP to regions of the central nervous 
system was further demonstrated in human tissue, where a similar high level of binding was 
shown in regions of the spinal cord, particularly in the dorsal horn (Tschopp et al., 1985). 
Headway was also made into probing the binding of CGRP to receptors expressed by cells of 
the cardiovascular system. Hirata et al showed in 1988 that radiolabeled CGRP had the 
capacity to bind to VSMCs isolated from rat and also ECs derived from bovine aortae. In 
addition to binding assays, the authors of this paper further characterized the significance of 
CGRP binding to a receptor by showing that the binding event elicited the stimulation of 
adenylyl cyclase activity in both cell types (Hirata et al., 1988). Following from this, Coupe et 
al demonstrated that both guinea pig and human heart tissue had the capacity to specifically 
bind CGRP, with the highest binding density concentrated within the coronary arteries 
(Coupe et al., 1990). 
Whilst autoradiographic studies can be informative of where a ligand is binding and 
therefore where a receptor for such a ligand is likely to be located, they shed little to no light 
on the nature of the receptor itself. Thorough characterization of a receptor can only be 
properly carried out through the deployment of a “pharmacological toolkit”, encompassing 
specific agonists and, more importantly, antagonists of the receptor in question. Much of 
the early quantitative knowledge of the CGRP receptor stemmed from the use of two 
distinct biological preparations: the guinea pig atria and rat vas deferens. In both of these 
preparations, full length human CGRP was demonstrated to produce a positive inotropic 
response in a concentration-dependent manner (Dennis et al., 1989). However, the use of 
CGRP fragments and linearised/cyclised derivatives of the CGRP peptide revealed 
discrepancies in activity between tissues. The linearised CGRP analogue 
[Cys(ACM)2,7]hCGRP was found to be a potent agonist in the rat vas deferens bioassay, but 
not guinea pig atrial preparations (Dennis et al., 1989). Later discovery of a truncated form 
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of the peptide sequence, CGRP8-37, helped advance the field of CGRP receptor 
pharmacology. It was shown to be capable of binding to CGRP receptors present in rat liver 
(Yamaguchi et al., 1988) and could concentration-dependently inhibit receptor binding of 
full length CGRP and its ability to generate a response, as measured by adenylyl cyclase 
activity (Chiba et al., 1989). Thus, CGRP8-37 was validated as a useful tool in probing the CGRP 
receptor and its utilization by Dennis et al in a subsequent study was pivotal in helping to 
describe CGRP pharmacology. CGRP8-37 was found to function as an antagonist to the effects 
of full-length CGRP only in the guinea pig atria and not in the rat vas deferens (Dennis et al., 
1990). This pointed to the existence of two (or more) distinct populations of CGRP receptor, 
subsequently defined as ‘CGRP1’ and ‘CGRP2’. CGRP1 receptors were classified according to 
their ability to be antagonised with high potency to CGRP8-37 (PKb > 7.0) whilst CGRP2 
receptors were characterised by low potency antagonism from CGRP8-37 (PKb< 6.0). Whilst 
the existence of such receptor heterogeneity has been debated for many years, it is now 
accepted that only one true CGRP receptor exists and the apparent existence of additional 
receptors may be explained by the peptide having affinity for other related receptors of 
distinct molecular composition, such as the amylin receptor AMY1 (Hay et al., 2008). 
Evidence supporting the finer details of the CGRP receptor, in particular its molecular 
composition, was more difficult to come by due to the complex nature of the receptor itself. 
Previous knowledge of the calcitonin receptor gene sequence informed early knowledge of 
the CGRP receptor. Initial work by Chang et al identified a novel cDNA that encoded a seven 
transmembrane domain protein that coupled to adenylyl cyclase but was unresponsive to 
CGRP exposure (Chang et al., 1993). Soon after this, Njuki et al isolated two rat clones that 
possessed high sequence homology to known calcitonin receptor sequences yet did not 
possess the tissue distribution fingerprint expected of the calcitonin receptor. Instead, these 
sequences were highly expressed in regions of the lung, in particular in close association 
with the pulmonary vessels. This discovery led to the christening of the term ‘calcitonin 
receptor-like receptor’ or ‘CLR’ (Njuki et al., 1993). Subsequent work performed by 
Flühmann et al uncovered a homologous structure to the rat CLR sequence in human 
cerebellum. Transfection of this cDNA into a cellular expression system and stimulation of 
cells by CGRP resulted in no measurable signal in terms of adenylyl cyclase activity 
(Flühmann et al., 1995). The resultant protein was found to be 461 amino acids in 
length,with seven transmembrane domains as part of its structure. The protein was found to 
share 96% homology with the previously identified rat protein and around 56% homology 
with human calcitonin receptor (Flühmann et al., 1995). Frustratingly, whilst this receptor 
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was initially shown to be unresponsive to CGRP stimulation, researchers were in fact looking 
at the correct protein but were unaware of the complexity of the receptor as a whole.  
This oversight only became apparent in 1996 when Aiyar and co-workers discovered that the 
same receptor cloned by Chang and Flühmann, when expressed in HEK293 cells (as opposed 
to OK and COS-7 cell lines), produced a sixty-fold increase in cyclic AMP (cAMP) generation 
over baseline following CGRP stimulation, which was blocked by CGRP8-37(Aiyar et al., 1996). 
This gain of function was clearly attributable to a factor endogenously expressed by HEK293 
but not in COS-7 that, when co-expressed with the CLR, could generate a signal in response 
to CGRP. The identity of this protein was dissected in a seminal paper by McLatchie et al in 
1998. By generating a cDNA library from SK-N-MC neuroblastoma cells (known to bind and 
respond to CGRP), the authors transfected the clones into a Xenopus oocyte cystic fibrosis 
transmembrane regulator assay and measured cAMP generation secondary to agonist 
stimulation as an inward cystic fibrosis channel current, as this is known to be regulated by 
cAMP activity (McLatchie et al., 1998). They identified a single cDNA that encoded a 148 
amino acid protein that was named ‘receptor activity modifying protein 1’, or RAMP1. This 
key paper then described how RAMP1 was an obligate binding partner of CLR and was 
essential to signal transduction from the CGRP receptor. The manner by which RAMP1 
conferred CGRP responsiveness was due to its role as a molecular chaperone, facilitating the 
terminal glycosylation of CLR and allowing for its export from the endoplasmic reticulum. In 
cells that do not express RAMPs, the CLR is retained by the endoplasmic reticulum and does 
not reach the cell surface, thereby explaining how cell lines that do not endogenously 
express RAMP1 cannot respond to CGRP stimulation (McLatchie et al., 1998). Where RAMPs 
are expressed in isolation, they are retained by the Golgi apparatus in the form of a 
disulphide-linked homodimer (Hilairet et al., 2001b). However, when the RAMP translocates 
to the cell membrane, it is stabilized in a heterodimeric complex with the CLR, facilitated by 
noncovalent interactions. Screening of public databases identified two other proteins with 
high homology to RAMP1, which were christened as RAMP family members RAMP2 and 
RAMP3 (McLatchie et al., 1998). RAMP2 and RAMP3 are important for the formation of 
functional AM receptors, AM1 and AM2. The authors suggested that differences in 
glycosylation states of the CLR induced by differential RAMP interactions was critical in 
conferring ligand specificity. For instance, terminally-glycosylated CLR allowed for binding of 
CGRP whilst core-glycosylated CLR allowed for AM binding. This was later contested by 
Hilairet et al, who showed that whilst glycosylation was an essential step in trafficking the 
receptor to the plasma membrane, it had no bearing on ligand specificity (Hilairet et al., 
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2001b). They therefore concluded that differences in ligand binding were likely to be 
attributed to differences in the steric conformation of a binding pocket produced by the 
CLR:RAMP interface.  
What remains unclear with regards to receptor subunit stoichiometry is how the formation 
of receptors is directed in cells that express more than one RAMP isoform, endogenously or 
experimentally. Experiments performed in rabbit aortic ECs showed that transfection of 
RAMP1 (not  endogenously expressed by this cell type) produced a receptor responsive to 
CGRP stimulation. This response was not affected by co-transfection with RAMP2 (already 
expressed in rabbit aortic ECs) but was significantly attenuated by co-transfection with 
RAMP3 cDNA (Muff et al., 1998). From this, the authors concluded that a level of 
competition exists between RAMP family members, where the co-expression of alternative 
isoforms might radically change receptor pharmacology. This hypothesis was tested by 
Bühlmann et al, who showed that overexpression of RAMP1 in cells that also express RAMP2 
leads to the loss of AM-mediated signalling in favour of the formation of a CGRP receptor 
(Bühlmann et al., 1999). Thus, CLR may preferentially couple to RAMP1 in the presence of 
other RAMPs, though the mechanism by which this might happen is not known. 
To facilitate research and discussion, the nomenclature of the calcitonin family of peptide 
receptors has been finalised. Dimerisation of CLR and RAMP1 leads to the formation of the 
CGRP receptor. Dimerisation of CLR and RAMP2 forms a receptor that is responsive to AM 
(the AM1 receptor) and interactions between CLR and RAMP3 form an additional receptor 
for AM, the AM2 receptor (Alexander et al., 2011). Rank potencies for typical agonists used 
to probe calcitonin receptor family pharmacology are listed in Table 1. 
Receptor Composition Rank order agonist potency 
CGRP CLR + RAMP1 αCGRP > AM ≥ AM2/IMD > AMY ≥ CT 
AM1 CLR + RAMP2 AM > αCGRP, AM2/IMD > AMY > CT 
AM2 CLR + RAMP3 AM = AM2/IMD ≥ αCGRP > AMY > CT 
 





1.2.8.2 Calcitonin receptor-like receptor (CLR) 
The CLR belongs to the Class B “secretin-like” family of G protein-coupled receptors (GPCR), 
which also includes receptors for calcitonin, vasoactive intestinal polypeptide, pituitary 
adenylate cyclase activating polypeptide and parathyroid hormone. It constitutes the typical 
seven transmembrane component of the receptor and shares approximately 55% sequence 
homology with the related calcitonin receptor (Flühmann et al., 1995). Human and mouse 
CLR are around 89% homologous, with the murine protein slightly longer in length (463 
versus 461 amino acid residues). As previously mentioned, expression of this protein in 
isolation is not sufficient to form a functional CGRP receptor as it requires the co-expression 
of a RAMP in order to be exported from the endoplasmic reticulum and inserted into the 
plasma membrane. In the absence of RAMPs, the endoplasmic reticulum retains the CLR. 
Therefore, it is the dimerisation with RAMPs that dictates the complexity of this unusual 
receptor.  
Owing to its requirement to form receptors for both CGRP and AM and also intermedin 
(AM2), CLR has a wide tissue expression profile, with a high level of expression within 
regions of the central nervous system associated with higher autonomic control, feeding and 
thirst (Hagner et al., 2002). With respect to cells of the cardiovascular system, CLR is 
expressed by both vascular endothelial and smooth muscle cells from a variety of species 
and tissues and from both conduit and resistance vessels (Kamitani et al., 1999a; Frayon et 
al., 2000; Jansen-Olesen et al., 2003; Nagoshi et al., 2004; Nikitenko et al., 2006). There is 
also a strong body of evidence supporting the expression of CLR by cardiac cells, particularly 
in reference to the AM receptor. In the heart, CLR is expressed throughout development and 
into adulthood (Dvorakova et al., 2003) within both cells of the endocardium and 
myocardium (Saetrum Opgaard et al., 2000). 
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1.2.8.3 Receptor activity modifying proteins (RAMP) 
As previously mentioned, the RAMPs were first described in a seminal paper published by 
McLatchie and colleagues in 1998 (McLatchie et al., 1998). The three RAMP family members 
are critical in conferring ligand specificity to CLR protein to form receptors for CGRP and AM. 
Dimerisation of CLR with RAMP1 leads to the formation of a CGRP receptor, RAMP2 
association forms the AM1 receptor and RAMP3 forms the AM2 receptor, which has 
appreciable affinity for CGRP ligand. Dimerisation of CLR with any of the three RAMP 
isoforms generates a nonselective receptor for AM2(Roh et al., 2004). Aside from the CLR, 
RAMPs may also associate with another Class B GPCR, the calcitonin receptor (CTR). These 
interactions promote the formation of the amylin receptors AMY1, AMY2 and AMY3. Where 
RAMPs do not interact with the CTR, the calcitonin receptor is formed (Muff et al., 1999). 
Despite only sharing around 30% sequence identity, all RAMPs possess a similar topology, 
consisting of ~150 amino acid primary sequence arranged into three major domains. They 
possess a short intracellular C-terminus of around 10 amino acids, a transmembrane domain 
of roughly 20 amino acids and an extensive extracellular N-terminus. Of the three family 
members, RAMP2 is the least conserved member of the family, containing a 26 amino acid 
insert into the extracellular domain (Parameswaran and Spielman, 2006). 
Perhaps unsurprisingly, owing to their general promiscuity with respect to forming a diverse 
range of receptors, the RAMPs are expressed somewhat ubiquitously throughout the body. 
However, the relative abundance of their expression varies depending on the tissue in 
question and also whether samples are extracted from healthy or diseased models/patients 
as RAMPs are differentially expressed in a wide range of pathophysiological conditions. The 
initial McLatchie publication described RAMP mRNA expression in human tissues. Here, 
RAMP1 expression was highest in heart, skeletal muscle and pancreas. RAMP2 was also high 
in these tissues, but was also highly expressed in placenta and lung, whilst RAMP3 seemed 
to exhibit consistently high mRNA expression in all tissues observed (McLatchie et al., 1998). 
A subsequent publication by Husmann et al attempted to map the expression of murine 
RAMP isoforms. They identified a high expression of RAMP1 in brain, lung and skeletal 
muscle extracts. RAMP2 had an even wider range of expression, with highest levels in heart, 
lung, skeletal muscle and brain. RAMP3 appeared to be less widely-expressed, with mRNA 
being expressed mainly in embryonic and adult brain lysates (Husmann et al., 2000).  
With reference to cells and tissues of the cardiovascular system, RAMP expression seems to 
vary greatly depending on the resident tissue of the cell. Early studies in human cells showed 
 83 
no expression of RAMP1 or RAMP3 mRNA in aortic smooth muscle cells, HUVEC and aortic 
ECs but high RAMP2 (and CLR) expression in all three cell types (Kamitani et al., 1999b). 
Conversely, brain-derived microvascular smooth muscle and ECs appear to highly express 
RAMP1 message and the other RAMPs to a much lesser extent (Moreno et al., 2002; Jansen-
Olesen et al., 2003). Such a discrepancy in expression may explain why CGRP is such a key 
player in the vascular nociceptive response in migraine. With respect to human dermal 
microvascular ECs RAMP1 expression is a little less clear. In 2006, Nikitenko et al showed 
that RAMP1 mRNA did not exist in this cell type, whilst signal for the other RAMP family 
members could be detected (Nikitenko et al., 2006). However, a more recent study 
performed by Huang et al in 2011 showed that human dermal microvascular cells and the 
HMEC-1 endothelial cell line expressed all RAMP isoforms (Huang et al., 2011). With these 
findings in mind, it is important for the researcher to be clear in defining which receptor 
their phenotype is being mediated by, if any, as a response alone does not indicate 
expression of a particular RAMP, given the potential for the calcitonin family of peptides to 
bind to multiple receptor subtypes.   
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1.2.8.4 Receptor component protein (RCP) 
It is now known that an additional third protein is required to form an optimally functional 
CGRP receptor, termed the CGRP receptor component protein (RCP). The RCP is a small, 
hydrophilic, membrane-associated protein that has little homology to other known protein 
sequences. RCP was first identified in guinea pig organ of Corti, where an isolated cDNA was 
shown to encode for a protein that conferred specific pharmacological sensitivity to CGRP 
stimulation of Xenopus oocytes, as measured by a cystic fibrosis transmembrane 
conductance regulator assay. Stimulation of cells with ligands known to stimulate other Gαs-
coupled receptors did not result in a positive response, indicating that the 17 kDa protein 
identified in this study was directly involved with CGRP receptor stimulation (Luebke et al., 
1996). Indeed, when antisense RNA was constructed against RCP and transfected into 
NIH3T3 cells, cAMP generation subsequent to CGRP receptor stimulation was lost. 
Disruption of RCP protein synthesis had no effect on the ability of CGRP to bind to its 
receptor, whilst significantly attenuating cAMP generation (Evans et al., 2000). This meant 
that the role of this particular protein was likely to be involved with the modulation of the 
second messenger response following receptor stimulation, rather than serving a structural 
role in stabilising the receptor. In support of this finding, the RCP was shown to co-
immunoprecipitate with the CLR protein, confirming that association of RCP with the CGRP 
receptor is important for optimal signal transduction (Evans et al., 2000). In addition to its 
role in driving the CGRP response, RCP also appears to be important in regulating signal 
generated by AM receptor stimulation, though potentially to a lesser extent than CGRP 
(Prado et al., 2001). This is perhaps unsurprising given this protein’s ability to associate with 
the CLR, which is also a critical subunit of AM receptors. Interestingly, it has recently been 
shown that in a mouse model of experimental autoimmune encephalomyelitis, the RCP is 
capable of translocating from the neuronal plasma membrane to the nuclear compartment. 
Although this has only been shown via immunofluorescent techniques, this may point to the 
description of an exciting new feature in RCP function, whereby it may regulate gene 
transcription in conjunction with its role in regulation cyclic nucleotide signal amplification 
(Sardi et al., 2014). 
Despite being discovered more than a decade ago, little is known about the function of RCP 
in driving the CGRP-mediated response and its relevance in health and disease. Shortly after 
the discovery of the protein, its expression profile was mapped in the guinea pig nervous 
system, with a particularly abundant gene expression within the hippocampus and 
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cerebellum, reflecting the early autoradiographical studies concerning radioactive CGRP 
binding in the brain (Oliver et al., 1999). Later studies performed in rats showed that RCP 
expression was high in other regions of the nervous system, including regions of the 
lumbosacral spinal cord and also the DRG(Pokabla et al., 2002). The authors of this study 
also highlighted an association between RCP tissue immunoreactivity and innervation of 
CGRP-ergic neurons, indicating a close relationship between receptor expression and the 
site of ligand release. Other notable sites of RCP expression include the ocular ciliary body 
(Rosenblatt et al., 2000), myometrium (Naghashpour et al., 1997) and testis (Balkan et al., 
1999). A potentially important role for the RCP in vivo has recently been uncovered in the 
setting of hypertension. Rats rendered hypertensive via subtotal nephrectomy and saline 
consumption were found to have an augmented depressor response to intravenous CGRP 
than sham-operated animals and isolated resistance vessels from these animals were found 
to be more sensitive to exogenous CGRP application (Supowit et al., 2011). This was an 
effect that was suggested to be directly attributable to an increased expression of RCP 
protein within the vasculature of the hypertensive rats, whereas expression of other CGRP 
receptor proteins was found to be unchanged. It is therefore conceivable that the fine-
tuning of RCP expression in disease conditions may drastically change CGRP-mediated 
responses. An illustration of CGRP receptor stoichiometry, basic pharmacology and 




















Figure 5: Diagram depicting CGRP-family receptor stoichiometries, pharmacology and commonly associated signalling pathways. CGRP; calcitonin gene-related peptide, AM; 
adrenomedullin, CLR; calcitonin receptor-like receptor, RAMP; receptor activity-modifying protein, RCP; receptor component protein, AC; adenylate cyclase, ATP; adenosine triphosphate, 
cAMP; cyclic AMP, EPAC; exchange protein activated by cAMP, CNG; cyclic nucleotide-gated ion channel, PKA; protein kinase A. Amino acid shorthand: X; any amino acid, R; arginine, S; 
serine, T; threonine, Ω; hydrophobic residue. 
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1.2.9 Molecular Pharmacology and Ligand Binding 
1.2.9.1 Agonist binding and receptor activation 
Much effort has been put into attempting to understand the molecular determinants of 
agonist/antagonist binding to CGRP receptors. Given the complex heterodimeric nature of the 
receptor, advances in this area of CGRP biology are laudable but we are far from comprehensively 
understanding the precise mechanisms involved in ligand binding. Reasonably soon after researchers 
began turning their focus onto the molecular pharmacology of Class B GPCRs, Hoare proposed a 
global model by which this family of receptors might bind ligands in order to activate the receptor 
and generate a signal. This generalised mechanism was termed the “two-domain model” (Hoare, 
2005). In this, the C-terminal region of the peptide agonist is ‘captured’ by the large extracellular N-
terminus of the Class B receptor with high affinity. This high-affinity capture results in the increased 
local availability of agonist and in particular an increased local concentration of the unbound N-
terminus of the ligand. This greatly increases the probability of weak interactions between the ligand 
and the juxtamembrane domain of the receptor, leading to subsequent receptor activation (Hoare, 
2005). This model if strengthened by the observation that truncated CGRP peptides (e.g. CGRP8-37) 
are capable of binding to the receptor with low affinity but do not activate it and therefore act as 
competitive antagonists. Conversely, the two-domain model appears to explain why small molecule 
antagonists designed against the CGRP receptor have high potency, as they are mostly believed to 
bind at the N-terminus of the receptor, thereby blocking high-affinity capturing interactions between 
endogenous ligand and its receptor. Mechanisms related to antagonist binding will be discussed 
later in this section. 
It has been known for some time that, despite being a relatively small peptide, there are distinct 
regions within the molecular structure of CGRP that appear to be critical for receptor binding and 
activation. Initial evidence for this emerged as early as 1989 from Chiba et al who found that 
truncation of the first seven amino acid residues from the N-terminus of the peptide to form CGRP8-
37 resulted in a CGRP receptor antagonist that had the capacity to bind receptor but not activate it 
(Chiba et al., 1989). Clearly, this pointed to a critical role of at least one of these residues in 
mediating receptor activation. To support this hypothesis, Maggi et al produced N-terminal 
fragments of the peptide and tested their hypotensive effect in the anaesthetized rat, where they 
were shown to be bioactive (Maggi et al., 1990). The importance of the N-terminus of CGRP in 
mediating receptor activation is in keeping with other peptide agonists of Class B GPCRs that have a 
common N-terminal motif required for activation. In the case of CGRP, this motif is formed by a 
disulphide-bonded ring between cysteine2 and cysteine7(Neumann et al., 2008). Comparative 
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molecular biology has revealed that there is a high-degree of sequence identity up to position 14 in 
species from mammals to bony fish, indicating that the N-terminus of the peptide appears to be 
evolutionarily conserved in order to retain its efficacy. Though there is little experimental evidence 
to inform which particular N-terminal residues are critical in mediating receptor activation, a recent 
paper from the Hay group has shown through site-directed mutagenesis of CGRP that Ala5Cys 
mutants possessed a 270-fold reduction in affinity and a reduced efficacy of cAMP generation and -
arrestin recruitment. In addition to this, Thr6Cys mutants possessed no agonist properties (Hay et 
al., 2013). Whilst the effects of these mutations are quite clear, it is less clear why the authors chose 
to mutate their focused residues to cysteine. Whilst this residue is small and hydrophobic and 
apparently innocuous, the inclusion of a thiol group as part of the sidechain introduces a highly 
reactive group to the peptide backbone. This residue may have seemed like a suitable replacement 
for Ala5 but it is less clear why the authors did not choose to mutate Thr6 to alanine to test the loss-
of-function effect. For a further review of the structure-activity relationship of CGRP interacting at its 
receptor, see Watkins et al 2012 (Watkins et al., 2012). 
To date there are limited data available concerning the three dimensional structure of the CGRP 
receptor, as determined by crystallographic techniques. In 2010, ter Haar et al solved the structure 
of the CLR/RAMP1 ectodomain in the unbound state and also when bound with small molecule 
antagonists of the receptor (Haar et al., 2010). However, what is still lacking is the resolution of a 
structure, ectodomain or otherwise, with CGRP bound to it. Thus, our knowledge of the molecular 
determinants of agonist binding is perhaps best informed by site-directed mutagenesis studies and 
comparing modes of binding of other ligands to Class B GPCRs. Current thinking is that CGRP binds to 
its receptor within a binding cleft at the interface between CLR and RAMP1. Within this 
environment, tryptophan-84 of RAMP1 appears to be critical in allowing ligand binding (Moore et al., 
2010) whilst multiple residues present within the CLR N-terminus appear to be also quite important. 
Directed mutagenesis of Leu41, Gln45, Cys48 and Tyr49 of the CLR to alanine resulted in diminished 
potency of CGRP at its receptor, as determined by cAMP assay. Furthermore, Leu41Ala, Ala44Leu, 
Cys48Ala and Tyr49Ala mutagenesis led to complete inhibition of agonist binding (Barwell et al., 
2010). It is thought that this interface between RAMP1 and CLR is only important in ligand anchoring 
rather than activation of the receptor itself. 
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1.2.9.2 CGRP Receptor Antagonists 
Critical to the advancement of our understanding of receptor pharmacology, it is essential to have at 
hand a specific pharmacological toolkit comprised of specific agonists and antagonists for the 
receptor. As previously discussed, the first antagonist for the CGRP receptor was developed in 1989 
by Chiba et al.(Chiba et al., 1989). Other peptide antagonists have also been investigated (e.g. 
CGRP27-37, which is the minimal fragment required for receptor binding; (Yan et al., 2011)) Whilst an 
invaluable tool, the peptide nature of  CGRP8-37 meant that it exhibited low potency and was an 
undesirable drug for in vivo use and a clear need was established to synthesise a stable and selective 
small molecule antagonist of the CGRP receptor. Development of selective non-peptide antagonists 
of the CGRP receptor (and, indeed, other Class B GPCRs) has been met with some difficulty owing to 
the fact that the endogenous ligand of the receptor is a peptide. Therefore, a low molecular weight 
antagonist working at the orthosteric site would have to prevent the binding of a much larger 
molecule that is likely to have a complex repertoire of interactions with its receptor. Furthermore, 
the heterogeneity of the CGRP family of receptors begets further complexity, where the design of 
novel antagonists must overcome structural differences between CLR/RAMP heteromers. However, 
the need was met in 2000 when Boehringer Ingelheim developed the new chemical entity 
BIBN4096BS, or olcegepant,: 1-piperidinecarboxamide,N-[2-[[5-amino-1-[[4-)4-pyridinyl)-1-
piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)-methyl]-2-oxoethyl]-4-(1,4-
dihydro-2-oxo-3(2H)-quinazolinyl)-,[R-(R*,S*)]. This novel non-competitive antagonist of the CGRP 
receptor was shown to be capable of blocking binding of endogenous ligand to receptor in both cells 
and tissue preparations from rodent and human and also produced a rightwards shift in cAMP 
accumulation curves (Doods et al., 2000). It displayed an affinity of 14.4 ± 6.3 pM for human CGRP 
receptors in SK-N-MC cells and 3.4 ± 0.5 nM for CGRP receptors found in spleen (Edvinsson et al., 
2001). This is a striking difference in affinity in comparison to CGRP8-37. In vivo preparations 
demonstrated that the antagonist, although not orally-active, was further capable of inhibiting 
increases in dermal blood flow following trigeminal ganglion stimulation in the marmoset (Doods et 
al., 2000). Whilst this antagonist has been shown to have increased potency over the peptide 
antagonist, it is considered to have 200-fold increased potency in humans and non-human primates 
than in rodent tissue (Doods et al., 2000). 
Based on the promising pharmacology of olcegepant, an additional member of the ‘gepant’ family 
was identified by Merck & Co, via high-throughput screening. Originally termed ‘compound 2’, the 
benzodiazepine-like lead structure was shown to possess affinity for the human CGRP receptor, with 
a Ki of 4.8μM. Optimisation of this structure led to the development of the more potent telcagepant; 
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N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-
1H-imidazo[4,5-b]pyridine-1-yl)piperidine-1-carboxamide. This compound was shown to have good 
oral bioavailability (Paone et al., 2007). Early characterization studies showed that telcagepant had a 
Ki of 1.1nM at CGRP receptors expressed in HEK293 cells and could inhibit capsaicin-induced 
increases in blood flow in the rhesus forearm (Salvatore et al., 2008). Merck continued with the 
success of telcagepant with the development of a more potent antagonist, MK-3207. This compound 
displayed a Ki of 0.024nM at human and rhesus CGRP receptors, but again this high potency was not 
conserved in species other than human and primate (Salvatore et al., 2010). 
Other less well-characterised antagonists have also been developed to block CGRP activity. A second 
compound was filed under the Boehringer patent WO98/11128, ‘compound 1’. Compound 1 was 
shown to have pKi values of 7.8 in SK-N-MC cells (compared to that of around 8.9 for CGRP8-37). It 
was shown to be a weak antagonist of CGRP responses in human cerebral and guinea pig basilar 
arteries (Edvinsson et al., 2001), but not in porcine coronary arteries (Hasbak et al., 2001). 
Interestingly, Compound 1 has been shown to antagonise the effects of CGRP in the same vascular 
bed, albeit from humans (Hasbak et al., 2003), demonstrating further the species difference for 
CGRP antagonists. There has also been a range of cyclic non-peptide antagonists based on CGRP27-37 
with potencies in the nanomolar range (Yan et al., 2011). 
More recently, Bristol-Myers Squibb have published data on a novel set of non-peptide antagonists 
of the CGRP receptor. With accumulating evidence for many small molecule antagonists 
unfortunately being potent inhibitors of hepatic cytochrome P3A4 (which led to the withdrawal of 
telcagepant from clinical trials for migraine), BMS have developed compounds that possess modified 
benzothiophene side chains in order to circumvent these issues, including BMS-694153, a compound 
with high affinity for the human CGRP receptor (Ki = 13pM). Significantly, this compound was shown 
to have excellent intranasal bioavailability in the rabbit, a physicochemical characteristic that may 
suit the treatment of an acute migraine attack (Degnan et al., 2008). For a further review of all major 
CGRP receptor antagonists, including their pharmacological characterization, please see Moore and 
Salvatore, 2012 (Moore and Salvatore, 2012). 
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1.2.9.3 Antagonist binding and molecular determinants of species-dependent potency 
A great stimulus in initiating work concerning the molecular pharmacology of antagonists binding to 
the CGRP receptor was the finding that these antagonists exhibited substantial species selectivity 
with respect to their potency. In brief, both of the ‘gepant’ series of CGRP receptor antagonists 
display roughly a thousandfold increase in potency at human and primate CGRP receptors in 
comparison to rodent and canine receptors (Doods et al., 2000; Salvatore et al., 2008). Adding 
further evidence to support differences in receptor composition between species, MK-3207, a CGRP 
receptor antagonist that is structurally-distinct from the gepants still appears to possess a potency 
around 400 times as high at human and primate receptors versus rat and dog (Salvatore et al., 
2010). Clearly, these differences in antagonist potency point to differences in the molecular 
composition of the CGRP receptor between species. 
An initial study by Mallee et al attempted to explore this problem more fully. This study focused on 
the clear difference in antagonist potency between human and rat CGRP receptors. They confirmed 
that the small molecule antagonists were more potent when acting at the human receptor and 
constructed receptor chimeras to address whether the CLR or RAMP1 portion of the receptor 
mediated this selectivity. They found that receptors comprised of human RAMP1 and rat CLR could 
be antagonised in a similar manner to that of hRAMP1/hCLR constructs, whilst rat RAMP1/human 
CLR constructs mimicked that of the native rat receptor (Mallee et al., 2002). Strikingly, this dramatic 
shift in potency was governed by a single amino acid mutation. Site-directed mutagenesis of rat 
RAMP1 lysine 74 to tryptophan (the homologous amino acid of the human receptor) resulted in a 
regain of function, indicating that antagonist potency is largely governed by a single amino acid 
residue found within the extracellular domain of RAMP1 (Mallee et al., 2002). Kusano et al made 
progress in resolving the crystal structure of the extracellular domains of human RAMP1 in 2008, 
which uncovered four additional residues that potentially could be important for antagonist binding: 
Arg67, Asp71, Glu78 and Trp84 (Kusano et al., 2008). Validation of these key residues in conferring 
antagonist affinity uncovered for the first time a key role for Trp84 in the regulation of not only 
affinity for small molecules, but also affinity for peptide fragment antagonists and peptide agonists 
alike (Moore et al., 2010). This residue exists as part of the binding interface between RAMP1 and 
the CLR, indicating that the ligand-binding domain of the CGRP receptor is formed of a hydrophobic 
pocket located between both structures. Interestingly, mutation of Trp84 to alanine results in a 
lowered membrane expression of the receptor, bolstering the role for RAMP1 as a molecular 
chaperone for CLR to reach the plasma membrane and supporting the role of Trp84 in mediating 
RAMP1:CLR interactions. 
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Subsequent studies also turned their attention to the potential role of the CLR in governing 
antagonist binding. The rationale for investigating the role of the CLR in antagonist binding came 
from the observation that CLR:RAMP1 and calcitonin receptor CTR:RAMP1 heterodimers possessed 
different affinities for CGRP receptor antagonists, indicating a role for the CLR. Salvatore et al 
constructed CLR/CTR chimeras and showed that residues 37-63 of the CLR were critical in 
determining antagonist binding, in particular those belonging to the ‘gepant’ class of drugs 
(Salvatore et al., 2006). However, aspects of transmembrane domain 7 appeared to be important for 
a second class of antagonists, such as compound 4 (Salvatore et al., 2006). Having antagonists that 
are dependent on binding to a site that is so far removed from the CLR:RAMP1 interface may be 
indicative of a site of allosteric modulation. The pivotal involvement of Trp74 of RAMP1 and residues 
present within the extreme N-terminus of the CLR was confirmed by Miller et al in 2010 (Miller et al., 
2010). Indeed, they expanded on Salvatore et al’s finding and showed that a further key residue 
within the CLR sequence for antagonist binding was methionine-42 (Miller et al., 2010).  
Whilst molecular determinants of both agonist and antagonist binding to the CGRP receptor have 
been identified, it has been difficult to determine the crystal structure of this family of receptors. 
Early ab initio modeling of RAMP1 provided evidence and predicted a structure composed of three 
alpha helices (Simms et al., 2006). Kusano and colleagues developed this prediction by scrutinising 
the soluble extracellular domanis of the RAMP1 molecule and indeed they confirmed that the 
structure was trihelical (Kusano et al., 2008). As previously mentioned, Trp74 was found to be an 
important residue as part of this structure and formed part of a hydrophobic cleft that existed 
between the CLR and RAMP1 that was essential for forming a ligand-binding domain. Alongside 
Arg67, Asp71 and Glue78, Trp74 was found to exist within the structure of the second alpha helix of 
RAMP1 whilst the aforementioned Trp84 was found to exist on the loop adjoining helix 2 and 3, with 
its side-chain oriented in the same direction as Trp74, towards the solvent-exposed side of the 
structure. 
However, these isolated resolutions of the RAMP1 extracellular domain shed no light on how both 
the CLR and RAMP1 complex together and this complexing is clearly critical for function. In order to 
address this issue, Koth and colleagues created a construct consisting of both extracellular regions of 
RAMP1 and CLR in order to act as a surrogate for studying drug interactions with the shared ligand-
binding domain between both molecules. Indeed, this construct was validated by its ability to 
compete with wild type CGRP receptors for binding CGRP in SK-N-MC cells. However, the construct 
displayed lower affinity for CGRP than the full-length receptor (IC50 = 12μM) but was shown to retain 
high-affinity binding for each of the small molecule antagonists (Koth et al., 2010). Resolution of the 
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crystal structure of the extracellular domain in the liganded and unliganded state may pave the way 
for rational drug design. Whilst difficulties do exist in resolving complex GPCR crystal structures, only 
with the full structure will we be able to gain a full understanding of how CGRP receptors interact 
with their endogenous ligands and exogenous drug molecules. 
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1.2.10 Intracellular signalling pathways 
As is typical with all GPCRs, binding of CGRP to its receptor results in a conformational change in the 
three-dimensional shape of the receptor, which facilitates coupling to intracellular signalling 
pathways. As is realised with other better-understood GPCRs, receptors do not have to be 
exclusively coupled to one pathway or another and there may be great diversity in signalling 
mechanisms stemming from one single receptor in order to bring about biological complexity (see 
Figure 5). This also appears to be the case with the CGRP receptor. 
The classical paradigm of CGRP receptor signalling involves coupling positively to adenylate cyclase, 
which generates the formation of cAMP from ATP (as seen in Figure [X]). As a consequence of this, 
CGRP receptor activity has commonly been characterised by measuring cAMP responses (Walker et 
al., 2010a). Local rises in cAMP can lead to the activation of three main intracellular effectors, as 
governed by the spatial distribution and compartmentalization of signal generators (such as 
adenylate cyclases), terminators (phosphodiesterase family enzymes) and effectors. These effectors 
may take the form of cyclic nucleotide-gated ion channels, exchange proteins activated by cAMP 
(EPACs) or the prototypical cAMP effector, PKA (Zaccolo, 2009). Activated PKA is capable of 
phosphorylating a multitude of serine/threonine-containing protein candidates that possess the 
consensus motif R-R-X-S/T- , where X denotes any amino acid residue and denotes hydrophobic 
residues (Ubersax and Ferrell, 2007). With respect to the biological action of CGRP, activation of PKA 
may be incredibly important with respect to mediating smooth muscle relaxation, vascular or 
otherwise. This vasorelaxation appears to be strongly influenced by PKA’s ability to phosphorylate 
K+ATPchannels to induce hyperpolarisation of the cell, thereby causing relaxation (Nelson et al., 1990; 
Quayle et al., 1994). There is also a substantial body of evidence supporting the coupling of CGRP 
receptors to mitogen-activated protein kinase (MAPK) cascades in various cell types. This 
recruitment of kinase cascades may be dependent or independent of upstream PKA activation 
(Kawase et al., 2005). 
Finally, raised intracellular levels of cAMP can influence long-term changes in cellular function by 
inducing de novo gene transcription by virtue of activation of the cAMP response element-binding 
protein (CREB)(Kawase et al., 2005; Vause and Durham, 2010), a transcription factor that may bind 
to sequences of DNA containing cAMP response elements within the promoter region of particular 
genes (Sassone-Corsi, 1998). In fact, the CGRP gene promoter itself is regulated by CREB, meaning 
elevation in neuronal cAMP can induce CGRP gene transcription (Freeland et al., 2000). 
Other than signalling through the cAMP axis, it is possible that activation of the CGRP receptor 
results in activation of alternative signalling pathways. These may comprise G i/o, G q/11, and -
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arrestin-dependent pathways (Walker et al., 2010a), although these are not very well understood. 
Interestingly, a role for G-protein  subunits has been uncovered and these subunits appear to be 
important in terminating the long-lasting pressor response of arteries in response to ET(Meens et al., 
2012). 
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1.2.11 Receptor tachyphylaxis 
An important feature in GPCR signalling is that of tachyphylaxis, or desensitisation. This process 
serves to attenuate hyperstimulation of a particular receptor in response to prolonged exposure of a 
particular agonist and it may occur in an agonist-dependent (homologous) or –independent 
(heterologous) manner. Whilst receptor desensitisation has been famously and extensively studied 
in typical Class A GPCRs, such as the 2-adrenoceptor, there is a growing body of evidence 
investigating the kinetics and behaviour of Class B receptor tachyphylaxis, including the CGRP family 
of receptors. 
Early investigations into CGRP receptor desensitisation in SK-N-MC cells were led by the hypothesis 
that desensitisation mechanisms were mediated by the CLR and, as such, repeated exposure to 
either CGRP or AM should lead to a similar reduction in response as both peptides share the 
requirement of the CLR. Drake et al showed in a short communication that pre-exposure of cells to 
CGRP led to a subsequent diminished response to CGRP and AM, which was prevented by the use of 
H-89 to block PKA. Conversely, it was shown that pre-treatment of cells with AM and subsequent 
stimulation with either CGRP or AM led to no loss in signal. These results hinted at agonist-
dependent differences in the desensitisation response (Drake et al., 1999). The same group 
expanded on this novel finding by investigating rat aortic VSMCs, managing to recapitulate their 
previous findings (Drake et al., 2000). Interestingly, however, the authors also showed that pre-
exposure of cells to isoproterenol (pan- -adrenergic receptor agonist, G s-coupled) or ATII (pan-
angiotensin receptor agonist, G q-coupled) also induced a diminished response to CGRP exposure, 
hinting at the possibility of heterologous desensitisation of the receptor by different receptor 
systems (Drake et al., 2000). Whilst these findings supported the idea that CGRP receptors do 
desensitise, they lacked mechanistic insight into precisely how this phenomenon was achieved. 
Furthermore, whilst a role for PKA was established within this system, this has since been contested 
and an additional role for protein kinase C (PKC) has been hypothesised (Pin and Bahr, 2008). 
In order to attain more information regarding the mechanisms of CGRP receptor tachyphylaxis, 
Kuwasako et al published a study in 2000 to shed light on this field. HEK293 cells stably transfected 
with fluorescently-labeled CLR and RAMPs were found to be responsive to stimulation by agonist 
and also underwent tachyphylaxis. The receptors appeared to internalise via their localisation to 
clathrin-coated pits, where a significant proportion of the internalised receptors were subsequently 
targeted to the lysosomal compartment for degradation, hinting at a prolonged desensitisation due 
to inefficient vesicular recycling of the receptor back to the plasma membrane (Kuwasako et al., 
2000). This result was quickly confirmed by Hilairet et al, who showed again that clathrin-coated pits 
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were required for receptor internalisation though this was downstream of receptor phosphorylation 
following activation and translocation of -arrestin from the cytosol to the activated receptor, a 
phenomenon typical of Class A GPCR desensitisation (Hilairet et al., 2001a). The finding that an initial 
receptor phosphorylation event is involved complements early publications that showed an 
inhibition of receptor desensitisation following PKA inhibition (Drake et al., 1999; 2000). 
Furthermore, CLR, RAMP1 and -arrestin were shown to remain complexed within the endosome 
after internalization. Subsequent work building on this result has shown that CGRP actually 
internalises to the endosomal compartment whilst remaining bound to the receptor itself (Cottrell et 
al., 2005).  
Experiments examining typical Class A GPCRs have shown that the fate of the desensitised receptor 
is not fixed following internalisation and this also appears to be the case with the CGRP receptor. 
Initial CGRP receptor recycling studies showed that duration of receptor stimulation could greatly 
affect the fate of the internalised receptor. Transient stimulation of the CGRP receptor with agonist 
for one hour could induce internalisation of receptor and recycling of the receptor back to the 
plasma membrane within 2-6 hours. This process was not affected by inhibition of de novo protein 
synthesis by cycloheximide but was inhibited by vacuolar disruption, implicating a role for the 
endosomes. Conversely, sustained stimulation of the receptor with CGRP resulted in a prolonged 
state of desensitisation where the receptor was targeted towards the lysosomal network for 
degradation. A role for ubiquitin-dependent proteolysis was excluded (Cottrell et al., 2007). A 
further layer of complexity in determining receptor fate was introduced with the discovery that the 
ECE-1 plays a role in CGRP receptor regulation. Specific splice variants of ECE-1 are localised to the 
endosomal compartment where they cleave CGRP ligand from the internalised receptor and degrade 
it. This removal of ligand from receptor encourages the dissociation of -arrestins and their 
translocation to the cytosol. This results in a more rapid recycling of the CGRP receptor back to the 
plasma membrane for further stimulation (Padilla et al., 2007). These initial findings were 
demonstrated HEK-293 and SK-N-MC cell lines but a recent paper has been published to show that 
this phenomenon is present in isolated rat mesenteric arteries and explanted VSMCs (McNeish et al., 
2012). In this study, inhibition of ECE isoforms resulted in a desensitisation of the vasodilator 
response to CGRP, an effect linked to a decrease in cyclic nucleotide generation. This regulation of 
signal by ECEs has been shown to occur with other neuropeptides, such as SP (Roosterman et al., 
2007), but not with other peptide ligands such as ATII(Padilla et al., 2007). 
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1.3 Aims and Hypotheses 
As previously mentioned, there is an active and clear body of research investigating CGRP-mediated 
vascular protection in a range of CVD models, including hypertension. There is a growing body of 
knowledge related to the ageing vasculature but to date no research has been performed on how 
CGRP regulates the ageing cardiovascular system in terms of gross physiological parameters or how 
it may influence subtle cellular processes that may predispose the cardiovascular system to disease. 
Based on current knowledge on the protective nature of CGRP within the cardiovascular system, the 
hypothesis of this PhD is that CGRP will be protective against age-associated vascular dysfunction 
and will possess a further protective nature in an animal model of geriatric hypertension. The aims 
of this project are threefold: 
1. To characterise the in vivo and ex vivo cardiovascular phenotype of the CGRP KO mouse in a 
model of natural ageing. 
2. To study how CGRP influences inflammation-associated leukocyte-EC interactions in vitro 
and to determine molecular mechanisms that may govern this process. 
3. To establish a model of geriatric hypertension and to characterise this model and investigate 
potential protective mechanisms therein. 
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2. | Method and materials 
2.1 Animals 
Male WT and KO αCGRP C57BL/6 mice were bred in-house and used throughout. All animals 
were maintained on standard chow, with access to food and water ad libitum. Mice were 
maintained in a climatically controlled, SPF environment on a 12-hour light/dark cycle. KO 
mice were age-matched with respective WT counterparts. All experiments were performed 
in line with the Animals (Scientific Procedures) Act 1986. Experiments were performed 
under PIL 60/12706 and PPL 70/7959. Juvenile mice were used at three months of age and 
aged mice were used at fifteen months of age. 
 
2.2 Generation of αCGRP KO mice 
WT and KO αCGRP mice were gifted by Dr. A.M. Salmon, Institut Pasteur, Paris, France. KO 
mice were generated by the targeted disruption of exon 5 of the CALC I gene via the 
insertion of a LacZ/CMV/Neo transgene (Salmon et al., 1999). This results in the removal of 
CGRP gene transcription, leaving calcitonin expression unaltered. Mice were bred in-house 
from both homozygous and heterozygous pairs. In the case of homozygous pairing, mice 
were backcrossed every ten generations to limit genetic convergence. Pairs produced litters 
with ratios in accordance with traditional Mendelian genetics. Further, KO mice displayed 




Genotyping of WT and KO αCGRP mice was performed by end-point PCR. Ear notches were 
taken under 2% isoflurane anaesthesia. Subsequent isolation of genomic DNA was 
performed using a commercially-available kit (ExtractRED-n-Amp Tissue PCR Kit, Sigma, UK), 
in accordance with the manufacturer’s instructions and PCR was performed on these 
samples using the following primers (Eurofins Scientific, Europe) and reaction conditions 
(Table 2), using a thermal cycler (PTC-225 Peltier Thermal Cycler, MJ Research, USA). 
 
Primer A: CCCCTAATGGCCTTGTGATTG 
Primer B: ACCTCCTGATCTGCTCAGCAG 
Primer D: GATGGGCGCATCGTAACCCG 







2                         (x30 cycles) 
72 7 
 
Table 2: Table illustrating thermocycling conditions necessary to genotype αCGRP WT and KO mice. 
 
The amplified genomic DNA was then visualised via agarose gel electrophoresis (1.8% w/v 
agarose, Sigma Aldrich) in tris/borate/EDTA acid (TBE, Biorad, UK). Electrophoresis was 
performed at 90V for 20 minutes to allow for resolution of DNA fragments. The gel was then 
visualised under ultraviolet light (G-Box, Syngene, USA). A single DNA band at 420bp 
denoted a KO mouse whilst a single DNA band at 290bp indicated the presence of a WT. A 
band at both locations denoted a heterozygote mouse. Figure 6 shows a representative PCR 
















Figure 6: Representative gDNA PCR reaction for αCGRP mouse genotyping. WT band appears at ~290bp; KO 
band appears at ~420bp. 
 102 
2.4 Anaesthesia 
For the majority of studies presented in this thesis, anaesthesia was not necessary. 
However, in the case of implantation of osmotic minipumps, surgical anaesthesia was 
required. Mice were anaesthetised with isoflurane. 4% isoflurane in oxygen carrier was used 
to induce anaesthesia at a flow rate of 4L/minute. Anaesthesia was then maintained at 2-3% 
isoflurane (3L/minute oxygen). Deep anaesthesia was assessed by a lack of reflex to a light 
pinch of the hindpaw. Animals were single-housed and returned to clean cages post-surgery, 
where they were allowed to recover in a thermal incubator (27°C) for half an hour before 
returning to holding rooms. 
Anaesthesia for non-recovery procedures was induced with 4% isoflurane (4L/minute 
oxygen) until reflexes were lost. Typically, exsanguination occurred via cardiac puncture, 
prior to cervical dislocation. 
 
2.5 Ageing 
For experiments examining the influence of αCGRP gene deletion on ageing processes, male 
αCGRP WT and KO littermate mice were used. Juvenile mice were used at three months of 
age and aged animals were fifteen months. The mice used were bred onto a C56BL/6J 
background, which have been shown to live to 815 ± 16 days (~25 months) in standard 
laboratory conditions (Jackson Laboratories, 2008). Thus, from this, we deemed our mice to 
be “middle-aged”. We thought this an appropriate time at which to study age-induced 
vascular inflammation, as middle-age is generally the time at which humans tend to 
manifest CVD.Mice were maintained on a standard diet throughout and group-housed until 







2.6 Angiotensin II-Induced Hypertension 
For the induction of experimental hypertension, male αCGRP WT and KO littermate mice 
were used at fifteen months of age and a small pilot experiment was performed using male 
αCGRP WT and KO littermates at three months of age. Mice were group-housed until in vivo 
experiments commenced, where they were then singly housed for approximately one 
month. 
To induce hypertension, Alzet osmotic minipumps (Charles River, UK) were implanted into 
mice. Minipumps had a 14-day pumping capacity with a drug infusion rate of 0.25 μL/hour. 
Pumps were filled with either vehicle (0.9% saline) or ATII (Sigma Aldrich, UK) at a 
concentration adjusted to the body weight of the animal to produce a continuous pumping 
dose of 1.1 mg/kg/day. Minipumps were implanted subcutaneously in the mid-scapular 
region via a small dorsal incision. Implantation was carried out under isoflurane anaesthesia 
as described above. Post-implantation, 1 mL saline was administered to retain moisture of 
the wound and the incision was closed using vicryl-coated sutures (5.0, Ethicon, Johnson and 
Johnson, UK) in a discontinuous pattern. Post-operative analgesia was administered via 
intramuscular injection of 50 μg/kg buprenorphine (Vetergesic, Alstoe Animal Health, UK). 
Mice were allowed to recover and then were returned to holding rooms. Hypertension was 
monitored over a two-week period, followed by termination of the animal. 
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2.7 Metabolic Caging 
Some animals were housed in metabolic cages for the measurement of food and water 
intake as part of the ATII-induced hypertension model. Mice were singly housed to 
metabolic cages for 18 hours overnight on the day before minipump surgery and on day 13 
of experimental hypertension. Food and water intake was monitored over this 18-hour 
period and urine excretion measured. 
 
2.8 Tail Cuff Volume-Pressure Recording 
Mouse blood pressure was measured using tail cuff volume-pressure recording (VPR) using 
the CODA 6 acquisition system (Kent Scientific, Torrington, CT, USA). This is a non-invasive 
system that has previously been validated within our group (Smillie et al., 2014). 
Furthermore, there is good correlation between results obtained from VPR and those 
obtained from the gold-standard technique in blood pressure monitoring, 
radiotelemetry(Feng et al., 2008). 
Prior to collecting blood pressure measurements, mice were trained for a period of one to 
two weeks in order to grow accustomed to the protocol to generate a stable baseline. Once 
a stable baseline was recorded, experimental data were collected. Mice were restrained in 
Perspex tubes and held in position with the introduction of a nose cone. Mice were then 
placed on a heated platform to induce vasodilatation of the peripheral vasculature to 
promote blood flow, as data collection is dependent on sufficient blood flow. An occlusion 
cuff was then placed around the base of the tail, followed by the placement of the VPR cuff 
below it. Measurements then commenced by inflation of the occlusion cuff followed by its 
gradual deflation over a period of fifteen seconds. The VPR cuff senses changes in tail blood 
flow associated with changes in occlusion cuff pressure and calculates blood pressure as a 
result of this. This measurement cycle was performed 20 times on each day of recording, 
where the first five measurements were excluded to allow for animal acclimatisation. 
Furthermore, on cycles where the animal showed visible signs of stress (movement or tail 
flinching), data were excluded. The mean systolic, diastolic and mean arterial pressures of 
the remaining replicates were calculated for each mouse on each day of recording.  
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2.9 Pulse Oximetry 
Mouse heart rate was determined in a subset of aged animals using peripheral pulse 
oximetry (Kent Scientific, Torrinton, CT, USA). Mice were restrained in Perspex tubes and 
held in position with the introduction of a nose cone. An oximetry device was then 
introduced around the base of the tail to measure heart rate by measuring changes in 
peripheral skin colouration associated with pulse. Heart rate was measured every 30 
seconds over a five minute period and these values were averaged to provide the mean 
heart rate for each mouse. 
 
2.10 Histology 
2.10.1 Preparation of Samples 
Mouse aortae were dissected from the animal with perivascular fat attached and fixed in 4% 
paraformaldehyde (PFA, Sigma Aldrich, UK) for three days. Following fixation, samples were 
processed into paraffin blocks using an automated tissue processor (Tissue-Tek VIP Vacuum 
Infiltration processorm Sakura Tissue Tek VIP 1000). Paraffin-embedded tissues were cut 
into 5 μm sections using a microtome (Reichert-Jung 2030 Biocut microtome). Sections were 
then floated on water and subsequently mounted onto poly-l-lysine-coated microscope 
slides (Sigma Aldrich, UK) before leaving to dry overnight. 
For staining, sections were deparaffinised in 100% xylene (VWR BDH Prolab International 
Ltd) for 10 minutes, followed by immersion in 100% ethanol (VWR BDG Prolab International 
Ltd) for 5 minutes, 95% ethanol for 5 minutes and 70% ethanol for a further 5 minutes. 
Slides were immersed in distilled water for 5 minutes. 
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2.10.2 Masson’s Trichrome Staining 
Aortae were labelled with Masson’s Trichrome stain. This is a three-colour stain that 
identifies cellular cytoplasms as red/pink, cell nuclei as purple and connective tissues as 
blue. Following deparaffinisation, slides were immersed in Bouin’s Solution (Sigma Aldrich, 
UK) heated to 65°C for 15 minutes. After rinsing with water, slides were then immersed in 
haemotoxylin for 1 minute, Biebrich scarlet for 1 minute (0.09% Biebrich scarlet, 0.1% 
fuschin and 1% acetic acid, Sigma Aldrich, UK) and aniline blue for 1 minute (2.4% aniline 
blue, 2% acetic acid, Sigma Aldrich, UK). The resulting stained sections were then 
dehydrated through an ethanol gradient (70%, 95% and 100% ethanol for 5 minutes each) 
and re-immersed in 100% xylene. Slides were then allowed to air-dry prior to addition of 
DPX mountant (Sigma Aldrich, UK) and a glass coverslip. Slides were then allowed to dry 
overnight prior to visualization and quantification. 
 
2.10.3 Visualisation and Quantification of Aortic Histology 
Aortae were visualised by microscopy, using a colour video camera (Olympus U-CAMD 3 soft 
imaging system) connected to a light microscope (Olympus BX51). Quantification of aortic 
morphology was performed using specialised morphometry software (Cell P software, 1986-
2007, Imaging Solutions, GmbH). Parameters were measured in four replicate sections per 
animal and averaged to give the mean measurement for each experimental subject. Smooth 
muscle and collagen width were measured by taking eight measurements per section at 
roughly 45-degree angles to each other and then an average of these measurements was 
taken. Smooth muscle and collagen areas were measured by tracing the internal and 
external circumferences of the medial and adventitial layers using a free-hand polygon-
drawing tool and subsequent calculation of the area by the software from these parameters. 
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2.11 Myography 
Second-order mesenteric arteries (approximately 30-40 μm diameter at rest, 100 μm under 
tension) were isolated from juvenile and aged male αCGRP WT and KO mice and transferred 
immediately to ice cold Krebs-Henseleit buffer (118 mM NaCl, 24 mM NaHCO3, 1 mM 
MgSO4, 4 mM KCl, 0.5mM NaH2PO4, 5.5 mM glucose and 2.5 mM CaCl2,, Sigma Aldrich, UK). 
Arteries were cleaned of perivascular fat and mounted under a microscope in a Mulvany-
Halpern wire myograph (DMT 610M), using 0.025 mm tungsten wire. Arteries were then 
stretched to their optimal internal circumference IC1 = 0.9xIC100, where IC100 is an estimate of 
the internal circumference of the vessel under a passive transmural pressure of 100 mmHg 
(13.3 kPa), in order to obtain optimal conditions for active tension development following 
pharmacological stimulation. Vessels were maintained throughout the experiment in 37°C 
Krebs solution, gassed with 5% CO2 in air. 
Tissue viability was assessed by magnitude of peak contractions induced by three 45-second 
incubations in high-potassium Krebs (38 mM NaCl, 24 mM NaHCO3, 1mM MgSO4, 80 mM KCl 
and 0.5mM NaH2PO4, 5.5 mM glucose and 2.5 mM CaCl2). Contractions of < 1.5 mN were 
discarded owing to poor tissue viability. Endothelial function was tested using 10 μM 
carbachol (Sigma Aldrich, UK), where a relaxation of >60% over 1 minute was deemed to 
indicate preservation of endothelial function. No tissue was found to have endothelial 
function, by this metric, which was ascribed to handling of the tissue by the experimenter. 
U46619 (Sigma Aldrich, UK) was used to submaximally preconstrict the artery prior to 
assessment of endothelial function, using a concentration that induced 80% maximal 
response, as assayed by a full concentration-response curve. U46619 was chosen as a 
preconstrictor agonist over another commonly used agonist, phenylephrine, owing to the 
stable level of tone it produces. Phenylephrine, in my hands, was found to induce quite 
transient constrictions that were not amenable to interrogating vasodilator function. 
U46619 produced vasoconstrictions that were very stable over a 20-minute time period. 
Typically, 10 nM was sufficient to induce 80% maximal constriction.  
Cumulative concentration-response curves were constructed to various vasoconstrictor and 
vasodilator agonists. Vasoconstrictors were added to the bath at half log concentrations 
every two minutes. Phenylephrine (Sigma Aldrich, UK) was assayed between 100 pM and 10 
mM, until a plateau of the response was achieved. U46619 was assayed between 100 pM 
and 3 μM. Where vasodilators were assayed, vessels were preconstricted submaximally with 
U46619 and allowed to achieve prolonged tone over a 5-minute period. Following this, 
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increasing concentrations of either αCGRP (Cambridge Bioscences, UK) or sodium 
nitroprusside (SNP; Sigma Aldrich) were added to the bath at half log increments for one 
minute. CGRP was assayed between 100 pM and 1 μM. SNP was assayed between 1 pM and 
30 mM. Vehicle controls (water) were used for each drug and were not found to significantly 
alter vascular tone. Vasoconstrictor responses were either expressed as raw force generated 
in millinewtons (mN) or as a percentage of the maximal force generated by high potassium 
Krebs solution. Vasodilator responses were expressed as percentage change in 
preconstrictor-induced vasoconstriction. 
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2.12 Plasma CGRP ELISA 
Plasma CGRP was measured using an ELISA kit (rat/mouse, Phoenix Pharmaceuticals Inc., 
USA). This kit detects 0.16-100 ng/mL CGRP. Plasma peptides were extracted using SEP-
COLUMNs (Phoenix Pharmaceuticals, USA) before use in the ELISA. Briefly, plasma was 
acidified with an equal volume of citrate ‘Buffer A’ (Phoenix Pharmaceuticals, USA). SEP-
COLUMNs were then equilibrated with one wash of ‘Buffer B’ (Phoenix Pharmaceuticals, 
USA), followed by three washes of Buffer A. Acidified plasma was then loaded onto the 
column and allowed to filter through the column. Columns were then washed twice with 
Buffer A and peptide was eluted by washing columns with Buffer B. Peptide eluates were 
then concentrated by lyophilisation.  In this assay, a pre-coated plate contained secondary 
antibodies raised against an anti-CGRP primary antibody. This antibody was competitively 
bound by CGRP in the sample/standard or by biotinylated peptides. Where biotinylated 
peptides were bound, interaction with streptavidin-HRP allowed production of a yellow 
product from substrate. The intensity of colouration was directly proportional to the amount 
of CGRP bound to the primary antibody, and thus the concentration found in the extracted 
plasma sample. This kit displayed 100% cross-reactivity with β-CGRP and thus could not 
discriminate between both isoforms, leading to observable signal in KO mice. There was no 
cross-reactivity with other CGRP family peptides and this kit was capable of detecting 
between 0-100 ng/mL CGRP in plasma. 
 
2.13 Multiplex Cytokine ELISA 
Plasma cytokines were assayed in a small subset of aged male αCGRP WT and KO mice using 
a seven spot multiplex mouse pro-inflammatory assay kit (Meso-Scale Discovery, 
Gaithersburg, MD, USA). Standard manufacturer’s instructions were followed and reagents 
supplied. Results were expressed as picograms cytokine per mL of sample, calculated against 
a supplied standard curve. This assay employs a standard sandwich immunoassay format, 
where specific cytokine capture antibodies are pre-fixed on the specific spots on the base of 
the well. Cytokine levels were quantified using a cytokine-specific detection antibody 
labeled with a tag that emits light following electrochemical stimulation. All detection 
antibodies exhibited less than 1% cross-reactivity with other analytes. 
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2.14 Cell Culture 
Cell culture experiments made use of either HUVEC (HUVEC) or THP-1 monocytic cells. 
HUVEC were purchased from Lonza, USA; THP-1 cells from ATCC, USA. All cells were 
maintained in either complete M199 or RPMI-1640 medium at 37°C in a 5% CO2 humidified 
incubator. Subculture of HUVEC was performed on 85% confluent cells by washing twice 
with pre-warmed phospho-buffered saline (PBS) and incubating at 37°C with trypsin-EDTA (1 
mL/75 cm2; PAA Laboratories, L11-004) until complete detachment of cells was achieved (1-
2 minutes). Cells were then resuspended in complete M199 and replated. HUVEC were 
initially expanded to third passage in T175 (175 cm2) flasks, pre-coated with 10 μg/mL 
bovine fibronectin (Sigma Aldrich, UK). HUVEC were grown in complete M199 medium, 
supplemented with 10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 2 mM L-
glutamine. Further EC supplements were included, as follows: 1 ng/mL EC growth factor 
(Sigma Aldrich), 3 μg/mL EC growth supplement from bovine neural tissue (Sigma Aldrich), 
10 U/mL heparin (Sigma Aldrich) and 1.25 μg/mL thymidine (Sigma Aldrich).  All experiments 
using HUVEC were performed at fourth passage. 
Subculture of THP-1 cells in suspension was performed by splitting cells once the initial 
culture had reached a density of 800,000 cells/mL and reseeding in complete RPMI at a 
density of 50,000 cells/mL. THP-1 were grown in complete RPMI-1640 medium, 




2.15 Parallel Plate Flow Chamber Assay 
For parallel plate flow chamber experiments, HUVEC were grown in 6-well plastic dishes and 
were allowed to form a confluent monolayer. Prior to flow assay, HUVEC were stimulated 
with 10 ng/mL human recombinant TNFα (R&D Systems, UK) or vehicle (ddH2O) for six hours 
to induce endothelial activation. Where the effect of CGRP on the leukocyte was being 
assessed, THP-1 cells were stimulated for 5 minutes with 300 nM CGRP or vehicle (Protocol 
1, Figure 7). Where the effect of CGRP on EC biology was being assessed, HUVEC were also 
stimulated with 300 nM human αCGRP (Bachem, Switzerland) or vehicle (ddH2O) for 1, 3 or 
6 hours (Protocol 2, Figure 8). Following the six-hour incubation, HUVEC medium was 
supplemented with 25 nM HEPES in order to act as a pH buffer for the duration of the 
experiment taking place outside the cell culture incubator. Prior to the perfusion 
experiment, THP-1 cells were labeled with 10 nM CellTracker Green (Molecular Probes, 
Invitrogen, Paisley, UK) in order to visualise their interactions with the endothelium. THP-1s 
were then harvested by centrifugation and resuspended in perfusion medium (complete 






































All flow chamber experiments were performed inside an environmental chamber at 37°C 
and 5% CO2 (SolentScientific). A Harvard syringe pump (Harvard Apparatus, USA) was used 
to generate a physiological flow rate of 0.25 mL/minute, which corresponds to a shear stress 
on the endothelium of 1.24 dyn/cm2, a value comparable to microvascular shear stress. 
Leukocyte-EC interactions were visualised using an Olympus IX81 time-lapse inverted 
fluorescence microscope, connected to a Hamamatsu C10600 ORCA-R2 digital video camera. 
Images were acquired as video files from a CCD camera with video recorder, using Volocity 
Imaging Software, Perkin Elmer. The parallel plate flow chamber assay was assembled and 
performed as follows, and illustrated in Figure 9: 
1. A silicon gasket was attached to the plastic flow chamber, comprised of inlet/outlet 
ports and a vacuum port to allow for firm attachment to the cell culture dish. 
2. Inlet/outlet and vacuum tubes were attached to their respective ports and the 
vacuum pump was switched on. 
3. Perfusion medium was washed through the inlet tube and drawn through the outlet 
tube to remove air bubbles. The flow chamber was then lowered onto the dish and 
the chamber was fixed onto the culture via vacuum. The syringe pump was then 
switched on and medium was allowed to perfuse the endothelium. 
4. Using phase-contrast microscopy, three regions of the endothelial monolayer were 
pre-selected as suitable platforms for leukocyte recruitment, based on a confluency 
of >90%. This led to unbiased quantification of leukocyte adhesion as regions were 
selected prior to perfusion of white blood cells. 
5. The inlet tube was then switched to a bijou containing the THP-1 cells and this was 
considered time zero of the flow experiment. Leukocyte-EC interactions were 
recorded from this time using a x4 objective. Three frame-views per minute were 
acquired for the phase contrast and GFP channels to visualise the endothelium and 
THP-1s, respectively. Adherent cells were then counted manually throughout the 













Figure 9: Figure illustrating flow chamber assay setup. Top part of the chamber containing inlet/outlet ports and vacuum pump tube was attached to the silicon gasket. Inlet/outlet tubes 
and vacuum pump tube were then attached to their respective ports. Vacuum force was then applied and the chamber was then placed onto the HUVEC monolayer until a vacuum was 
achieved. The attached chamber was then was placed over the objective of an inverted fluorescence microscope in an environmental chamber heated to 37°C and maintained with 5% 
CO2. A syringe pump applied suction force that drew the THP-1 cell suspension through the chamber at a specified flow rate. The flow-through waste medium containing unbound cells 
was collected in an effluent syringe. Video footage of the microscope image was recorded by a CCD camera with video recorder, connected to the computer, acquired with Volocity 
visualization and analysis software. 
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2.16 Analysis of gene expression using real-time quantitative polymerase chain 
reaction (RTqPCR) 
2.16.1 RNA isolation and purification 
Total tissue RNA was extracted and purified from samples using Qiagen Microarray RNA 
extraction kits (Qiagen, UK), in accordance with the manufacturer’s instructions. Samples to 
be processed for RNA extraction were dissected with clean tools and placed immediately 
into 500 μL RNAlater solution (Applied Biosystems, Life Technologies Ltd, Paisley, UK) for a 
minimum of 24h at 4°C, followed by long-term storage at -80°C until required. 
During RNA extraction, tissue samples were removed from RNAlater and placed into a 
microcentrifuge tube containing 700 μL QIAzol reagent and a 5mm stainless steel bead. 
Samples were then homogenised using a Tissue Lyser II LT for 2 minutes at 20Hz. 200 μL 
chloroform was then added to each sample, followed by centrifugation at 12,000 rpm for 15 
minutes at 4°C to induce organic phase separation. The upper aqueous phase containing 
nucleic acids was then sequentially purified and eluted with silica-based spin columns for 
RNA extraction using ethanol (70% in RNAse/DNAse-free water) and wash buffers 
(phosphate buffers: RW1 and RPE which facilitate binding of nucleic acid to silica columns 
and allow excess ethanol and unwanted cellular components to be eluted and discarded). 40 
μL RNA was then eluted in nuclease-free water and stored at -80°C until required. 
 
2.16.2 Quantification of RNA yield 
RNA concentration and purity were determined by use of a spectrophotometer (Nanodrop 
1000, Thermoscientific, UK). 1 μL sample was loaded onto the spectrophotometer and 
absorbance was measured at 260nm, allowing RNA concentration to be calculated on the 
basis that 1 unit of absorbance corresponds to 40 μg/mL RNA. The ratio of absorbance at 
260/280nm gave an estimate of RNA purity, with regards to contamination by protein 
(typically giving an absorption peak at 280nm). The ratio of absorbance at 260/230nm gave 
an estimate of organic solvent contamination (i.e. ethanol, absorbing at 230nm). Where RNA 
did not seem ‘clean’, it was cleaned up via ethanol precipitation. If samples still had 
evidence of impurity following ethanol cleanup, samples were not used for further analysis. 
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2.16.3 Reverse Transcription 
RNA (500ng) was reverse-transcribed into complimentary DNA (cDNA) using the High 
Capacity RNA to cDNA kit (Applied Biosystems, UK), in accordance with manufacturer’s 
instructions. Total RNA was aliquoted in nuclease-free water to produce the required 
concentration. RNA was then reverse-transcribed using a thermal cycler (DNA Engine Tetrad 
2 Peltier Thermal Cycler) at 37°C for 60 minutes, 95°C for 5 minutes and then held at 4°C for 
a minimum of 5 minutes. cDNA was then stored at -20°C before use in RTqPCR experiments. 
Samples that underwent the reverse transcription reaction without active enzyme were 
used as negative controls, to prove that signal observed in later experiments was dependent 
on the formation of cDNA. 
 
2.16.4 RTqPCR 
Real time quantitative PCR (RTqPCR) was performed using aforementioned cDNA samples 
using a SybrGreen-based PCR mix (Sensi-Mix, SYBR-green no ROX, Bioline, UK). Briefly, a 10 
μL reaction mix was created using 5 μL SYBR Green, 0.5 μL of forward and reverse primers 
(stock concentration 10 μM), 2 μL nuclease-free water and 2 μL of sample cDNA. 
Target genes were amplified using a three-step program in a PCR thermocycler (Rotor-Gene 
6000, Qiagen) under the following conditions: (1) the polymerase enzymes were first 
activated by heating samples to 95°C for 10 minutes, (2) then subjected to 40 cycles of 95°C 
for 10s to denature strands, 57°C for 15 seconds to anneal primers to target cDNA and 72°C 
for 10 seconds to amplify product. (3) Samples were then finally melted at 68-90°C. Details 
of primers used and their respective PCR products are summarised in Table 3. Target gene 
expression was expressed as copies/μL sample and standardised to the internal reference 
genes GAPDH, β-actin and PLA2. Efficiency of the RTqPCR reaction was assessed by 
examination of the product melt curve to ensure only one PCR product was formed. Using 
GeNorm v1.2 software, a normalisation factor for each sample was obtained, based on 
calculation of the geometric mean of the reference genes analysed (Vandesompele et al., 
2002). RTqPCR was performed on all samples simultaneously to minimise experimental 
artefacts related to sample/internal standard degradation, variations in sample preparation 
and efficiency of PCR reactions.  
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 Forward Sequence Reverse Sequence Amplicon 
Size (bp) 
αCGRP AGCAGGAGGAAGAGCAGGA CAGATTCCCACACCGCTTAG 71 
βCGRP CCTGCAGGCCTGAGTCAC GGCATGGTGAGTTCAACTTTATG 64 
CLR CTCCTGAGACTATTCCCACAGAA CAAGATGTTGCTGTATCATCATAGG 72 
eNOS GACCCTCACCGCTACAACAT GTCCTGGTGTCCAGATCCAT 62 
F4/80 CAACCTGCCACAACACTCTC AGTCCTGAGTTGCACGTACA 52 
HO-1 GGTCAGGTGTCCAGAGAAGG CTTCCAGGGCCGTGTAGATA 70 
HPRT-1 TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 90 
MCP-1 ACTGAAGCCAGCTCTCTCTTCCTC TTCCTTCTTGGGGTCAGCACAGAC 274 
MPO CCTGGAGTCAATCGCAATGG TCCTTGGTCAGCTGATCGTT 92 
NOX2 TGCCAACTTCCTCAGCTACA GTGCACAGCAAAGTGATTGG 73 
NOX4 GAACCCAAGTTCCAAGCTCA AAGGCACAAAGGTCCAGAAA 63 
PLA2 TGGATATAAACCATCTCCACCA GGGAAGGGATACCTATGTTCAGA 77 
p16 CCCGCCTTTTTCTTCTTAGC TTCTCATGCCATTCCTTTCC 172 
p53 ACAGTCGGATATCAGCCTCG GCTTCACTTGGGCCTTCAAA 159 
RAMP1 TGACTATGGGACTCTCATCCAG CCTGCTTGGTGCAGTAAGTG 137 
RAMP2 CTGAGGACAGCCTTGTTGTCA GGCATCGCTGTCTTTACTCC 374 
SDHA CCCTGAGCATTGCAGAATC TCTTCTTCCAGCATTTGCCTTA 70 
TRPV1 CAACAAGAAGGGGCTTACACC TCTGGAGAATGTAGGCCAAGAC 77 
VCAM-1 TGGTGAAATGGAATCTGAACC CCCAGATGGTGGTTTCCTT 86 
 
Table 3: List of primer sequences used in RTqPCR experiments, including forward and reverse sequences and 
target amplicon size. 
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2.17 Analysis of gene expression using transcriptome array 
Microarray experiments were performed in collaboration with Dr. Matthew Arno of the 
Genomics Centre, King’s College London. RNA extraction from HUVEC cultures was done 
personally and Dr. Matthew Arno performed subsequent experimental steps leading up to 
data analysis. We also thank Dr. Matthew Arno for assistance in data analysis. 
Briefly, total RNA was extracted from HUVEC treated in a similar manner to those used in 
flow chamber assays, with respect to CGRP and TNFα, using a Qiagen RNeasy Plus Mini Kit 
extraction kit. HUVEC monolayers were washed twice with ice-cold PBS and then lysed 
directly using 350 μL Buffer RLT plus to cover the surface of the dish. The lysate was then 
passed through a 20-gauge needle fitted to an RNase-free syringe to shear genomic DNA. 
The lysate was then transferred to a gDNA eliminator spin column and centrifuged for 30 
seconds at 10,000 rpm prior to the addition of an equal volume of 70% ethanol. The sample 
was then transferred to an RNeasy spin column and centrifuged for 15 seconds at 10,000 
rpm. Following subsequent washes with Buffer RW1 and Buffer RPE, RNA was eluted from 
the spin column in 40 μL RNase-free water and stored at -80°C prior to use. 
Total RNA integrity was analysed using Agilent RNA 6000 Nano Kit and Agilent 2100 
Bioanalyser (Agilent Technologies, USA), in accordance with the manufacturer’s protocol. 
RIN values representing RNA integrity were obtained and samples with RIN values >8 were 
deemed acceptable for use in microarray experiments. 500 ng RNA was then reverse-
transcribed into cDNA using the High Capacity RNA to cDNA kit (Applied Biosystems, UK), in 
accordance with manufacturer’s instructions. Total RNA was aliquoted in nuclease-free 
water to produce the required concentration. RNA was then reverse-transcribed using a 
thermal cycler (DNA Engine Tetrad 2 Peltier Thermal Cycler) at 37°C for 60 minutes, 95°C for 
5 minutes and then held at 4°C for a minimum of 5 minutes. cDNA was then stored at -20°C 
before use in microarray experiments. HUVEC cDNA was then labeled and fragmented and 
then used to hybridise Affymetrix GeneChip Human Transcriptome Array 2.0. Chips were 
then washed and stained using the GeneChip Fluidics Station 450, in accordance with 
manufacturer’s instructions. Following staining, the Affymetrix GeneChip Scanner (GCS3000) 
was used to scan the chips. Data generated by chip scanning was normalised, summarized 
and background corrected using the standard gene-level Robust Multi-array Average (RMA) 
method, as included in the Expression Console package from Affymetrix. For analysis of 
array data, two-tailed student’s t-test was applied, using the Benjamini and Hochberg false 
discovery rate (FDR) multiple testing correction, in order to limit the detection of false 
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positives from multiple testing. For this, a FDR threshold of q = 0.05 was used. Here, the p-
values of differences in expression of each gene are ranked from smallest to largest. The 
largest p-value remains as it is, whilst the second largest p-value is multiplied by the total 
number of genes identified, divided by its rank in the list and so on throughout the ranked 
list. If this value is less than 0.05, it is considered to be a statistically significant effect. 
Differentially-expressed genes were then enriched into known biological pathways using 
MetaCore GeneGo software (Thomson Reuters), in order to understand better how 
observed changes related to biologically-meaningful phenomena. Enrichment pathways 
were ranked according to the likelihood that genes identified in microarray analysis 
appeared in pre-defined networks. The hypergeometric mean was used to take into account 
the number of objects appearing in the microarray dataset, the number of objects in the 
intersecting networks and the number of objects in the entire network database. This 
returned a p-value that showed the likelihood that the intersection between the microarray 
dataset and a particular network was obtained purely by chance. As some p-values were 
classed as being very significant, these values were multipled by –log10 for ease of 
visualisation in a histogram. The top 10 most significantly enriched pathways were then 
ranked and graphed. 
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2.18 Western Blotting 
2.18.1 Sample Preparation 
Tissue samples were dissected from mice and snap frozen in liquid nitrogen, prior to storage 
at -80°C. Tissues were then homogenised in 700 μL sodium dodecyl sulphate (SDS) lysis 
buffer (50 mM Tris base pH 6.8, 10% glycerol and 2% SDS) supplemented with 0.02% 
protease inhibitor cocktail (4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, bestatin, 
E-64, leupeptin and aprotinin) and phosphatase inhibitor (1 tablet/10 mL PhosSTOP, Roche, 
UK) in a microcentrifuge tube containing a 5 mm stainless steel bead, using a Tissue Lyser II 
LT (2-5 minutes, 30Hz). Tissue homogenates were centrifuged at 13,000rpm for 15 minutes 
at 4°C and supernatants were then collected and stored at -20°C. Cell culture samples were 
collected on ice by the addition of 200 μL lysis buffer, followed by mechanical disruption 
before transferring to a microcentrifuge tube. 
 
2.18.2 Determination of protein concentration 
To determine sample protein content, the BCA assay was performed using the BioRad 
Reagent A/Reagent B kit (Bio-Rad, UK). To generate a standard curve to calculate sample 
concentration, bovine serum albumin (BSA, 5 μL of 0.1-2 mg/mL) was dissolved in double-
distilled water. Samples were diluted 1:10 in ddH2O if found to be too concentrated. Both 
standards and samples were loaded in duplicate into clear wells of a 96-well microplate and 
incubated with 25 μL Reagent A and 200 μL Reagent B. The plate was placed on a microplate 
shaker and incubated for 15 minutes at room temperature. Following this, the plate was 
read at an absorbance spectrum of 750nm on a plate spectrophotometer (SpectraMAX 190, 
SOFTmaxPRO software v3.13, Molecular Devices Corporation, California, USA). Protein 
standard curves were generated by expressing the mean optical density values obtained at 
750nm relative to the known protein concentration of the BSA standard. Standard curves 
with correlation coefficients of > 0.90 were acceptable for use. Sample protein 






Following quantification of protein concentration, 30 μg of protein was reduced with 10% 2-
mercaptoethanol and 0.2% bromophenol blue used as a sample marker. Protein samples 
were then boiled at 95°C for 5 minutes to denature. Samples were then loaded alongside a 
molecular weight marker into lanes of a pre-set SDS-PAGE gel prior to electrophoresis. The 
gel was comprised of a lower resolving gel (10% polyacrylamide of composition: 3 mL 30% 
acrylamide (National Diagnostics, UK); 2.25 mL 0.5M tris-HCl (pH 8.8); 3.75 mL of ddH2O; 45 
μL 10% ammonium persulphate and 15 μL tetramethyethyldiamine) and an upper stacking 
gel (5% polyacrylamide of composition: 1.75 mL ddH2O; 750 μL Tris-HCl pH 6.8; 500 μL of 
30% acrylamide, 25 μL 10% ammonium persulphate and 10 μL tetramethylethyldiamine). 
The final concentration of acrylamide in the resolving gel was altered depending on the mass 
of the protein of interest. 12% gels were run for proteins of mass 20-60 kDa, 10% gels were 
run for proteins of 60-100 kDa and 8% gels were run for proteins of >100 kDa. SDS PAGE was 
performed in running buffer (10% tris-glycine buffer (BioRad, USA), 0.5% 20% SDS pH 7.2 in 
ddH2O) at 150V for approximately 1.5-2 hours. 
 
2.18.4 Immunoblotting 
Following SDS-PAGE, gels were allowed to equilibrate in transfer buffer (10% Tris-glycine 
buffer (BioRad, USA), supplemented with 20% methanol (Fisher Scientific, UK) in ddH2O). 
Polyvinyldiene difluoride (PVDF) membranes were activated in methanol for one minute and 
then equilibrated in transfer buffer. Gels and membranes were assembled into a sandwich 
and transferred to a semi-dry electrophoretic transfer apparatus (BioRad, USA). The 
separated proteins were then electro-transferred onto the PVDF membrane at 20V for 2 
hours whilst bathed in transfer buffer. 
Following transfer of proteins to PVDF, the membrane was rinsed in PBS to remove excess 
transfer buffer. Then, the membrane was blocked with 5% skimmed milk powder in 
phospho-buffered saline (PBS) plus 0.01% Tween-20 (PBST) for 1 hour at room temperature, 
in order to block non-specific binding sites present on the membrane. Membranes were 
then washed for 15 minutes in PBS followed by alternating 5-minute washes of 
PBS/PBST/PBS. Primary antibodies were diluted in 5% milk in PBS and were either incubated 
for 1h at room temperature or overnight at 4°C. Membranes were then washed in 
alternations of PBS/PBST in accordance with the aforementioned washing protocol. 
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Subsequently, horseradish peroxidase-conjugated secondary antibodies were incubated 
with the blot for 1h at room temperature, followed by another 30 minute wash procedure 
to remove excess. A list of primary and secondary antibodies used throughout this thesis is 
shown in Table 4. 
For protein detection, the membrane was incubated with 1 mL enhanced 
chemiluminescence solution (Millipore, UK) for 60 seconds and then exposed to 
photographic film. Photographic films were scanned into a computer and densitometric 
image analysis was performed using ImageJ software (v1.32, NIH, USA). Proteins were 
usually expressed as arbitrary densitometric units, relative to an internal housekeeping 
protein, such as β-actin. Where phospho-specific antibodies were used, these proteins were 

















Antibody Manufacturer Catalogue No Species Dilution 
Anti-β-actin Sigma Aldrich A1978 Mouse 1 : 2000 
Anti-4HNE Abcam ab46545 Rabbit 1 : 2000 
Anti-VCAM-1 Santa Cruz sc-8304 Rabbit 1 : 1000 
Anti-eNOS Santa Cruz sc-654 Rabbit 1 : 500 
Anti-phospho-eNOS Cell Signalling 95715 Rabbit 1 : 500 
Anti-JAM-A Abcam ab52647 Rabbit 1 : 1000 
Anti-JAM-C Abcam ab89665 Mouse 1 : 1000 
Anti-Nitrotyrosine Abcam ab61392 Mouse 1 : 500 
Anti-PECAM-1 Santa Cruz sc-1506 Goat 1 : 1000 
Anti-Goat Dako P0449 Rabbit 1 : 2000 
Anti-Mouse Dako P0260 Rabbit 1 : 2000 
Anti-Rabbit Dako P0448 Goat 1 : 2000 
 
Table 4: Table detailing primary and secondary antibodies used throughout this thesis, including target 
protein, manufacturer, catalogue number, species and working dilution used. 
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2.19 Data Analysis 
Data were analysed in Microsoft Excel and GraphPad Prism 5.0, expressed as mean ± standard error 
of the mean (SEM). Where groups had smallsample sizes (i.e. 3-5), the SEM is used as a predictive 
value to illustrate data variation only.In this case, SEM is shown for these groups in order to allow 
illustration of data variability in a similar manner to the rest of the data shown in this thesis. All data 
sets were tested for normality using the Shapiro-Wilks test. Where they conformed to Gaussian 
distribution, data were analysed using the appropriate parametric test. Where data were found to 
be non-normally distributed, non-parametric tests were used. Specific statistical tests used for each 
data set are specified in each figure legend.  
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3. | Chapter Three: Characterisation and Phenotyping of the Ageing 
αCGRP WT and KO Mouse 
3.1 Introduction 
As discussed in the general introduction, relatively few papers have been published concerning the 
role of CGRP in regulating (patho)physiological processes as part of the ageing process. Of these, 
none have used the CGRP KO mouse to address this research question. As a result, there is little 
information concerning how αCGRP gene deletion affects parameters of growth and development 
in the mouse. However, in a major study by Walker et al., data suggest that by 3 months of age, 
αCGRP KO mice begin to be protected against diet-induced obesity when compared to their WT 
counterparts. This was attributable to a lowered degree of general adiposity and improved overall 
metabolic health (Walker et al., 2010b). However, this study only followed the growth of these mice 
until around 8 months of age, which may not be considered as truly geriatric. Development of other 
organs essential to cardiovascular regulation has not been studied in the ageing αCGRP mouse. 
There is a larger body of evidence that considers the changing dynamics of CGRP at the mRNA, 
protein and functional level as the organism ages. Many of these studies use the SHR model of 
hypertension and thus it is unclear as to whether CGRP is altered as a result of ageing, hypertension 
or a combination of both. The general consensus here, however, appears to be that CGRP 
expression within its principle site of synthesis (i.e. the DRG) declines as the SHR ages (Yamaga et 
al., 2001). As the animal becomes more hypertensive, the innervation of CGRP-positive nerve fibres 
in the vascular environment is also thought to decrease (Kawasaki et al., 1990a; 1991). Thus, less 
releasable CGRP is present (Kawasaki and Takasaki, 1992; Sun et al., 1998). This reduction in 
bioavailability may be reflected in the bloodplasma compartment, although this is currently 
unknown. Accompanying alterations in CGRP bioavailability with age may also be coupled with 
changes in functionality.  Indeed, Chan & Fiscus have shown that caudal arteries and aortae isolated 
from elderly rats are significantly less capable of mounting a vasorelaxant response to exogenous 
CGRP both in vitro and in vivo (Chan and Fiscus, 2002). Despite being an interesting phenotype, this 
study has yet to be reproduced and the mechanism governing this attenuation in bioactivity is 
hitherto unknown. It is known that vascular reactivity to CGRP can be altered in CVD states, such as 
in a model of subtotal nephrectomy-salt induced hypertension. In this, the vascular response to 
CGRP is enhanced due to increased vascular expression of the RCP protein (Supowit et al., 2011). 
Thus, it is conceivable that changes in CGRP bioactivity may be related to alterations in receptor 
expression at the vascular level. At this stage, it is unknown how CGRP expression and functionality 
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is regulated by ageing in isolation and, indeed, how it is regulated over time in the mouse. 
Secondary to this, there is no current information on how CGRP receptor expression is altered as 
part of the ageing process. 
3.2 Hypothesis 
Deletion of αCGRP will not affect gross parameters of growth and development as mice age from 3 
months to 15 months. We hypothesise that expression of CGRP at the gene and protein level will 




1. To investigate the role of αCGRP gene deletion on mouse growth and development in young 
and aged αCGRP WT and KO mice. 
2. To investigate how the dynamics of αCGRP gene and protein expression are regulated in 
young and aged αCGRP WT and KO mice. 
3. To investigate how vascular reactivity is altered in resistance vessels obtained from young 
and aged αCGRP WT and KO mice and how expression of CGRP receptor components may 




3.4.1 Developmental characteristics of the ageing αCGRP WT and KO mouse 
In order to evaluate the effect of αCGRP gene deletion on gross developmental parameters with 
advancing age, mice were weighed at 3 and 15 months of age. Figure 10A shows that total body 
weights of juvenile WT and KO mice were comparable (27.80 ± 0.58 g vs 26.95 ± 0.40 g, 
respectively) and body weight increased significantly as both WT and KO mice aged to 15 months, 
although no differences were detected between WT and KO (42.91 ± 3.73 g vs 49.30 ± 3.22 g, 
respectively). We also sought to determine how body fat composition changed with age by 
weighing of the epididymal adipose tissue. Figure 10B demonstrates that epididymal fat content is 
similar between juvenile WT and KO mice (241.90 ± 31.23 mg vs 265.75 ± 27.04 mg, respectively) 
and significantly increased in mass with advancing age in both genotypes, with no significant 
differences between aged WT and KO (2436.71 ± 339.99 mg vs 2771.66 ± 711.92 mg, respectively). 
In order to exclude increased fat content as a function of increased body weight, Figure 10C 
illustrates how fat content changes when expressed as a ratio to body weight. In this case, fat 
content is significantly increased in both WT and KO mice as they age to 15 months. This indicates 
that animals have more fat as they get older, regardless of body size. Again, no differences were 
detected between WT and KO mice at either timepoint. 
Aside from body weight/fat content analysis, we examined how the growth of some organs was 
affected by CGRP gene deletion, both at 3 and 15 months of age. We found juvenile WT and KO 
animals had similar wet heart weights (136.40 ± 6.27 mg vs 141.92 ± 4.96 mg, respectively) that 
increased significantly as the animals aged (203.54 ± 18.35 mg vs 201.66 ± 11.22 mg, respectively) 
(Figure 11A). When heart weight was expressed as a ratio to body weight, this difference was not 
apparent, indicating that hearts grew in line with increases in body weight (Figure 11B). Similar 
results were observed for left andright kidney weights (Figures 12A-D) and spleen weights (Figures 
















Figure 10: Growth parameters of juvenile (3 months) and aged (15 months) αCGRP male WT and KO mice. Results show 
A) total body weights of male juvenile and aged αCGRP WT and KO mice; B) total epididymal fat weight of male 
juvenile and aged αCGRP WT and KO mice; C) epididymal weight expressed as a function of body weight of male 
juvenile and aged αCGRP WT and KO mice. Data expressed as mean ± SEM, n = 6-12. Statistical significance was 
evaluated by two-way ANOVA plus Bonferroni post hoc test. ****p < 0.0001 where juvenile and aged animals of the 








Figure 11: Heart weights of juvenile (3 months) and aged (15 months) αCGRP male WT and KO mice. Results show A) 
total heart weights of male juvenile and aged αCGRP WT and KO mice; B) heart weight expressed as a function of body 
weight of male juvenile and aged αCGRP WT and KO mice. Data expressed as mean ± SEM, n = 6-12. Statistical 
significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. ***p < 0.001; ****p < 0.0001 where 














Figure 12: Left and right kidney weights of juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. 
Results show A) total left kidney weights of male juvenile and aged αCGRP WT and KO mice; B) left kidney weight 
expressed as a function of body weight of male juvenile and aged αCGRP WT and KO mice; C) total right kidney weights 
of male juvenile and aged αCGRP WT and KO mice; D) right kidney weight expressed as a function of body weight of 
male juvenile and aged αCGRP WT and KO mice. Data expressed as mean ± SEM, n = 6-12. Statistical significance was 
evaluated by two-way ANOVA plus Bonferroni post hoc test. ***p < 0.001; ****p < 0.0001 where juvenile and aged 











Figure 13:  Spleen weights of juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Results show A) 
total spleen weights of male juvenile and aged αCGRP WT and KO mice; B) spleen weight expressed as a function of 
body weight of male juvenile and aged αCGRP WT and KO mice. Data expressed as mean ± SEM, n = 6-12. Statistical 
significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. ***p < 0.001; ****p < 0.0001 where 
juvenile and aged animals of the same genotype have been compared. 
 
3.4.2 Temporal dynamics of CGRP mRNA and peptide expression in the ageing αCGRP WT and 
KO mouse 
We investigated how CGRP gene and protein expression changed as a function of age. Figure 14 
shows data obtained from a CGRP ELISA performed on plasma samples extracted from juvenile and 
aged αCGRP WT and KO mice. The antibody used in this assay cannot discriminate between CGRP 
isoforms and thus detects total CGRP circulating in the plasma. We found that circulating levels of 
CGRP are comparable in juvenile WT and KO animals (294.42 ± 81.34 ng/g vs 274.08 ± 77.87 ng/g, 
respectively). These levels did not change as animals grew older and there were no significant 
differences between genotypes (221.75 ± 61.21 ng/g vs 263.50 ± 70.65 ng/g, respectively). 
Therefore, further experiments were carried out to examine the isoform-specific expression of 
CGRP at the mRNA level within DRG, which may have more relevance than measuring CGRP in the 
plasma. Figure 15A confirms that αCGRP KO mice do not express any mRNA for αCGRP within the 
DRG. However, we have shown that αCGRP gene expression within the DRG is significantly elevated 
in juvenile vs aged WTs (383.75 ± 65.23 copies/μl vs 3157.50 ± 1015.05 copies/μl). Figure 15B 
illustrates how CGRP gene expression alters with age in αCGRP WT and KO mice. This figure shows 
that there is a significant compensatory upregulation of CGRP DRG transcript in juvenile αCGRP KO 
mice (2172.50 ± 773.43 copies/μl in WT vs 13491.67 ± 2082.54 copies/μl in KO). CGRP levels were 
high and similar in aged WT and KO mice (13491.00 ± 2082.53 copies/μl vs 10470.00 ± 4504.10 











Figure 14: Total plasma immunoreactive CGRP obtained from juvenile (3 months) and aged (15 months) male αCGRP 
WT and KO mice. Data expressed as nanograms CGRP per gram of protein, mean ± SEM, n = 4-12. Statistical significance 









Figure 15: mRNA expression of α and βCGRP isoforms in DRG of juvenile (3 months) and aged (15 months) male αCGRP 
WT and KO mice. Results show A) αCGRP mRNA expression in DRG obtained from male juvenile and aged αCGRP WT 
and KO mice; B) βCGRP mRNA expression in DRG obtained from male juvenile and aged αCGRP WT and KO mice Data 
expressed as copies per microliter, mean ± SEM, n = 4-13. Statistical significance was evaluated by two-way ANOVA 





3.4.3 Evaluation of vascular reactivity of mesenteric resistance arteries in the ageing αCGRP WT 
and KO mouse 
Phenotyping of vascular reactivity in juvenile and aged αCGRP WT and KO mice was performed via 
small vessel wire myography. Initial studies illustrated in Figure 16 show the differential vascular 
response to 80 mM K+ stimulation. Juvenile WT and KO mice responded similarly to this stimulus, 
producing a force of 3.57 ± 0.41 mN vs 3.89 ± 0.34 mN, respectively. The response to high 
potassium was significantly increased in both WT and KO animals as they aged, with no difference 
between genotypes (5.36 ± 0.39 mN vs 5.04 ± 0.25 mN, respectively). Figure 17 shows endothelial-
dependent vasodilatory responses to 10 μM carbachol, where we show that none of the vessels 
used in our experiments produced >60% vasodilatation to this agonist, indicating that the 
endothelium was likely mechanically ruptured during preparation and therefore was not a 
contributing factor throughout experiments. 
Experiments then focused on the ability of vessels obtained from juvenile and aged αCGRP WT and 
KO mice to react to pharmacological agents known to produce vasoconstriction and vasodilatation. 
Figure 18 illustrates cumulative concentration-response curves constructed in response to 
phenylephrine (PE) stimulation. Figure 18A shows raw data expressed as force generated by PE 
whilst Figure 18 shows constriction expressed as total force generated by the vessel with 80 mM K+ 
stimulation. Here the data show that vessels obtained from juvenile WT and KO mice respond to PE 
in a similar manner, as measured by Emax (108.60 ± 4.71 % HiK vs 110.60 ± 4.50 % HiK, respectively) 
and EC50 analysis (logEC50 -5.89 ± 0.13 vs -6.08 ± 0.10, respectively). However, as animals aged to 15 
months, sensitivity to PE was significantly increased whilst Emax was preserved. Aged WT vessels had 
a lowered logEC50 of -7.53 ± 0.13 that was significantly different from their juvenile counterparts, 
whilst aged KO vessels had a logEC50 of -6.95 ± 0.10. A significant difference in logEC50 was detected 


















Figure 16: Myogenic response of isolated second order mesenteric arteries to high potassium stimulation (80mM K
+
), 
obtained from juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Data expressed as force in 
millinewtons (mN), mean ± SEM, n = 10-13. Statistical significance was evaluated by two-way ANOVA plus Bonferroni 














Figure 17: Assessment of endothelial viability in second order mesenteric arteries obtained from juvenile (3 months) 
and aged (15 months) male αCGRP WT and KO mice, stimulated with 10 μM carbachol. Data expressed as percentage 









Figure 18: Myogenic response of isolated second order mesenteric arteries to increasing concentrations of 
phenylephrine (PE) stimulation, obtained from juvenile (3 months) and aged (15 months) male αCGRP WT and KO 
mice. Results show A) total force generated by arteries obtained from male juvenile and aged αCGRP WT and KO mice; 
B) force generated expressed as a percentage of the maximal response of the contraction generated to 80mM K
+
. Data 
expressed as force in millinewtons (mN) or percentage of 80mM K
+




Table 5: Data illustrating pharmacological analysis of CCRCs constructed to PE in mesenteric arteries obtained from 
juvenile and aged male αCGRP WT and KO mice. Results show Emax (mN), Emax (%Hi K response) and logEC50 (M), 
expressed as mean ± SEM, n = 8-11. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post-hoc 
test. ****p < 0.0001, **p < 0.01 where juvenile and aged animals of the same genotype have been compared; ##p < 0.01 








Phenylephrine Juvenile WT Juvenile KO Aged WT Aged KO 
Emax (mN) 3.90 ± 0.27 4.49 ± 0.24 5.12 ± 0.24** 5.60 ± 0.19** 
Emax (%Hi K
+) 108.60 ± 4.70 110.60 ± 4.50 104.60 ± 4.60 117.00 ± 4.46****## 
logEC50 (M) -5.84 ± 0.20 -6.07 ± 0.14 -7.58 ± 0.13**** -6.86 ± 0.09****## 
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Subsequent experiments were undertaken to assess how vessels reacted to the thromboxane 
receptor agonist, U46619. Figure 19 illustrates concentration-response curves constructed in 
responseto U46619 stimulation. Figure 19A shows raw data expressed as force generated by 
U46619 whilst 19B shows constriction expressed as total force generated by the vessel with 80 mM 
K+ stimulation. Here the data reveal that vessels obtained from juvenile WT and KO animals respond 
in a similar manner, in terms of both Emax (119.80 ± 8.50 %High K
+vs 133.60 ± 8.30 %High K+, 
respectively) and logEC50 (-8.27 ± 0.21 M vs -8.14 ± 0.18 M, respectively) values. However, as the 
animals aged, there was a significant shift to the right of logEC50 values for both aged WT and KO 
mice (-6.79 ± 0.13 M vs -6.88 ± 0.19 M, respectively). Emax values were not found to change as the 
animals grew older. A summary of pharmacological parameters is included in Table 6. 
Finally, a series of concentration-response curves were constructed to vasodilator compounds to 
assess the ability of the murine vasculature to relax. Figure 20 illustrates time control experiments, 
showing that vascular tone achieved by U46619 did decline over the typical fifteen-minute 
experimental window, but not significantly so. This indicates that any changes in vascular tone due 
to a vasodilator agonist is attributable to that compound and not from a natural loss of vascular 
tone. Figure 21A illustrates CCRCs obtained in response to vascular stimulation with αCGRP 
following preconstriction with sufficient U46619 to generate 80% maximal constriction of the 
vessel. We found that juvenile WT and KO vessels again responded in a similar manner, in terms of 
both Emax (24.33 ± 6.92 %U46619 tone vs 39.02 ± 4.27 %U46619 tone, respectively) and logEC50 (-
8.44 ± 0.26 M vs -8.80 ± 0.23 M, respectively). As WT animals aged, there was a trend towards a 
reduction in sensitivity to exogenous CGRP stimulation, as measured by logEC50 that did not reach 
statistical significance. However, vessels obtained from aged KO animals produced a significant 
rightwards shift in logEC50 (-7.66 ± 0.42 M) when compared to juvenile counterparts and they also 
differed significantly from their aged WT counterparts (-7.73 ± 0.31 M). There was a trend towards a 
decrease in Emax values as animals aged that did not reach statistical significance. A summary of 
pharmacological parameters is included in Table 7. To control for VSMC impairment with age, we 
constructed CCRCs for the NO donor, sodium nitroprusside (SNP), illustrated in Figure 21B. There 
existed no differences in logEC50 or Emax values across groups for this agent. A summary of 










Figure 19: Myogenic response of isolated second order mesenteric arteries to increasing concentrations of U46619 
stimulation, obtained from juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Results show A) 
total force generated by arteries obtained from male juvenile and aged αCGRP WT and KO mice; B) force generated 
expressed as a percentage of the maximal response of the contraction generated to 80mM K
+
. Data expressed as force 
in millinewtons (mN) or percentage of 80mM K
+
, mean ± SEM, n = 6-10. 
 
 
Table 6: Data illustrating pharmacological analysis of CCRCs constructed to U46619 in mesenteric arteries obtained from 
juvenile and aged male αCGRP WT and KO mice. Results show Emax (mN), Emax (%Hi K response) and logEC50 (M), 
expressed as mean ± SEM, n = 6-10. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post-hoc 
test. ****p < 0.0001, *p < 0.05 where juvenile and aged animals of the same genotype have been compared. 
  
U46619 Juvenile WT Juvenile KO Aged WT Aged KO 
Emax (mN) 4.12 ± 0.35 5.49 ± 0.42 6.15 ± 0.65* 5.62 ± 0.59 
Emax (%Hi K
+) 119.80 ± 8.50 133.60 ± 8.30 124.90 ± 10.20 108.10 ± 11.07 











Figure 20: Myogenic response of isolated second order mesenteric arteries to a single concentration of U46619 
sufficient to induce 80% maximal vessel constriction, over fifteen minutes. Data expressed as percentage change in 












Figure 21: Myogenic response of isolated second order mesenteric arteries to increasing concentrations of vasodilators 
CGRP and SNP, obtained from juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Results show A) 
change in force of vessels preconstricted with EC80 concentrations of U46619, followed by CGRP stimulation in arteries 
obtained from male juvenile and aged αCGRP WT and KO mice; B) change in force of vessels preconstricted with EC80 
concentrations of U46619, followed by SNP stimulation in arteries obtained from male juvenile and aged αCGRP WT 
and KO mice. Data expressed as percentage change in U46619-mediated preconstricted tone, mean ± SEM, n = 10-12 
for CGRP, n = 5-8 for SNP. 
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Table 7: Data illustrating pharmacological analysis of CCRCs constructed to CGRP in mesenteric arteries obtained from 
juvenile and aged male αCGRP WT and KO mice, preconstricted with U46619. Results show Emax (%U46619 response) and 
logEC50 (M), expressed as mean ± SEM, n = 10-12. Statistical significance was evaluated by two-way ANOVA plus 
Bonferroni post-hoc test. *p < 0.05 where juvenile and aged animals of the same genotype have been compared; #p < 
0.05 where age-matched animals were compared to genodiscordant counterparts. 
 
 
Table 8: Data illustrating pharmacological analysis of CCRCs constructed to SNP in mesenteric arteries obtained from 
juvenile and aged male αCGRP WT and KO mice, preconstricted with U46619. Results show Emax (%U46619 response) and 




CGRP Juvenile WT Juvenile KO Aged WT Aged KO 
Emax (%U46619) 24.33 ± 6.92 39.02 ± 4.27 38.62 ± 8.86 55.79 ± 7.04 
logEC50 (M) -8.44 ± 0.26 -8.80 ± 0.23 -7.73 ± 0.31 -7.66 ± 0.42*# 
SNP Juvenile WT Juvenile KO Aged WT Aged KO 
Emax (%U46619) 34.95 ± 7.80 22.89 ± 6.29 18.03 ± 5.16 25.61 ± 5.95 
logEC50 (M) -5.87 ± 0.30 -6.01 ± 0.20 -6.12 ± 0.19 -5.63 ± 0.19 
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3.4.4 Temporal dynamics of vascular CGRP receptor complex gene expression 
Finally, we sought to examine the effect of αCGRP gene deletion on the regulation of CGRP receptor 
gene expression within the vasculature, both in juveniles and aged animals. Figure 22A 
demonstrates that aortic mRNA expression of the CLR is comparable between juvenile WT and KO 
animals (53.61 ± 27.02 copies/μl vs 15.92 ± 13.56 copies/μl, respectively). There is a significant 
increase in the expression of the CLR in aged WTs (187.70 ± 52.42 copies/μl) that was not different 
from aged KOs (99.66 ± 55.20 copies/μl). However, expression of the CLR did not significantly 
increase with age in the KO group. There were no other significant changes in aortic mRNA 















Figure 22: Gene expression analysis of CGRP receptor mRNA of aortic lysates obtained from juvenile (3 months) and aged 
(15 months) male αCGRP WT and KO mice. Results show A) mRNA expression of CLR in aortic lysates; B) mRNA 
expression of RAMP1 in aortic lysates; C) mRNA expression of RCP in aortic lysates. Data expressed as copies mRNA per 
microliter, mean ± SEM, n = 6-10. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. 
*p < 0.05 where juvenile and aged animals of the same genotype have been compared. 
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3.5 Discussion 
In this Chapter, we aimed to characterise the response to ageing in male αCGRP WT and KO mice by 
examining gross aspects of their development, with respect to key cardiovascular organs (heart, 
kidney) and organs that may contribute pathologically to the metabolic syndrome (abdominal fat), 
including organs that may indicate immune system dysfunction (spleen). Further, we aimed to clarify 
how CGRP bioavailability alters as part of the ageing process and how this bioavailability may 
impinge upon bioreactivity and CGRP receptor expression. Alterations in these key processes may 
help us understand how CGRP contributes towards pathology, if it exists, in the ageing mouse. 
3.5.1 Deletion of αCGRP does not adversely affect weight gain, adiposity or organ development 
in the ageing mouse 
We initially attempted to characterise the growth and developmental characteristics of juvenile and 
aged αCGRP WT and KO mice. In brief, as expected, we discovered that animals increased their body 
weight as they aged to fifteen months. No differences were observed between genotypes for this 
parameter. We also witnessed a significant increase in epididymal fat content as animals aged. 
Interestingly, however, this increase did not appear to be directly linked to a general increase in 
body size. Instead, it would appear that mice aged fifteen months had a higher percentage of their 
body weight attributable to fat than their juvenile counterparts.  Our results are in contrast to that 
of an important study published by Walker et al. in 2010. Here, the authors report that CGRP WT 
and KO mice have similar body weights when youngbut as the animals age to 250 days (~9 months), 
CGRP KO mice appear to have lower body weights (Walker et al., 2010b). Further, KOs protected 
against high fat diet-induced obesity, meaning one might expect differences in epididymal adiposity 
to be reflected in our results. It is possible, however, that differences in adiposity may only be 
revealed in a pathological model of obesity, rather than simply with increases in fat occurring as part 
of the natural ageing process. Our results also showed that organ weights (heart, kidney and spleen) 
progressively increased in line with body weight as the animals aged but CGRP gene deletion did not 
affect tissue weights. Overall, we concluded that CGRP gene deletion did not appear to adversely 
affect whole body growth or development of organs essential to cardiovascular (heart, kidney) or 
immunological (spleen) function. 
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3.5.2 Local expression of CGRP is increased in the ageing mouse: evidence for a compensatory 
role for βCGRP in the αCGRP KO mouse 
We have shown for the first time how circulating levels and localised tissue expression of both CGRP 
isoforms change over time in the αCGRP KO mouse. Analysis of plasma CGRP provided surprising 
results where we found that levels of circulating CGRP were virtually indistinguishable when 
comparing juvenile WT and KO animals. The ELISA used to detect plasma CGRP makes use of an 
antibody with a paratope that is unable to discriminate between CGRP isoforms, presumably owing 
to their high sequence homology. Therefore, we assume that the signal observed in the KO mice is 
due to βCGRP expression. It would therefore appear that βCGRP expression is increased in αCGRP 
KO mouse as part of a compensatory mechanism to counteract the deletion of the primary isoform. 
We have previously shown a similar result in vehicle-treated αCGRP WT and KO mice as part of an 
ATII model of hypertension. Here, both genotypes had similar circulating levels of CGRP (Smillie et 
al., 2014). One novel and perhaps surprising finding of ours in this study was that circulating CGRP 
levels appeared to go unchanged as mice aged to fifteen months. Further to this, the degree of 
compensation from βCGRP appeared to be maintained throughout this time. It is curious that total 
levels of CGRP appear to be similar when comparing WT and KO mice. Even with a level of 
developmental compensation, one might expect KO mice to have slightly less circulating peptide. A 
potential reason the observed βCGRP signal is so high could be owing to its alleged restriction of 
expression to the enteric nervous system (Mulderry et al., 1988). Whether these nerve fibres 
originate from the DRG or from peripheral adventitial neurons located within the mesentery itself 
(Somasundaram et al., 2006; 2012) is unknown. Regardless, these nerves are in close proximity to 
one of the largest vascular beds in the body, meaning that any overspill has good access to the 
circulation, thus amplifying the signal of circulating peptide. 
It could be argued that the plasma is not the most ideal depot to measure CGRP concentrations as it 
is often considered to be a ‘spillover’ from the site of release at the neurovascular junction. 
Therefore, it may be more relevant to consider expression of the peptide at its predominant site of 
synthesis, the DRG. As it is currently impossible to use antibodies to discriminate between αCGRP 
and βCGRP, the best-available technique to determine tissue expression is that of gene expression 
analysis via PCR. I have shown in this thesis that αCGRP gene expression is significantly increased 
within the DRG as mice age from three to fifteen months. This is somewhat surprising, given that rat 
studies pointed to a general decline in the expression of the peptide as they grew older (Kawasaki et 
al., 1990a; 1991; Kawasaki and Takasaki, 1992; Yamaga et al., 2001). However, to reiterate, these 
studies are often confounded by the use of SHRs and they investigate multiple and differing ageing 
timepoints, which might add further confusion. Additionally, it is possible that mice have very 
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different temporal expression patterns of these peptides, in comparison to rats. Whilst an intriguing 
result, it is unknown what this elevation in expression is in response to. One conjecture might be 
that increases in cytokine activity that are characteristic of the ageing process could be influencing 
CGRP gene expression. Of these in particular, TNFα has been shown to mobilise intracellular calcium 
in cultured DRG neurons, sufficient to produce activation of p38 MAPK and other stress-related 
kinases (Pollock et al., 2002; Durham and Russo, 2003). Activation of kinases such as these by TNFα 
is capable of inducing CGRP gene expression and subsequent release from the cell (Bowen et al., 
2006). There is a longstanding train of thought that considers CGRP and TNFα to have a relationship 
akin to that of more traditional ‘physiological antagonists’, where neuronal CGRP counteracts the 
effects of immune cell-derived TNFα (Assas, 2014). With this in mind, our results might be explained 
by CGRP gene transcription being elevated as part of a feedback network, in order to work against a 
pro-inflammatory mediator, such as TNFα.  
We also investigated how βCGRP gene expression was regulated both in juvenile and aged αCGRP 
WT and KO mice. We found that KO mice aged three months had significantly higher expression of 
the beta isoform when compared to age-matched WTs. This compliments our data obtained from 
plasma analysis of total CGRP, where we identified a potential compensatory role for βCGRP in the 
αCGRP KO mouse. This finding further strengthens the need to investigate the expression dynamics 
of each isoform at the tissue level, rather than solely investigating what is circulating in the plasma. 
Others using the mixed calcitonin/αCGRP KO mouse have shown that βCGRP mRNA expression 
within the DRG was twofold lower in the KO as compared to the WT (Gangula et al., 2000). Groups 
using the pure αCGRP KO mouse, identical to those used in this thesis, have shown that there is no 
change in mRNA expression of the β isoform in multiple regions of the spinal cord (Schutz et al., 
2004). Therefore, there is some discrepancy between results presented in this thesis and those in 
the published literature, the reason for which is somewhat unclear. However, an interpretation of 
our findings could potentially be that both genes for αCGRP and βCGRP are closely linked and 
therefore a negative feedback circuit could be established whereby the absence of one peptide 
stimulates the production of the other. Whilst failing to reach statistical significance, we also saw a 
strong trend towards an elevation in βCGRP transcript in DRG as both our WT and KO mice reached 
fifteen months of age. This result is in line with our observed increase in αCGRP expression with age. 
Given that both CGRP isoforms are structurally very similar and possess almost identical 
pharmacology, these findings may point to problems with making use of the αCGRP KO mouse, 
particularly if the study does not make efforts to investigate how βCGRP may be behaving. Thus, 
potential interesting phenotypes in animal models of disease may be masked by the Janus-faced 
 143 
nature of this particular KO mouse. To address this potential problem, it would be prudent to 
develop a double KO mouse that possesses deletion of both alpha and beta isoforms of the peptide. 
However, it would be difficult to generate such a mouse by traditional crossbreeding methods, as 
both genes for CGRP peptides are located closely together on the same chromosome. Alternatively, 
short-term studies employing the use of CGRP receptor antagonists may be of some benefit. In 
terms of understanding more the role of CGRP as part of the ageing process, the development of a 





3.5.3 Ageing differentially regulates contractile responses to α-adrenoceptor and thromboxane 
receptor agonists in mesenteric resistance arteries 
Through functional vascular reactivity studies examining key pharmacological agents known to 
induce vasoconstriction, we have uncovered some interesting results pertaining to the ageing 
process. Little is known of age-related changes in the regulation of splanchnic vasomotor control by 
perivascular nerves. Given that the mesenteric arcade represents one of the most important 
vascular resistance beds in the regulation of blood pressure, any alteration to vasomotor properties 
of this bed could have significant consequences for systemic haemodynamics. We first examined the 
ability of the mesenteric resistance arteries isolated from juvenile and aged αCGRP WT and KO mice 
in response to stimulation with hyperkalaemic Krebs buffer. This allowed us to examine the 
endogenous contractile properties of the vessels that are independent of receptor stimulation. 
Results show that vasoconstriction produced by 80 mM potassium is significantly increased in 
mesenteric arteries obtained from fifteen-month-old mice versus those at three months. This 
increase in contractility to high concentrations of potassium has been shown by others in the rat 
(Lang et al., 1995). Further, studies in senescence-accelerated mice have shown enhanced 
potassium-dependent contractions, albeit in the aorta (Novella et al., 2011). Indeed, even the 
senescence-resistant mouse displayed an age-dependent increase in potassium-induced 
contractility. The reason for this is unclear, although authors of the aforementioned paper ascribed 
this phenotype to a direct action on voltage-gated calcium channels or distal mechanisms related to 
influxes of calcium. It is known that ageing can enhance the proliferation of VSMCs (Orlandi et al., 
2006) and therefore older mesenteric arteries might be able to mount a larger potassium-dependent 
response as a result of simply having a larger VSMC population. However, we have no direct 
empirical evidence of this phenomenon. Alternatively, these results point to alterations to the 
activity of voltage-gated calcium channels or more distal mechanisms that act in response to calcium 
influx. 
We also investigated how mesenteric resistance arteries isolated from juvenile and aged αCGRP WT 
and KO mice responded to stimulation with the α1-adrenoceptor agonist, PE. There is a reported 
close regulatory relationship between sensory afferents and sympathetic nerves and this 
relationship can impinge upon the regulation of vascular tone (Kawasaki, 2002). Because 
sympathetic nerve activity increases with age throughout the body (Seals, 2004) and the mesenteric 
vasculature is richly innervated by these fibres, we hypothesised that vascular reactivity in response 
to α1-adrenoceptor (α1-AR) stimulation might become altered as the organism ages. We found that 
there was a significant improvement in vascular sensitivity to PE stimulation as both genotypes of 
mice aged to fifteen months. This finding is in stark contrast to a recent study published by the Segal 
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laboratory that showed that mesenteric arteries(Westcott and Segal, 2013) and gluteus maximus 
microvessels(Sinkler and Segal, 2014)obtained from C57BL/6 mice aged 24 months displayed 
diminished sensitivity and maximal contractions to PE. A simplistic explanation for increased 
reactivity to PE in juvenility would be an increase in adrenoceptor expression within the mesenteric 
vasculature. However, mRNA expression of α1-AR subtypes within the mesentery has been shown to 
remain stable throughout twenty-four months in ageing rats (Xu et al., 1997). However, whilst 
receptor expression remains stable, it is possible that post-translational modifications to the 
receptor may alter functionality. Alternatively, it is known in humans that sympathetic nerve activity 
is increased with age (Sundlöf and Wallin, 1978), which presumably may result in a hyperstimulation 
of adrenoceptors that leads to their desensitisation, thereby reducing potency of agonists such as 
PE. Additionally, these receptors may have undergone changes to the intracellular signalling 
cascades they are coupled to, in order to augment vasoconstriction. For example, alterations to 
calcium-handling pathways within the VSMC(Rubio et al., 2002). 
In contrast to our findings with stimulation of the vasculature with sympathomimetic compounds, 
we found stark differences in vascular reactivity with respect to stimulation with the thromboxane 
receptor agonist, U46619. Here, we have shown that mice aged 15 months display a significant 
reduction in pharmacological sensitivity to thromboxane receptor stimulation. Others have made 
use of a senescence-prone mouse model to show that female mice of this strain produce increased 
vasoconstriction in response to U46619, although these studies were conducted in the aorta. The 
authors ascribed this change to a reduction in endogenous NO release and a phenotypic switch from 
the production of vasodilator to vasoconstrictor prostanoids from the endothelium (Novella et al., 
2011). It is known that vascular thromboxane receptor expression is increased in these senescence-
accelerated mice (Novella et al., 2010). Further, in obese mice, thromboxane receptor expression in 
carotid artery has been shown to increase in order to promote U46619-mediated vasoconstriction 
(Traupe et al., 2002). Thus, with these findings in mind, our results are a little surprising.Table 9 
reports a summary of findings related to vascular reactivity experiments. 
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Table 9: Table summarising results obtained from vascular reactivity experiments, describing effects of ageing and 
mouse genotype on vasoconstrictor/vasodilator processes. 
 
  
Drug Effect of Age Effect of Genotype 
80 mM K+ Increased contractility with age No effect 
Phenylephrine Increased contractility with age No effect 
U46619 Decreased contractility with age No effect 
CGRP Decreased dilatation with age Decreased contractility in aged KOs vs aged WTs 
SNP No effect No effect 
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3.5.4 Ageing is associated with an impaired CGRP-dependent vasodilatation in mesenteric 
resistance arteries despite apparent increases in CGRP receptor gene expression 
Whilst we have made efforts to examine how the expression of CGRP isoforms is regulated as part of 
the ageing process, this does not provide any indication of bioactivity. A maintenance or even 
upregulation of expression does not guarantee conserved or increased activity. Therefore, we 
sought to examine the bioactivity of exogenous CGRP on isolated mesenteric arteries from juvenile 
and aged αCGRP WT and KO mice. Here, we have shown that ageing significantly impairs sensitivity 
to exogenous CGRP, at least in the KO mouse. There is a clear trend for the same phenomenon in the 
WT mouse, though this difference did not reach statistical difference. This change in CGRP potency 
with age did not appear to be linked to a decrease in the capacity of the vasculature to mount a 
relaxant response, as our SNP responses remained intact. Thus, we concluded that the change could 
be ascribed to a CGRP receptor-dependent phenomenon. However, we do not know whether the 
loss of CGRP response is endothelial-dependent or –independent, owing to vessels from all 
experimental groups being unresponsive to acetylcholine stimulation. However, unpublished results 
from our laboratory have shown that CGRP responses in isolated mesenteric arteries are unaffected 
by mechanical removal of the endothelium. Indeed, many suggest that vasodilatation produced by 
CGRP in the smaller resistance arteries is more dependent on VSMC K+ATP channel-induced 
hyperpolarization (Quayle et al., 1994; Wellman et al., 1998), whereas the response in the larger 
conduit arteries appears to be more reliant on NO generation (Hao et al., 1994; Lu and Fiscus, 1999). 
Therefore, we might not expect the role of the endothelium in producing vasodilatation in this 
vascular bed to be particularly important. 
Studies have shown that vascular sensitivity to CGRP both in vivo and in vitro becomes diminished 
with age in the rat (Chan and Fiscus, 2002). However, no mechanism has been proposed to date to 
explain this phenomenon. A study has been performed where CGRP potency has been seen to 
increase in hypoxic porcine intramyocardial arteries in the absence of alterations in RAMP1/CLR 
expression, at least at the mRNA level (Hasbak et al., 2005). The authors concluded that the 
increased potency arose from hypoxic conditions affecting the resting conformation of the receptor 
itself, thus altering agonist affinity. Others have reported increases in CGRP bioactivity during 
hypertension and this change was ascribed to increased vascular expression of the RCP (Supowit et 
al., 2011). In this study, we have seen a significant increase in aortic CLR mRNA expression as WT 
animals age and a trend towards a similar increase in CLR expression in juvenile vs aged KO mice. At 
first glance this may raise the expectation of increased potency for CGRP as more CLR mRNA might 
potentially be translated to protein to form a receptor. However, in the absence of elevations of 
RAMP1 transcript, it is possible that functional receptor expression levels are unchanged. Further to 
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this, unlike Supowit et al., we do not see any difference in aortic mRNA expression of the signal 
amplifying protein, RCP. Of course, one must concede that this gene expression analysis has been 
performed in a different vascular bed to that studied in the functional experiments and therefore 
expression might be regulated in a very different manner within this tissue. Another caveat of gene 
expression studies is that they do not necessarily represent what is happening at the protein level 
and therefore might not be indicative of how functional CGRP receptors are being regulated. Table 9 
reports a summary of findings related to vascular reactivity experiments. 
It is conceivable that ageing might affect receptor subcomponent expression in the opposite 
direction in order to decrease potency. I consider that regulation of CGRP receptor expression would 
represent one of the most rational explanations of how agonist potency may become altered, given 
what evidence currently exists in the literature. Doubtless, other mechanisms may be present, 
particularly those related to the development of a pro-inflammatory vascular environment with 
ageing. For instance, an increased expression and activity of peptidases responsible for metabolising 
CGRP within the vascular compartment, leading to decreased bioavailability and thus activity. 
Alternatively, increased ROS formation as part of the vascular inflammatory response may lead to 
oxidation of criticalcysteine residues present in the RAMP1 structure, such as Cys40, Cys57, Cys72 
and Cys104. These four residues are critical for the heterodimerisation of RAMP1 with CLR to allow 
for subsequent export from the ER and insertion into the plasma membrane (Steiner et al., 2003). 
Thus, oxidised RAMP may be retained intracellularly and thus expression of the CGRP receptor at the 




To conclude, this chapter has shown that αCGRP WT and KO mice do not differ in gross 
developmental parameters as they age from juveniles (3 months) to ‘middle-aged’ (15 months). 
Further to this, we have identified a potential compensatory mechanism present in αCGRP KOs 
where the removal of the alpha isoform of the peptide induces an upregulation of beta isoform gene 
expression within the DRG, which in turn produces a sizeable detectable peptide signal within the 
plasma of these mice. With respect to functional changes observed in these mice, this chapter has 
uncovered striking ex vivo results related to mesenteric vascular reactivity. We have shown that 
vasodilatation in response to stimulation by CGRP is markedly diminished in aged versus juvenile 
animals, despite apparent increases in CGRP receptor mRNA expression within vascular tissues. In 
addition, we witnessed pharmacological changes in vasoreactivity to the constrictor agonists 
phenylephrine and U46619, although the mechanisms behind these changes are unknown. In 
summary, deletion of αCGRP does not appear to promote a gross adverse phenotype as mice age 




4. |Chapter Four: Characterising the In Vivo Cardiovascular 
Phenotype and Vascular Inflammatory Response in the αCGRP 
WT and KO Mouse 
4.1 Introduction 
The role of CGRP in the regulation of baseline cardiovascular haemodynamics appears to be 
minimal. Mice that lack αCGRP usually have normal blood pressures (Lu et al., 1999; Smillie 
et al., 2014) and both laboratory animals and humans receiving acute administration of 
CGRP receptor antagonists or ligand-directed antibodies do not experience changes in 
baseline haemodynamics(Moore and Salvatore, 2012; Bigal et al., 2013; Walter et al., 2014). 
Conversely, however, there is a strong literature concerning the role of CGRP in various 
diseases of the cardiovascular system, including hypertension and inflammatory processes 
that accompany it. Animals that have had CGRP receptor activity disrupted by 
pharmacological antagonists have been shown to exhibit exacerbated elevations in blood 
pressure in comparison to control animals in a wide range of hypertensive models, 
accompanied with a greater degree of vascular inflammation (Gangula et al., 1997; Supowit 
et al., 1997; 1998). Similar phenotypes have been observed in CGRP KO mice (Oh-hashi et 
al., 2001; Kurihara et al., 2003) and we have recently published results showing enhanced 
hypertension, vascular remodeling and dysfunction in CGRP KO mice, within an ATII model 
of hypertension (Smillie et al., 2014). Conversely, hypertensive animals receiving the 
phytoalkaloid rutaecarpine (a reported TRPV1 agonist and thus releaser of CGRP) witnessed 
an improvement in disease parameters (Hu et al., 2003; Deng et al., 2004b; Qin et al., 2007; 
Li et al., 2008). Furthermore, mice engineered to overexpress RAMP1, a critical component 
of the CGRP receptor, are protected against hypertension-induced vascular dysfunction 
(Sabharwal et al., 2010). Thus, there is great evidence to implicate CGRP as a protective 
mediator within the setting of hypertension and also other diseases whereby the 
cardiovascular system becomes stressed (Russell et al., 2014). 
However, as already discussed in the previous chapter, little is known about the role of CGRP 
within the setting of cardiovascular ageing. It is generally considered that ageing is 
associated with a pro-inflammatory environment and the cardiovascular system is not 
exempt from this inflammation, or “inflammaging”(Franceschi and Bonafè, 2003). Vascular 
wall ageing begins with chronic proinflammation, a form of sterile inflammation that occurs 
in the general absence of infection by microorganisms. Phenotypic shifts in ECs and VSMCs 
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promote this level of inflammation (Wang et al., 2013). This is why ageing is the single 
biggest independent risk factor for the development of CVD, as it generates a fertile 
substrate in which disease can take hold. 
This subtle, subclinical proinflammation is often characterised by increased ROS generation 
and an inability to appropriately defend against this increased ROS burden(Puca et al., 
2013). Vascular cells may have shifted their phenotype to one that is considered more pro-
inflammatory and, indeed, some cells may have become senescent, further increasing the 
risk for pro-inflammatory factors such as cytokines being secreted by these cells. Such 
subclinical inflammatory processes may induce the expression of cell adhesion molecules, 
which in turn may positively influence the recruitment of circulating inflammatory cells 
(López-Otín et al., 2013). These inflammatory cells (monocytes, in particular) may be 
recruited by dysfunctional ECs in the early stages of atherosclerosis to form early vascular 
lesions, which in the human could progress to more severe vascular disease (Hopkins, 2013). 
4.2 Hypothesis 
Deletion of αCGRP in juvenile mice (3 months) will not affect blood pressure but as animals 
age (15 months), gene deletion will result in increased blood pressure. Elevated blood 
pressure will be accompanied by exacerbated vascular inflammation, leading to enhanced 
recruitment of circulating inflammatory cells into the vascular wall. 
4.3 Aims 
1. To investigate the role of αCGRP in the regulation of blood pressure and subsequent 
vascular remodeling in young and aged αCGRP WT and KO mice. 
2. To investigate mechanisms by which CGRP might influence the genesis of vascular 
inflammation in young and aged αCGRP WT and KO mice. 
3. To investigate how αCGRP affects vascular inflammatory processes related to 







4.4.1 In vivo haemodynamic parameters and vascular morphologies of the ageing 
αCGRP WT and KO mouse 
Following on from the initial growth and developmental characterisation of αCGRP WT and 
KO mice, we sought to discover how deletion of αCGRP might impinge upon in vivo 
cardiovascular function in these animals. To do so, we measured blood pressure and heart 
rate via non-invasive tail cuff volume pressure recording and peripheral pulse oximetry, 
respectively. Figure 23A shows systolic blood pressure recordings obtained from male 
αCGRP WT and KO mice, aged 3 or 15 months. Systolic blood pressures were comparable in 
our juvenile control groups (124.60 ± 4.17mmHg vs 132.20 ± 5.88 mmHg for WT and KO, 
respectively) and blood pressure was not found to change as the mice aged to 15 months 
(125.10 ± 3.96mmHg vs 123.60 ± 1.91 mmHg for WT and KO, respectively). Figures 23B and 
23C detail diastolic and mean arterial pressures, respectively, showing similar trends. In 
addition to the measurement of blood pressure, we also assessed heart rate in a small 
sample of the aged cohort (Figure 23D). Again, we found there to be no differences in heart 
rate between WT and KO animals (566.80 ± 8.20 beats per minute vs 552.00 ± 35.10 beats 


























Figure 23: In vivo cardiovascular parameters of juvenile (3 months) and aged (15 months) αCGRP male WT and 
KO mice. Results show A) systolic blood pressures of male juvenile and aged αCGRP WT and KO mice; B) 
diastolic blood pressures of male juvenile and aged αCGRP WT and KO mice; C) mean arterial blood pressures 
of male juvenile and aged αCGRP WT and KO mice; D) heart rates of male juvenile and aged αCGRP WT and KO 
mice. Data expressed as mm Hg, mean ± SEM, n=6-8 for blood pressure and beats per minute (BPM), mean ± 
SEM, n=4 for heart rate. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test 
or unpaired student’s t-test, where appropriate. No significant differences were detected between 
experimental groups. 
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To complement our in vivo assessment of haemodynamics within our groups of juvenile and 
aged αCGRP WT and KO mice, we assessed the extent of large vessel remodeling that might 
reflect alterations in blood pressure via classical histological techniques. Figure 25 displays 
representative light photomicrographs of aortic sections obtained from juvenile and aged 
αCGRP WT and KO mice, stained with Masson’s Trichrome. Here, cell nuclei are stained dark 
red/purple; the cytoplasm is stained pink and connective tissues are stained blue. From 
initial observation, it is clear that there are no gross differences from aortae obtained from 
different animals. However, it is possible that the degree of collagen fragmentation and 
disorganisation seen in older vessels is greater than that of their younger counterparts, 
although this has not been quantified. Morphological analysis of these sections was also 
performed, where we measured both smooth muscle and collagen width and total area, 
shown in Figure 24. Figure 24A shows the width of SMC populations within the aortae. 
Juvenile WT and KO mice possess similar SMC widths (69.88 ± 9.09 μm vs 72.25 ± 7.80 μm, 
respectively). This parameter does not change significantly as mice aged to fifteen months 
(75.21 ± 5.32 μm vs 89.47 ± 3.55 μm for aged WT and aged KO, respectively). When we 
measured the total area of aorta occupied by SMCs, we again found there to be no 
differences between groups (Figure 24B). Further to characterising SMC morphology within 
the aortae, we also sought to investigate evidence of altered collagen structuring in the 
tunicae adventitia of these vessels. Figure 24C represents analysis of collagen width within 
the vessel. Again, young animals possessed similar degrees of collagen width (16.60 ± 2.13 
μm vs 21.67 ± 0.95 μm for juvenile WT and KO animals, respectively). However, we found 
that aged WT animals had a significantly higher collagen width within the aorta (27.29 ± 1.23 
μm) when compared to their juvenile counterparts. Aged KO animals had similar collagen 
widths (25.63 ± 2.24 μm), though these were not found to differ significantly either from 
their juvenile counterparts or when compared to aged WTs. Total area of the adventitial 
region of the vessel occupied by collagenous structures is shown in Figure 24D. We found no 
statistically significant differences in collagen area across all groups. Therefore, we 
concluded that the extent of vascular remodeling occurring as part of the ageing process 
was minimal, in line with no observable changes in haemodynamic parameters. Further, 

















Figure 24: Morphological analysis of aortae obtained from juvenile (3 months) and aged (15 months) male αCGRP WT 
and KO mice. Results show A) smooth muscle cell width of aortae obtained from male juvenile and aged αCGRP WT 
and KO mice; B) smooth muscle cell area of aortae obtained from male juvenile and aged αCGRP WT and KO mice; C) 
collagen width of aortae obtained from male juvenile and aged αCGRP WT and KO mice; D) total collagen area of 
aortae obtained from male juvenile and aged αCGRP WT and KO mice. Data expressed as μm, mean ± SEM for width 
measurements and mm
2
, mean ± SEM for area measurements, n=4-7. Statistical significance was evaluated by two-way 























Figure 25: Representative light micrographs of upper thoracic aorta sections obtained from juvenile (3 months) and 
aged (15 months) male αCGRP WT and KO mice. 
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4.4.2 Characterisation of vascular eNOS expression and activity within the aortae of ageing 
αCGRP WT and KO mice 
As NO is a critical signalling molecule involved in the regulation of both blood pressure and vascular 
inflammation, we sought to investigate how the processes involved in the generation of NO might 
differ during the ageing process, and how these processes may be influenced by CGRP. Initially, we 
probed total mRNA lysates obtained from the aortae of juvenile and aged αCGRP WT and KO mice 
to examine vascular eNOS gene expression. Figure 26 illustrates aortic eNOS mRNA expression. 
Here, we found that gene expression remained relatively stable in juvenile WT and KO animals 
(1487.37 ± 406.47 copies/μl vs 1204.80 ± 170.02 copies/μl, respectively). This level of expression did 
not appear to significantly change as animals aged to fifteen months, however one might argue that 
a trend towards a reduction in eNOS gene expression can be observed in the aged KO group, when 
compared to aged WT (1313.42 ± 267.22 copies/μl vs 811.83 ± 96.04 copies/μl for aged WT and 
aged KO, respectively). Thus, eNOS gene expression did not appear to change significantly as 















Figure 26: Gene expression analysis of eNOS in aortic lysates obtained from juvenile (3 months) and aged (15 months) 
male αCGRP WT and KO mice. Results show A) mRNA expression of eNOS in aortic lysates. Data expressed as copies 
mRNA per microliter, mean ± SEM, n=6-10. Statistical significance was evaluated by two-way ANOVA plus Bonferroni 
post hoc test. No statistically significant differences were found between groups. 
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Analysis of gene expression can only shed light on one aspect of the regulation of an entire 
biological process. Thus, we thought it prudent to analyse the expression of aortic eNOS at the 
protein level via immunoblotting. Figures 27 and 28 illustrate the data obtained from this 
experiment. Here, we have shown that eNOS protein expression is comparable in juvenile WT and 
KO tissues. Protein expression of eNOS did not appear to change as animals aged, indicating a 
preservation of eNOS expression throughout the ageing process that was unaffected by αCGRP gene 
deletion. Building on our knowledge of both eNOS gene and protein expression, we continued to 
probe this pathway by measuring the potential activity of eNOS enzyme, using a phospho-specific 
antibody that recognises a phosphorylated epitope within the eNOS protein sequence. This epitope 
is inclusive of a phosphorylated ser1177 residue, known to be important for enzyme activation. 
Figures 29 and 30 show results obtained from measuring the degree of phosphorylation of vascular 
eNOS at this critical residue. Here, we see that eNOS is significantly hyperphosphorylated at ser1177 
in juvenile KO animals when compared to juvenile WTs (0.08 ± 0.02 AU for juvenile WTs vs 0.25 ± 
0.06 AU for juvenile KOs), indicative of increased enzymatic activity. Further to this, WT animals 
experience a significant increase in the phosphorylation state of eNOS as they age to 15 months 
(0.08 ± 0.02 AU for juvenile WT vs 0.28 ± 0.10 AU for aged WT). Aged KO mice represented the 
group with the lowest degree of ser1177 phosphorylation (0.03 ± 0.03 AU), which was found to be 
significantly lower than the phosphorylation status of both juvenile KOs and aged WTs. This result 
indicates an initial hyperphosphorylation of eNOS in juvenile mice lacking αCGRP that is completely 
abolished as these animals age to fifteen months. This result is in stark contrast to that observed in 
WT animals, which significantly increase the level of ser1177 phosphorylation as they age. In 
summary, both ageing and the deletion of αCGRP can bring about both statistically and biologically 






Figure 27: Representative immunoblot of aortic eNOS expression in male juvenile and aged αCGRP WT and KO mice, 



















Figure 28: Immunoblot analysis of the expression of eNOS in aortic lysates obtained from juvenile (3 months) and aged 
(15 months) male αCGRP WT and KO mice. Data expressed as the densitometric ratio between eNOS and β-actin, mean 
± SEM, n=4-9. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. No statistically 







Figure 29: Representative immunoblot of aortic phospho-eNOS expression in male juvenile and aged αCGRP WT and KO 













Figure 30: Immunoblot analysis of the expression of Ser1177 phospho-eNOS in aortic lysates obtained from juvenile (3 
months) and aged (15 months) male αCGRP WT and KO mice. Data expressed as the densitometric ratio between p-
eNOS and total eNOS, relative to β-actin, mean ± SEM, n=4-9. Statistical significance was evaluated by two-way ANOVA 
plus Bonferroni post hoc test. #p < 0.05 where juvenile and aged animals of the same genotype have been compared; 
*p < 0.05 where age-matched WT and KO animals have been compared. 
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4.4.3 Evaluation of the oxidative vascular environment of ageing αCGRP WT and KO mice 
The regulation of NOsignalling is a complex process and is not solely dependent on the level of 
eNOS expression or indeed, its activation state. Its bioactivity is determined by its rate of removal, 
which is in part controlled by ROS. ROS are also involved in the genesis of vascular inflammation, so 
we considered that studying of the vascular environment with respect to oxidative stress an 
important area of research. To first address this area, we examined how gene expression of classical 
pro- and anti-oxidant enzymes differed in the aortae of juvenile and aged αCGRP WT and KO mice. 
Results obtained are illustrated in Figure 31. Figure 31A refers to aortic NOX2 gene expression, 
where we found that levels were comparable in juvenile WT and KO mice (137.87 ± 34.75 copies/μl 
vs 100.77 ± 16.11 copies/μl, respectively). NOX2 expression was significantly increased in aged WT 
animals (272.28 ± 54.97 copies/μl) when compared to their juvenile counterparts. Aged KO animals 
trended towards having higher expression than their juvenile counterparts (172.16 ± 21.53 
copies/μl) although a statistically significant difference was not observed. Figure 31B shows a similar 
pattern of results for NOX4 expression. Gene expression levels were similar in juvenile WT and KO 
mice (3926.50 ± 941.09 copies/μl vs 3772.80 ± 616.21 copies/μl, respectively). NOX4 mRNA 
significantly increased in aged WTs (14180.29 ± 3212.27 copies/μl) when compared to their juvenile 
counterparts. NOX4 expression in the aged KOs appeared to increase (10796.00 ± 2505.78 
copies/μl), though again this was not a statistically significant difference from juvenile animals. 
Aside from pro-oxidant enzyme gene expression, we also investigated the expression of anti-oxidant 
enzymes, specifically HO-1. Again, we found similar levels of expression in juvenile WT and KO mice, 
shown in Figure 31C (211370.40 ± 17635.86 copies/μl vs 181751.40 ± 24201.53 copies/μl). Aged 
WTs had significantly higher levels of HO-1 mRNA (471088.60 ± 114171.00 copies/μl) when 
compared to their juvenile counterparts. Aged KO animals did not differ significantly in HO-1 gene 

























Figure 31: Gene expression analysis of vascular oxidative stress markers of aortic lysates obtained from juvenile (3 
months) and aged (15 months) male αCGRP WT and KO mice. Results show A) mRNA expression of NOX2 in aortic 
lysates; B) mRNA expression of NOX4 in aortic lysates; C) mRNA expression of HO-1 in aortic lysates. Data expressed as 
copies mRNA per microliter, mean ± SEM, n=6-9. Statistical significance was evaluated by two-way ANOVA plus 






Further to the analysis of pro-/anti-oxidant gene expression within the aortae of juvenile and aged 
αCGRP WT and KO mice, we also examined macromolecular markers of oxidative damage, by 
looking for evidence of nitrosylated tyrosine residues present within vascular proteins and the 
presence of the lipid peroxidation product, 4-hydroxynonenal (4-HNE). Figures 32 and 33 show 
nitrotyrosine expression in aortic lysates, determined by immunoblotting. We show that there is a 
large degree of variability of nitrated tyrosine residues and expression was found to be comparable 
between all groups. In contrast to this, we found changes in the amount of peroxidised lipid 
products present within the aortic milieu of juvenile and aged αCGRP WT and KO mice. Figures 34 
and 35 show that there was no difference in 4-HNE accumulation between juvenile WT and KO mice 
(0.61 ± 0.44 AU vs 0.65 ± 0.11 AU, respectively). However, levels were significantly increased in aged 
WT mice (1.45 ± 0.04 AU) when compared to their juvenile counterparts. Additionally, aged KO 
animals had significantly higher expression of 4-HNE when compared to juvenile KOs (2.08 ± 0.49 
AU). This did not differ significantly from aged WTs though there was a trend towards it being 
increased. Thus, whilst nitrotyrosine levels appeared to go unchanged between experimental 









Figure 32: Representative immunoblot of aortic nitrotyrosine expression in male juvenile and aged αCGRP WT and KO 


















Figure 33:Immunoblot analysis of the expression of nitrated tyrosine residues in aortic protein lysates obtained from 
juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Data expressed as the densitometric ratio 
between nitrotyrosine and β-actin, mean ± SEM, n=4-8. Statistical significance was evaluated by two-way ANOVA plus 









Figure 34: Representative immunoblot of aortic 4-HNE expression in male juvenile and aged αCGRP WT and KO mice, 














Figure 35: Immunoblot analysis of the expression of lipid peroxidation product, 4-HNE in aortic lysates obtained from 
juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Data expressed as the densitometric ratio 
between 4HNE and β-actin, mean ± SEM, n=4-8. Statistical significance was evaluated by two-way ANOVA plus 





4.4.4 Assessment of localised vascular inflammation and leukocyte infiltration in the aortae of 
ageing αCGRP WT and KO mice 
As a pro-oxidant environment can strongly influence the progression of vascular inflammation 
during ageing, we sought to gain an understanding of how this inflammation is driven and how it 
may be influenced by CGRP. Figure 36 illustrates data obtained from a multiplex plasma cytokine 
array with samples obtained from aged male αCGRP WT and KO mice. We found no significant 
differences in the circulating levels of cytokines IL-1, IL-6, IL-10, IL-12, TNFα and IFNγ (Figure 36A-F). 
However, we did observe a trend towards a potential difference in the levels of KC between these 
mice. Figure 36G shows that levels of circulating KC tended to be lower in aged αCGRP WT mice 




















Figure 36: Analysis of circulating proinflammatory cytokine expression in plasma obtained from aged (15 months) male αCGRP WT and KO mice. Results show cytokine concentrations for 
A) IL-1; B) IL-6; C) IL-10; D) IL-12; E) TNF-α; F) IFN-ϒ; G) KC. Data expressed as pg/ml, mean ± SEM, n=3-4. Statistical significance was evaluated by paired two-tailed Student’s t-test. No 
significant differences were found between groups. 
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Accompanied with ageing is the increased likelihood of cells within tissues of the vasculature to halt 
cell division and become senescent. The presence of senescent cells can greatly exacerbate the 
actions of a pro-inflammatory milieu to bring about vascular dysfunction. Figures 37A and 37B show 
the mRNA expression of the senescence markers p16 and p53, respectively. We found that levels of 
aortic p16 did not change significantly with age and was no affected by αCGRP gene deletion. 
However, we did observe an elevation in aortic p53 expression in WT animals as they aged from 
three to fifteen months (85.56 ± 9.12 copies/μl in juveniles vs 144.95 ± 16.35 copies/μl in aged 
mice). There was a trend towards KO tissues having higher p53 expression as they got older, though 








Figure 37: Gene expression analysis of cellular senescence markers associated with ageing obtained from aortae of 
juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Results show A) mRNA expression of p16 in 
aortic lysates; B) mRNA expression of p53 in aortic lysates. Data expressed as copies mRNA per microliter, mean ± SEM, 
n=6-10. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. *p < 0.05 where juvenile 
and aged animals of the same genotype have been compared. 
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As a consequence of increased pro-inflammatory factors with age, there is the increased likelihood 
of circulating inflammatory cells being recruited into the vascular wall to further contribute to 
inflammation. To measure this, we looked for differences in VCAM-1 mRNA expression in the aortae 
obtained from juvenile and aged male αCGRP WT and KO mice. Figure 38A shows that VCAM-1 
expression in juvenile WT and KO mice was comparable (23179.79 ± 3297.79 copies/μl vs 32231.60 ± 
5308.63 copies/μl, respectively). As mice aged, levels of VCAM-1 expression were significantly 
elevated when compared to their juvenile counterparts (105133.70 ± 13018.94 copies/μl in aged WT 
vs 89596.00 ± 25418.29 copies/μl for aged KOs). However, there was no effect from the deletion of 
αCGRP in either juvenile or aged mice on VCAM-1 expression. In line with this pattern of expression, 
we observed raised F4/80 mRNA expression in aortic lysates as animals aged from three to fifteen 
months, indicative of monocyte/macrophage infiltration (Figure 38B). However, αCGRP deletion had 
no effect on this process. Investigations into neutrophil recruitment into the vascular wall by 
analysing aortic myeloperoxidase (MPO) expression yielded a similar pattern of results as mentioned 
before, although copy numbers were very low, indicating perhaps that neutrophil infiltration is not a 
















Figure 38: Gene expression analysis of vascular markers associated with leukocyte infiltration obtained from aortae of 
juvenile (3 months) and aged (15 months) male αCGRP WT and KO mice. Results show A) mRNA expression of VCAM-1 
in aortic lysates; B) mRNA expression of F4/80 in aortic lysates; C) mRNA expression of MPO in aortic lysates. Data 
expressed as copies mRNA per microliter, mean ± SEM, n=6-10. Statistical significance was evaluated by two-WAY 
ANOVA plus Bonferroni post hoc test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 where juvenile and aged 











In Chapter 3, I showed that deletion of αCGRP in male juvenile and aged mice did not lead to 
impairments in gross parameters of murine development. In this Chapter, I aimed to further 
characterise the response to ageing in αCGRP WT and KO mice with respect to in vivo 
haemodynamic parameters, associated markers of vascular remodelling and markers for leukocytic 
vascular inflammation. We hypothesised that as vascular reactivity to CGRP was diminished with 
age, as shown in Chapter 3, intracellular signalling pathways related to CGRP might be less capable 
of mounting a defense against elevated blood pressure and associated vascular inflammation.  
4.5.1 Of mice, men and mechanisms of ageing 
Mice are undoubtedly the favourite mammalian model in use to study a wide range of 
(patho)physiological processes. Regardless of the research field, they are used because they have 
many advantages in a laboratory setting: they are small, easy to care for, and breed well in captivity, 
such that the cost of maintaining large populations is not overwhelmingly prohibitive. Furthermore, 
their basic biology and genome are strikingly similar to that of humans and are largely well 
understood. This feature, combined with advances in genetic technologies, has facilitated 
considerable advances in scientific endeavour. Despite these advantages, the use of mice has been 
called into question with regards to the study of the biological processes of ageing, owing to the 
perception that murine ageing is not directly comparable to that of humans. It is obvious that the 
lifespan of a mouse is significantly shorter than that of man, pointing to differences in our 
evolutionary histories that might have helped shape these phenotypes. More subtle differences 
between the two organisms begin to emerge when one examines their biology in more detail. For 
example, mice have considerably long telomeres in comparison to humans (so long they are known 
as ‘mega-telomeres’) and high telomerase activity in many of their somatic tissues, meaning that the 
relative contribution of replicative senescence to the ageing phenotype in mice may be less of that 
than in humans (Kipling and Cooke, 1990). Furthermore, mice are capable of synthesising their own 
vitamin C whilst humans cannot. Vitamins are now understood to play a crucial role in contributing 
towards the ageing process so mice may well be ‘protected’ against an ageing phenotype that may 
be associated with vitamin deficiencies. However, the main problem with the use of mice (and, 
indeed, most laboratory animals) as models of human ageing is that they do not demonstrate all the 
typical age-related diseases seen in humans, including CVD. Thus, it has been posited that mice are 
unrepresentative of human ageing and therefore may not be as useful as we once thought. 
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The argument that mice are not a useful research tool used to study ageing and age-associated 
disease because they do not succumb to traditional gerontological diseases is unhelpful. The very 
fact that mice do not appear to develop CVD as they age, despite having a highly homologous 
genome and evolutionarily conserved ageing processes to humans is an important discovery. This 
tells us that it is likely that differences in the way our respective environments interact with our 
genomes is the real driver of the development of age-induced disease. Mice bred in standard 
laboratory conditions do not smoke, drink alcohol, eat a typical western diet or encounter infection. 
These are all significant risk factors for the development of CVD with age in humans. It is often the 
case that one has to introduce a significant environmental stressor in order to induce pathology in 
mice (for example, the feeding of a high-fat diet to induce hyperlipidaemia-associated disease, such 
as atherosclerosis). The advantage to using mice in ageing research is that one can often take a 
relatively reductionist approach by eliminating a multitude of confounding environmental factors in 
order to study the key mechanisms that underpin the ageing process. This approach would be 
impossible to take in a human cohort. 
Many of the fundamental mechanisms of ageing appear to be conserved throughout the tree of life 
and many aspects of ageing are quite malleable throughout the species. Indeed, mice appear to be 
susceptible to aspects of oxidative stress-induced ageing and manipulation of the systems that 
govern this process can result in alterations in healthspan. That is to say, the amount of time spent 
in good health, rather than a simple extension of life. For example, genetic deletion of antioxidant 
defense enzymes can lead to an increased risk of age-related disease whilst mice that overexpress 
these types of enzymes can often live for longer in good health. Additionally, mice engineered to 
have a reduced susceptibility to cellular senescence or an improved clearance of senescent cells 
leads to retention of youthful characteristics (Baker et al., 2011). Taken together, a reduction of the 
impact of “inflammaging” processes can promote healthspan in laboratory animals, which translates 
to humans. Furthermore, pharmacological and dietary interventions implemented to improve 
lifespan and healthspan have been more or less successful in most eukaryotic organisms, starting in 
yeast and including mice(Blagosklonny et al., 2009; Ungvari et al., 2010). This indicates a level of 
evolutionary conservation between organisms in the malleability of ageing processes. Some of the 
positive results obtained from intervention studies have been recapitulated in laboratory animals 
such as mice and also non-human primates. Therefore it is not too much of a stretch of the 
imagination to consider this may be a phenomenon also present in humans. 
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4.5.2 Deletion of αCGRP does not adversely affect baseline haemodynamics or vascular 
remodeling in the ageing mouse 
One of our early findings from the in vivo profiling of juvenile and aged αCGRP WT and KO mice was 
that there appeared to be no differences in baseline haemodynamics between these groups of mice. 
Blood pressures were normal in juvenile mice (roughly 120/80 mmHg) and these healthy pressures 
were maintained throughout life as animals aged to fifteen months, where the removal of αCGRP 
gene had no outcome. This is perhaps unsurprising given what is already known about the 
haemodynamic phenotype of this particular mouse. Lu et al. were the first to characterise blood 
pressure and heart rate in the juvenile αCGRP KO mouse. They showed that mean arterial pressure 
and heart rate were similar in resting animals and, further to this, blood pressure was unchanged 
between genotypes following subjection to a forced-swimming test. However, it is of note that the 
heart rate of the KO mice was lower than WT following exercise (Lu et al., 1999). Others using the 
same mouse have shown increases in both basal blood pressure and heart rate (Oh-hashi et al., 
2001; Kurihara et al., 2003), however our group has recently published showing that baseline blood 
pressures are similar in WT and KO mice and differences only emerge when the cardiovascular 
system becomes stressed (Smillie et al., 2014). Other groups have made use of a CGRP KO mouse 
generated via the complete interruption of the CALC I gene, where both CGRP and calcitonin have 
been deleted. Results obtained from these mice have been a little more unanimous as to the role of 
CGRP in the regulation of haemodynamics, where deletion of both peptides tends to favour the 
development of spontaneous hypertension (Oh-hashi et al., 2001; Li et al., 2004). These results are 
often over-interpreted as supporting a role for CGRP in the regulation of basal blood pressure, 
though obviously this is an inappropriate conclusion to arrive at for a mouse that is essentially a 
“double knockout”.  
As the regulation of vascular tone is a process that requires such detailed fine-tuning, it is perhaps 
unsurprising that evolution has not favoured the development of a relatively expensive biosynthetic 
pathway to regulate this process at a tonic level of activity. When one considers the role of 
sympathetically-derived noradrenaline (NA) in regulating vascular tone, this small molecule lends 
itself to high-frequency activity. The biosynthetic pathway is initially expensive to build (requiring 
multiple enzymes), but once built, production of NA from tyrosine is energetically cheap. 
Furthermore, released NA is readily taken back up by the neuron to be stored for future release, 
meaning this is an efficient system for a process that is constantly active (Burnstock, 2009). One also 
only has to look at the characteristics of interneuronal chemical signalling within the central nervous 
system to appreciate that similar high-frequency activities most often make use of small molecule 
transmitters and employ more complex molecules as modulators of this activity. The de novo 
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synthesis of a peptide, its cleavage, axoplasmic transport to the nerve terminal, storage and release 
is energetically cumbersome on the cell, never mind the fact that CGRP is usually broken down 
within minutes of release by potentially more than one enzyme, with no strong evidence to support 
its re-uptake(Sams-Nielsen et al., 2001; Gupta et al., 2010; Sheykhzade et al., 2011). Therefore, it 
seems incongruous that CGRP should be involved in the tonic regulation of blood pressure and 
rather is involved in the fine-tuning of the vasomotor response in the face of stress and defined 
stimuli. 
We have shown that there is no effect of CGRP gene deletion on haemodynamic parameters when 
compared to WT mice and I have postulated that this is the case owing to the relative expense of 
maintaining the CGRP signalling axis at a tonic level of activity under normal physiological conditions. 
Perhaps unsurprisingly, we also have shown that ageing does not induce perturbations in blood 
pressure in mice. As mentioned in the previous section, mice do not spontaneously develop 
cardiovascular complications as they get older and disease in mice more often than not needs to be 
induced by some kind of stressor. It is possible that the ageing process hitherto the fifteen-month 
mark does not represent enough of a biological stress upon the cardiovascular system to propagate 
an overtly abnormal phenotype, such as hypertension. A figurative interpretation of this may better 
emphasise this point by describing intrinsic biological ageing as the fertile substrate in which the 
extrinsic seed of disease can be planted and encouraged to grow. 
Associated with haemodynamic changes during hypertension are structural alterations to the 
vasculature, in response to changes in pressure and also inflammation that accompanies the disease. 
For this reason, we thought it prudent to investigate these structural changes of the vessel wall as a 
marker of increased blood pressure that may potentially occur in the absence of detectable 
increases in blood pressure. We have shown that there were no differences in aortic smooth muscle 
cell content in CGRP WT and KO mice, either in juveniles or aged animals. Recent data published by 
our group has shown that hyperplasia of the aortic vascular smooth muscle can occur in response to 
ATII-induced hypertension. In this setting, hypertensive juvenile CGRP KO mice were shown to have 
a significantly higher degree of hyperplasia in comparison to WTs (Smillie et al., 2014). 
Administration of rutaecarpine (a reported TRPV1 agonist, discussed in the introduction to this 
thesis)to renovascular hypertensive rats has also been demonstrated to reverse mesenteric 
resistance vessel VSMC remodeling via a mechanism that is speculated to involve activation of 
TRPV1, leading to subsequent CGRP release (Qin et al., 2007). Others have also shown that CGRP can 
protect against adverse VSMC remodeling, particularly within the setting of pulmonary 
hypertension. Here, in vivo adenoviral transfer of the CGRP gene can limit VSMC remodeling in the 
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pulmonary vasculature of mice subjected to chronic hypoxia (Champion et al., 2000; Bivalacqua et 
al., 2002). CGRP also has an antiproliferative effect on VSMCs in response to mitogenic stimuli, such 
as ATII(Qin et al., 2004). This inhibitory effect of CGRP on VSMC proliferation has been ascribed to 
regulation of an ERK/MAPK-dependent pathway (Qin et al., 2004). Therefore, it has been shown that 
CGRP has the potential to regulate VSMC activity in certain conditions. A study performed in ageing 
rats demonstrated that aortic morphology was unchanged when compared to younger animals and 
VSMC proliferation and migration could only be induced by balloon injury (Wu et al., 2007). With this 
and our own results in mind, it is entirely possible that ageing to fifteen months in the mouse does 
not represent a significant stress to the cardiovascular system to allow for VSMC remodeling and a 
more substantial insult is required to reveal the relative contribution of ageing to the disease 
process.  
Whilst we detected no changes in VSMC morphological phenotype across experimental groups, we 
did detect a significant increase in adventitial collagen width when WT animals aged to fifteen 
months. A similar trend was observed in KO animals that did not reach statistical significance. 
Further, there was a general trend towards juvenile KO mice having an increased aortic collagen 
width measurement. Curiously, this significant difference was lost when the total area of collagen 
was measured. Again, results from our laboratory have shown that collagen deposition is enhanced 
in the setting of ATII-induced hypertension and CGRP can protect against this accumulation (Smillie 
et al., 2014). Others have shown that CGRP is protective against hepatic fibrosis in a Concanavalin A 
model of chronic hepatitis (Kamiyoshi et al., 2009) and also against cardiac fibrosis during pressure-
overload heart failure (Li et al., 2013b). Therefore, it would appear that CGRP has the potential to 
protect against aberrant fibrotic remodeling in certain disease conditions. It is known that there is a 
significant vascular remodeling response to ageing with respect to fibrosis, including in the large 
elastic arteries. This usually results in the conduit vessels (such as the aorta) becoming stiff. 
Stiffening of the aorta can often be a precursor to isolated systolic hypertension due to pressure 
waves emanating from the heart following systole not being appropriately absorbed. This results in 
the pressure wave being reflected back towards the heart, increasing cardiac afterload and thereby 
increasing systolic blood pressure(Jani and Rajkumar, 2006). The mechanisms behind which vessels 
can become stiff with age are numerous, although generally speaking an increase in collagen 
deposition and a reduction in elastin availability is a hallmark characteristic of the response (Fleenor, 
2013). The discrepancy in our findings (increased collagen width but no significant increase in total 
area) may have transpired from a statistical underpowering of this experiment. Collagen width is 
measured by averaging eight replicate measurements from one section of aorta, pertaining to one 
animal. This measurement lends itself to a reduction in variability, which improves the chances of a 
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statistically significant event being identified. This indeed may be the case, as we do see a trend 
towards an increase in collagen area in both groups with age. Alternatively, this may be considered 
an artefactual finding attributable to the preparation of the sample during fixation and embedding. 
The vessel’s shape may have become distorted, owing to stretching of regions of the vessel, which 
may falsely give the impression of a larger width. Despite these shortcomings, we generally identify 
an increase in collagen with age, which is in keeping with the published literature. We saw no 




4.5.3 eNOS is not differentially expressed in juvenile and aged αCGRP WT and KO mice but CGRP 
gene deletion does regulate enzyme activity 
A key regulator of vascular homeostasis is NO. The principle site of synthesis of NO within the 
vasculature is the EC, where endothelial NO synthase (eNOS, NOS3) constitutively generates NOvia 
the conversion of L-arginine. A reduction in NO bioavailability (commonly referred to as ‘endothelial 
dysfunction’) is associated with a wide range of cardiovascular complications, including hypertension 
and atherosclerosis. Furthermore, it is generally considered that the vascular ageing response is 
characterised by a reduction in NO bioavailability. NO was a key molecular candidate for us to study 
within the context of ageing, not only because it is a significant player in the regulation of vascular 
tone and thus systemic blood pressure, but also owing to its potent anti-inflammatory effect which 
may occur in the absence of changes in pressure. 
We made efforts to probe multiple components of the NO pathway in juvenile and aged αCGRP WT 
and KO mice. We have shown that both aortic eNOS mRNA and protein expression was unchanged 
as mice aged to fifteen months and there appeared to be no effect of αCGRP gene deletion at either 
stage of development on these processes. The literature surrounding the regulation of eNOS gene 
and protein expression with age is substantial, but also very unclear. Analysis of mRNA gene 
expression by other groups has yielded results that both support increases (Barton et al., 1997) and 
decreases of eNOS gene expression (Tang and Vanhoutte, 2007) in the aortae of ageing rats. Others 
investigating changes in eNOS mRNA in the mesenteric circulation of ageing humans found that 
expression did not change over time (Cernadas et al., 1998a). Studies performed in cultured human 
ECs from different vascular beds have also supported the finding that eNOS mRNA expression goes 
unchanged with age (Donato et al., 2009). Results are so variable owing to the variability in the 
research methods used to investigate this phenomenon. Factors including choice of organism 
studied, the particular strain of that organism and the timepoint at which the organism is studied, 
never mind the vascular bed called into investigation can all present confounding variables that lead 
to a wide range of conclusions. Those studying eNOS protein have also not come to a unanimous 
conclusion regarding its differential expression over time. Some have reported significant increases 
in protein expression in the aortae and mesenteric arteries of ageing rats. However, others have 
failed to show a difference in expression in the mesenteric vessels of the same species (Sun et al., 
2004). Thus, our data concerning mRNA and protein expression of aortic eNOS in ageing mice 
contributes towards the burgeoning literature surrounding this phenomenon, but unfortunately 
does not result in the crystallization of a solid conclusion. We have recently shown that CGRP gene 
deletion can influence eNOS expression in an ATII model of hypertension. Hypertensive KO mice 
were shown to have an exacerbated loss of eNOS mRNA and protein at both 14 and 28 days of 
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hypertension (Smillie et al., 2014). However, it is not clear whether this is a reflection on the loss of a 
potent vasodilator in the face of hypertension or if CGRP actively regulates eNOS expression in these 
mice. Our results from ageing mice that do not suffer from hypertension would suggest alterations 
in total eNOS expression might be at least partly-dependent on rises in pressure. 
It is evident that data concerning the expression of vascular eNOS at both the levels of mRNA and 
protein is unclear. However, this analysis does not reflect the full picture concerning NO 
bioavailability. Clearly, other regulatory processes must be changing in the absence of a clear 
expression phenotype, as NO bioavailability is overall generally considered to decrease as one ages. 
In addition to transcriptional and translational regulations, eNOS presents a significant degree of 
regulation via post-translational modifications. Specifically, eNOS is significantly regulated by the 
phosphorylation status of a critical serine residue (Ser1177), typically mediated by PI3K/Akt (Sessa et 
al., 1999). Using phospho-specific antibodies for this residue, we have shown a complex pattern of 
regulation in juvenile and aged αCGRP WT and KO mice. In young animals, we found that the degree 
of phosphorylation was significantly higher in KO animals versus WT. Further to this, as WT animals 
aged from three months to fifteen, phosphorylation of eNOS was significantly increased. This was a 
response that failed to be retained in the aged KO animals, where Ser1177 phosphorylation was 
significantly lower than juvenile KO mice and age-matched WTs. This indicates a complete flattening 
of the response and an inability to maintain the hyperphosphorylation of eNOS enzyme present in 
juvenile KOs throughout the ageing process. Others have shown that total eNOS enzyme present 
within the mesentery of aged rats was preserved as the animals grew older, yet the amount of 
phosphorylated eNOS was decreased (Sun, 2004). This may be linked to a loss in Akt activity (the 
enzyme responsible for ser1177 phosphorylation) (Soucy et al., 2005) with age and a decline in the 
amount of enzyme localised to the caveolae of the plasma membrane (Smith et al., 2006) – a 
process essential for eNOS function. It is interesting that in our WT mice, we witness an increase in 
phospho-eNOS expression where others see a loss. This may be due to differences in species studied 
and also the particular timepoint we have chosen to examine – there may be a compensatory 
upregulation in enzyme activity in ‘middle-age’, whereby the cardiovascular system is attempting to 
restore homeostasis until it is no longer able to maintain this at a later timepoint. Indeed, studies in 
aged humans have shown increased eNOS phosphorylation in isolated ECs (Donato et al., 2009). 
Despite this discrepancy, it is clear that the aged KO mice are less capable of mediating this 
compensation and may suffer vascular inflammation as a result. 
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4.5.4 The vascular redox status of αCGRP WT and KO mice is unaltered in the ageing mouse 
One of the hallmark features of the ageing process is an increased propensity to develop a pro-
oxidant vascular environment. For this reason, we sought to investigate how the redox status of the 
vasculature altered as part of the ageing process in mice and how the deletion of αCGRP impinges 
upon this process.  
We initially characterised the vascular redox status of juvenile and aged CGRP WT and KO mice by 
profiling aortic mRNA expression of pro- and anti-oxidant enzymes. Whilst it is generally thought 
that the mitochondria represent one of the biggest producers of ROS as part of the ageing process, 
undoubtedly other enzymes and systems can converge upon this process. Of note in ageing is the 
NOX family of enzymes. Numerous evidences of either increased NOX expression and/or activity 
within the ageing cardiovascular system have been reported (Assar et al., 2013) and, indeed, ROS 
production by this family of enzymes has been thought to contribute towards reduced NO 
bioavailability with age and pharmacological blockade of these enzyme systems can attenuate age-
associated endothelial dysfunction (McCrann et al., 2009; Zhou et al., 2009). We identified a general 
upregulation in aortic mRNA expression of NOX2 and NOX4 as CGRP WT and KO mice aged from 
three to fifteen months. However, no differences were detected between WT and KO mice at either 
three or fifteen months of age. Thus, CGRP deletion had little influence on the mRNA expression of 
these ROS-producing enzymes. To further investigate the induction of oxidative stress, we examined 
the expression of the anti-oxidant enzyme, HO-1. We chose to investigate this particular gene as its 
expression is rapidly induced following activation of the Nrf2 gene transcription pathway and is thus 
a useful readout of elevated ROS(Baird and Dinkova-Kostova, 2011). Nrf2 is a transcription factor 
that is usually retained in the cytoplasm by its repressor protein, Keap1. Keap1 is removed from this 
complex by electrophiles (such as ROS), allowing Nrf2 to transmigrate into the nuclear compartment 
to induce gene expression of antioxidant and phase 2 detoxifying enzymes, including HO-1 (Lewis et 
al., 2010). We found that aortic mRNA expression of HO-1 was raised in aged animals when 
compared to juveniles. This elevation may be interpreted in one of two ways. First, one may assume 
that an elevation in HO-1 would render the aged aorta to be protected against free radical-induced 
damage. However, one must conduct a more robust study in order to make this conclusion by 
examining protein expression and even activity of this enzyme to understand its action with age. 
Second, there is a wide range of anti-oxidant enzymes present within the vasculature to counteract 
damage from ROS and these would need to be more thoroughly profiled. A safer interpretation of 
our limited study might be that elevated HO-1 at the mRNA level is a marker of a pro-oxidant 
vascular milieu. However, we once again showed that CGRP gene deletion had no influence on the 
level of HO-1 expression, indicating that the degree of ‘stress’ present within the vasculature of WT 
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and KO mice may be comparable. Conversely, we have published showing elevations of HO-1 
expression in a severe model of hypertension where KO mice were less able to maintain antioxidant 
defenses over longer periods of disease (Smillie et al., 2014), indicating that CGRP has the potential 
to regulate this process in some disease models. 
Further evidence of vascular oxidative stress with ageing was investigated by immunoblotting for 
ROS-modified macromolecules within the aortae of juvenile and aged αCGRP WT and KO mice. We 
first investigated the expression of proteins containing nitrated tyrosine residues. Nitrotyrosine 
residues are indicators of oxidative stress due to the nature of their formation. These post-
translational modifications are created via the interaction between NO and superoxide radical, 
forming peroxynitrite. Peroxynitrite is a highly reactive molecule that can modify cellular 
macromolecules, including amino acids present with protein structures (Pacher et al., 2008). This 
reaction is irreversible, but at a very slow rate, and thus presence of nitrated proteins can be used as 
a long-term marker of oxidative/nitrative stress. Indeed, other groups have shown that nitrotyrosine 
expression increases as part of the ageing process, in laboratory animals (van der Loo et al., 2000; 
Miller et al., 2007) and in humans (Donato et al., 2007). With this in mind, we were surprised to 
uncover that nitrotyrosine expression in juvenile WT and KO mice was similar to that found in aged 
WT and KO mice, where once again genetic deletion of αCGRP had little influence on this process. 
This may be because the formation of nitrated tyrosine residues is dependent on two independent 
radicals (NO and superoxide) coming together to react to form peroxynitrite. Thus, if levels of one 
radical are high but the other low, this will result in a poor formation of peroxynitrite and thus poor 
nitration of proteins. Following this result, we then sought to quantify the expression of another 
macromolecular marker of oxidative stress, 4-HNE. 4-HNE is formed by the peroxidation of cellular 
lipids by ROS (Zarkovic, 2003) and its formation is increased as part of the ageing process (Şakul et 
al., 2013). Our results have shown that formation of 4-HNE adducts was relatively low in the aortae 
of juvenile mice and was comparable between αCGRP WT and KO mice. As animals aged, there was 
a significantly increased formation of HNE adducts in WT mice and KO mice also experienced a 
significant elevation in HNE expression at fifteen months of age, indicating a greater degree of 
oxidative stress. Interestingly, we recently showed that both nitrotyrosine and 4-HNE expression in 
the aortae of CGRP WT and KO mice was unchanged in normotensive and hypertensive animals 
(Smillie et al., 2014). Therefore, it is possible that longer timescales or greater insults are needed to 
reveal build-ups of macromolecular damage related to oxidative and nitrative stresses. 
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4.5.5 αCGRP gene deletion does not influence the development of vascular inflammation in 
aged mice 
As a consequence of endothelial dysfunction and increased oxidative stress within the vascular 
compartment as a function of age, the risk of the development of vascular inflammation is high. We 
investigated aspects of the vascular inflammatory response in male juvenile and aged αCGRP WT 
and KO mice. In a small cohort of aged WT and KO animals we performed analysis of circulating 
cytokines. On the whole, we showed that the cytokine profiles of WT and KO aged animals were 
largely similar. However, we did uncover a trend towards an increased bioavailability of KC (CXCL1). 
A link has been demonstrated between CGRP and CXCL1 in the past, where treatment of LPS-
stimulated human dermal microvascular ECs with CGRP was sufficient to attenuate cytokine release 
from these cells, of which CXCL1 was one such cytokine (Huang et al., 2011). Therefore, genetic 
deletion of CGRP may over time lead to an increased bioavailability of KC/CXCL1, which may 
predispose the vasculature to the development of inflammation. CXCL1, when bound to its receptor 
CXCR2, acts as a potent neutrophil chemotactic agent(Ley, 2003). If the KC/CXCL1 signal is not tightly 
regulated, then this may result in collateral damage from inappropriate activity of cells of the innate 
immune system. It is interesting that we did not observe a difference in TNFα bioavailability as a 
complex physioimmunological antagonism is thought to exist between this cytokine and CGRP. For 
example, treatment of endotoxic mice with CGRP improves mortality whilst concomitantly 
decreasing TNFα production (Gomes et al., 2005; Kroeger et al., 2009). The lack of difference 
between groups, coupled with the subtle difference in plasma availability of KC/CXCL1 may simply 
be a reflection of the severity of this model, meaning that differences owing to the contribution of 
CGRP gene deletion are harder to see in a relatively subtle model of cardiovascular stress. 
Inherent to the ageing process is the accumulation of senescent cells within the vascular tissues. 
Senescence is usually brought about by attrition of the telomeres past a certain critical point on the 
chromosome, due to excessive mitotic cell division. Markers of cellular senescence include the cell 
cycle inhibitor proteins p16 and p53 (Muñoz-Espín and Serrano, 2014). As senescent cells are 
capable of changes in phenotype that help propagate vascular inflammation by virtue of their 
‘senescence-associated secretory phenotype’ or ‘SASP’, we investigated the expression of p16 and 
p53 in order to gain an understanding of how significant a contribution cellular senescence may have 
been towards vascular inflammation in our model (Muñoz-Espín and Serrano, 2014). We showed 
that p16 mRNA expression did not change as our mice aged from three to fifteen months and there 
was no significant effect related to the deletion of αCGRP. However, we did detect a significant 
increase in p53 mRNA expression in aged WT animals versus their juvenile counterparts, indicating 
that 15 months of age is a substantial time to induce senescence. Admittedly, we have no direct 
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measurement of senescent cells (detected, for instance, by senescence-associated beta-
galactosidase activity) but the expression of these markers appears to be tightly correlated with 
other measures of senescence (Muñoz-Espín and Serrano, 2014) . Regions of senescent cell 
populations within the vasculature are associated with atherosclerotic lesions and, indeed, those 
regions of the vasculature that are at higher risk of developing lesions (i.e. arteriolar bifurcations) 
also appear to be populated by senescent cells at an earlier timepoint than other regions of the 
vascular tree (Huzen et al., 2011). 
As a result of the low-grade stress that accompanies ageing as detailed above, we also sought to 
investigate how classical markers of vascular inflammation were affected in our model. To do this, 
we measured mRNA expression of the inflammatory markers VCAM-1, F4/80 and MPO in the aortae 
of juvenile and aged αCGRP WT and KO mice. We have shown that vascular mRNA expression of the 
cell adhesion molecule VCAM-1 was significantly increased as both WT and KO animals aged from 
three to fifteen months. However, there was no contribution from the genetic deletion of αCGRP. 
Increases in VCAM-1 expression with age within the aortae of mice has been shown several times 
before (Hemmeryckx et al., 2013). Indeed, interactions between VCAM-1 expression and CGRP have 
also been examined, particularly in the setting of renal injury. In hypernatraemic models of renal 
stress, calcitonin/αCGRP KO mice were found to have increased glomerular VCAM-1 expression in 
comparison to WT counterparts (Bowers, 2005). As VCAM-1 is a critical molecule in the regulation of 
firm arrest of mononuclear cells (specifically, monocytes) onto the activated endothelium, any 
alteration in its expression can have a profound effect on immune cell recruitment. In a subsequent 
study, elevation of cell adhesion molecule expression was found to increase the infiltration of F4/80-
positive mononuclear cells into the renal cortex. F4/80-positive cell populations were higher in the 
KO animals, even after the hypertension induced by high sodium was normalised by hydralazine (Li 
et al., 2013a). We also investigated the presence of F4/80-positive cells in the aortae of our mice via 
RTqPCR. We found that the deletion of αCGRP had no influence on aortic mononuclear cell 
infiltration in juvenile or aged mice when compared to WTs. However, as expected, we did witness a 
significant increase in the amount of F4/80-positive cells infiltrating into the vasculature as the 




In conclusion, this chapter has shown that αCGRP deletion in juvenile (3 months) and aged (15 
months) mice does not contribute to an adverse cardiovascular phenotype, at least with respect to 
adverse haemodynamics and associated vascular remodeling. We have also shown that the oxidative 
environment within the aortae of these mice is similar, with comparable levels of pro- and anti-
oxidant gene expression that all appear to elevate with age. Whilst we could not detect changes in 
nitrated tyrosine residues as evidence of peroxynitrite activity, we did observe a significant elevation 
in the peroxidised lipid product, 4-HNE in aged KO animals. As a consequence of aberrant oxidative 
signalling, we investigated aspects of leukocyte infiltration into the vascular wall. We found VCAM-1 
expression to be higher as the animals aged, an effect that αCGRP gene deletion did not influence. 
Further to this, aortic F4/80 copy numbers also increased in old animals, but once again 
monocyte/macrophage recruitment was unaffected by αCGRP.  
Whilst markers of inflammation did not appear to differ in mice where αCGRP had been removed, its 
deletion appeared to have a significant influence on vascular NO generation. CGRP had no influence 
on both the transcription and translation of eNOS gene within the aorta of male juvenile and aged 
αCGRP WT and KO mice, though it did have an effect at the post-translational level. Juvenile KOs 
appeared to have a hyperphosphorylated critical serine residue (ser1177), indicative of increased 
eNOS activity. This degree of hyperphosphorylation was not maintained as animals reached 15 
months, despite WT aged mice having elevated ser1177 phosphorylation. These subtle post-
translational modifications may have consequences on how CGRP might influence signalling through 
the NO axis, without necessarily impinging on normal physiology to result in a hypertensive 
phenotype.  
In summary, whilst we have obtained evidence to suggest that CGRP might influence vascular NO 
generation in juvenile and aged αCGRP WT and KO mice, this does not translate to alterations in the 
vascular hypertensive or inflammatory phenotype. WT and KO mice have largely similar 
inflammatory profiles as they age from three to fifteen months, although we have uncovered 
evidence to suggest that KO mice might suffer slightly more from a pro-oxidant vascular milieu. A 



















Figure 39: Schematic diagram representing key results obtained from Chapter 4 and potential related signalling pathways contributing towards the phenotype. Solid lines depict events 
observed in this thesis. Dotted lines depict potential signalling pathways related to what is currently known within the published literature. 
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5. | Chapter Five: Investigating a role for αCGRP in monocyte-
endothelial cell interactions under dynamic flow conditions in 
vitro 
5.1 Introduction 
We have shown in Chapter 4 that ageing in mice is sufficient to induce vascular 
inflammation characterised by an increased propensity towards developing a pro-oxidant 
environment, elevated vascular gene expression of cell adhesion molecules and increased 
expression of vascular F4/80 mRNA, indicative of monocyte/macrophage infiltration. 
However, as we deemed that ageing was not a severe enough stimulus to produce CGRP-
mediated protection in this model at this particular timepoint, we next aimed to investigate 
what anti-inflammatory activity, if any, CGRP directly possessed, in the absence of complex 
in vivo physiological factors. Thus, this Chapter will investigate how CGRP may drive or limit 
leukocytic inflammation in vitro. 
5.1.1 The Leukocyte Adhesion Cascade 
One of the key processes in driving the proinflammatory reaction underlying many CVDs is 
that of leukocyte capture and recruitment from the circulation by the vascular endothelium. 
The leukocyte adhesion cascade is a multi-step, complex process that is regulated by events 
and molecular interactions occurring on both the side of the endothelium and the leukocyte. 
Many subtleties and nuances are emerging to challenge and build upon the classical 
paradigm of the adhesion cascade. However, the traditional descriptive model is still of great 
value and can broadly be broken down into three main stages: tethering and rolling, firm 
adhesion and diapedesis. These steps and the key molecules that regulate them vary 
depending on which leukocytes are to be recruited but very general aspects of recruitment 
will now briefly be discussed, in turn.  
1. Tethering and Rolling: Quiescent ECs do not typically recruit leukocytes, as they do 
not express the necessary adhesion molecules to capture circulating cells. This helps 
limit aberrant inflammation and only allows for inflammatory cell recruitment when 
it is required, for example during injury or infection. ECs can become activated in 
response to legitimate exogenous threat (such as release of bacterial endotoxins or 
secondary release of pro-inflammatory cytokines from resident leukocytes) or from 
stimuli related to non-infectious disease pathogenesis, including aberrant activation 
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of the renin-angiotensin system in hypertension or from increased ROS formation 
during ageing (Alom-Ruiz et al., 2008). Activation of the endothelium results in a 
shift in phenotype to one that is characterised by increased leukocyte-endothelial 
interactions, by virtue of the upregulation of cell adhesion molecules and integrins, 
and also liberation of chemokines to facilitate the transmigration process. 
 
Initial tethering and rolling of the leukocyte is predominantly mediated by the 
selectins. P-selectin is rapidly liberated from the Weibel-Palade bodies of activated 
ECs and translocates to the plasma membrane, whereas E-selectin is synthesised de 
novo and appears in the membrane within a few hours. L-selectin is predominantly 
expressed by the leukocyte. Endothelial-expressed selectins typically interact with P-
selectin glycoprotein ligand 1 on the leukocyte with a high on-off rate. These 
interactions are facilitated by laminar blood flow, allowing for the ‘rolling’ of the 
leukocyte along the luminal side of the endothelium (Ley et al., 2007). 
 
2. Leukocyte Activation and Firm Adhesion: Rolling of the leukocyte along the 
activated endothelium is not sufficient to facilitate transmigration. Activated ECs 
express and release a number of potent chemoattractants that can reach high local 
concentrations due to their retention by the endothelial glycocalyx. These 
chemokines bind with high specificity to their cognate GPCRs located on the 
leukocyte, leading to their activation. CXCL8 appears to be important for neutrophil 
activation, whilst CXCL4 seems to induce monocyte firm adhesion (Ley et al., 2007). 
Activation of the leukocyte triggers an incredibly rapid inside-out signalling system, 
whereby cell-surface integrins become modified to increase their affinity for their 
counter-ligands. For example, in the case of monocyte adhesion, leukocyte Very Late 
Antigen-4 is positively modified to encourage interactions with VCAM-1 located on 
the endothelium to initiate arrest. These high affinity interactions between 
leukocyte and endothelium lead to the arrest and firm adhesion of the white blood 






3. Endothelial Transmigration: The final step in leukocyte recruitment is that of the 
movement of the white blood cell from the circulation into the interstitium via the 
carefully coordinated process of endothelial transmigration. Leukocytes can traverse 
the vascular endothelium in one of two ways – transcellularly, where the leukocyte 
is internalised by the EC and transported from the luminal to abluminal membrane 
and subsequently released, or paracellularly, where the leukocyte manouevres itself 
through endothelial intercellular junctions to reach the abluminal side. Though both 
processes occur, paracellular migration is the most common way leukocytes 
transmigrate through the endothelium (Wittchen, 2009). Paracellular transmigration 
usually involves the structural reorganization of endothelial tight junctions. ECs may 
become contractile and pull away from each other to generate gaps between cells 
for leukocytes to move through. Furthermore, ECs may redistribute junctional 
molecules to and from the junctional membrane in order to facilitate paracellular 
transmigration. For example, junctional VE-cadherin may be removed from the 
cellular interface in order to reduce junctional stability(Mamdouh et al., 2008). 
Conversely, molecules such as platelet endothelial cell adhesion molecule-1 
(PECAM-1) and junctional adhesion molecule-A (JAM-A) may be mobilised towards 
the junctional membrane to act as counterligands to bind to leukocyte adhesion 
molecules to subsequently ‘guide’ the leukocyte through the intercellular gap (Ley et 
al., 2007). Once having navigated the endothelial junction, the leukocyte is free to 
then move towards the source of tissue damage. This is usually achieved by the 
migration of the cell up a concentration gradient of chemokine. 
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5.1.2 The role of αCGRP in regulating leukocytic inflammation 
Considering that CGRP has been associated for some time as a “pro-inflammatory 
neuropeptide”, it is surprising that only a handful of studies have been performed 
investigating the direct role of this molecule in the regulation of leukocyte-EC interactions. 
Much of the work contributing towards the idea of CGRP being ‘pro-inflammatory’ stems 
from in vivo studies and, indeed, recent studies into CGRP biology may be challenging this 
misconception. Generally, studies of acute inflammation provide evidence to suggest that 
CGRP is a pro-inflammatory agent, whereby it can potentiate the activity of other 
inflammatory neuropeptides, such as SP (Brain and Williams, 1985; Gamse and Saria, 1985). 
Several in vivo studies have investigated the role of CGRP in the modulation of the 
inflammatory response to sepsis. Investigations in this field largely support a protective role 
for CGRP, where treatment of septic mice with the neuropeptide improved survival whilst 
simultaneously limiting neutrophil-mediated peritonitis, decreasing availability of pro-
inflammatory cytokines and increasing availability of anti-inflammatory cytokines (Gomes et 
al., 2005). This protective phenotype might be produced by induction of ICER activity 
(Kroeger et al., 2009). It is of note that RAMP1-deficient mice are also more susceptible to 
tissue immune cell infiltration and increases in pro-inflammatory cytokines following both 
endotoxaemia and systemic polymicrobial sepsis (Tsujikawa et al., 2007; Jusek et al., 2012). 
Early studies examining the capacity of CGRP to influence leukocyte adhesion found that the 
neuropeptide could induce adhesion of both primary neutrophils and U937 monocyte-like 
cells to endothelial monolayers (Sung et al., 1992; Zimmerman et al., 1992), an effect that 
was apparently mediated by the endothelium, rather than the leukocyte and did not require 
de novo protein synthesis. However, it should be noted that some of these experiments 
were performed using supraphysiological concentrations of CGRP, under static conditions 
and thus are not ideally representative of in vivo conditions. Some groups have shown that 
high concentrations of CGRP can activate the neutrophil directly (Richter et al., 1992), whilst 
others have provided evidence to the contrary (Tanabe et al., 1996). These mixed results are 
also reflected when considering the role of CGRP in the regulation of monocyte/macrophage 
activity, especially with respect to its ability to regulate antigen presentation by these cells 
(Grant, 2001). An excellent study published by Huang et al. in 2011 showed that CGRP was 
capable of attenuating LPS-induced chemokine release from human microvascular ECs via 
inhibition of NFκB-dependent gene transcription. This resulted in decreased neutrophil and 
mononuclear cell transmigration through a transwell apparatus in vitro(Huang et al., 2011). 
To my knowledge, minus the work performed by Sung et al. (1992) and Huang et al. (2011), 
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no studies have been performed investigating the direct role of CGRP in the regulation of 
monocyte-EC interactions, and certainly none have been performed investigating 
recruitment under physiological flow conditions. 
I believe that CGRP has been identified as a pro-inflammatory neuropeptide in some cases in 
vivo by virtue of its profound vasodilator activity. Potent vasodilatation leads to increased 
tissue blood flow. This not only allows for increased numbers of erythrocytes into the vessel, 
but also circulating inflammatory cells and associated circulating chemotactic factors. Thus, 
in experimental models of inflammation where presumably there is a basal level of 
endothelial activation and vascular inflammation, a potent vasodilator like CGRP will act to 
bring in more leukocytes to contribute to inflammation. Thus, CGRP’s “pro-inflammatory” 
nature is a secondary effect due to enhanced blood flow. What is less clear is how CGRP 
directly mediates leukocytic inflammation, in the absence of complex physiological 
responses. The best way this question can be addressed is through reductive, mechanistic in 
vitro experiments. To this end, we will use HUVEC to act as endothelial platforms to recruit 
inflammatory cells. We have chosen to make use of THP-1 monocytic cells to investigate 
leukocyte-EC interactions, with results in mind from our in vivo experiments, where we 
witnessed increases in infiltration of F4/80-positive cells (indicative of cells of 
monocyte/macrophage lineage) into the vascular wall of aged mice, but not increases in 
MPO-positive cells (largely indicative of neutrophils). Whilst THP-1s were once derived from 
a juvenile acute monocytic leukaemia patient (Tsuchiya et al., 1980) and might not 
necessarily be truly representative of primary monocyte activity, they are frequently used as 
a model system for monocytes. Unlike primary monocytes obtained from donors, THP-1s 
possess a homogeneous genetic background, which allows for a simpler interpretation of 
results obtained from their use. Furthermore, they are easier to maintain than primary cells 
and larger cell numbers can be used, meaning they are a more attractive cell line to use for 
preliminary experiments for practical reasons. Functionally, they closely resemble primary 
monocytes with respect to morphology and their expression of classical monocyte markers. 
The ability of THP-1s to differentiate into macrophages following stimulation with phorbol 
esters is also comparable to primary cells. Finally, their ability to interact with ECs is well-




Treatment of TNFα-activated HUVEC (HUVEC) with CGRP will attenuate THP-1 monocyte 
recruitment under dynamic flow conditions in vitro. 
5.3 Aims 
1. To investigate how CGRP influences monocyte-EC interactions under flow conditions 
in quiescent ECs. 
2. To investigate how CGRP influences monocyte-EC interactions under flow conditions 
in activated ECs. 
3. To investigate the mechanisms by which alterations in monocyte-EC interactions 




5.4.1 Acute stimulation of THP-1 monocytes with CGRP does not induce adhesion to 
HUVEC under flow, nor does it attenuate TNFα-induced adhesion 
With early CGRP leukocyte-EC interaction studies from the literature in mind, we first 
performed experiments investigating how acute stimulation of THP-1 cells for 5 minutes 
with 300nM CGRP would affect leukocyte-endothelial interactions under flow, in quiescent 
and TNFα-activated HUVEC (see Figures 7 and 8 in Chapter Two for an overview of the 
experimental protocol). Figure 40 illustrates that activation of HUVEC by TNFα for six hours 
is absolutely required for THP-1 recruitment, as non-activated HUVEC recruited 0 cells over 
the course of the fifteen minute flow experiment. Further to this, we have shown that 
stimulation of THP-1 cells for five minutes with 300nM CGRP is not sufficient to induce 
adhesion in non-activated HUVEC. 
Following a six-hour pre-treatment with 10 ng/mL TNFα to activate HUVEC, we witnessed a 
significant increase in recruitment of 79.09 ± 6.88 THP-1 cells per field of view at the fifteen 
minute timepoint, in comparison to non-activated controls. Further to this, acute 
stimulation of THP-1s with 300nM CGRP for five minutes had no effect on adhesion events 
(78.72 ± 12.86 cells per field of view). Thus, we conclude from these results that: 
1. HUVEC activation by TNFα is required to induce THP-1 adhesion. 
2. Stimulation of THP-1s for five minutes with 300nM CGRP does not facilitate 
adhesion to quiescent HUVEC. 
3. Stimulation of THP-1s for five minutes with 300nM CGRP does not change number 

























Figure 40: In vitro parallel plate THP-1 adhesion assay, investigating the effect of acute (5 minutes) THP-1 
stimulation with 300nM CGRP on adhesion to quiescent and TNFα-activated HUVEC under flow conditions for 
15 minutes. Data expressed as adherent cells per microscopic field of view, mean ± SEM, n=3. Statistical 
significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. ***p<0.001 where quiescent and 












5.4.2 Prolonged stimulation of HUVEC with CGRP attenuates TNFα-induced THP-1 
adhesion in a time-dependent manner 
With the finding that acute stimulation of THP-1 cells with CGRP did not modulate adhesion 
to HUVEC, we sought to understand how stimulation of the endothelium with CGRP 
influenced this process (see Figure 8 in methods for schematic detailing the protocol for this 
experiment). When HUVEC were activated, they were stimulated with TNFα for six hours. 
When cells were also treated with CGRP, this was either for the full six hours, three hours 
(halfway through TNFα stimulation) or one hour (at the five-hour TNFα timepoint). Vehicle 
treatment for each compound (TNFα or αCGRP) was stimulation of cells for the full six hours 
(i.e. the maximal amount of time each compound was used for). Figure 41 illustrates that, 
again, quiescent ECs do not recruit THP-1 cells under flow and stimulation with TNFα is 
required for this to happen. Further to this, co-treatment of quiescent ECs with 300nM CGRP 
for 1, 3 or 6 hours was not found to induce adhesion. 
As expected, we discovered that 6 hours 10 ng/mL TNFα pre-treatment was required to 
induce THP-1 adhesion to HUVEC, where at the maximal perfusion experiment timepoint of 
15 minutes, we observed 44.70 ± 8.57 adherent cells per field of view. There was a trend 
towards a reduction in THP-1s adherent to HUVEC treated with CGRP for 1 hour (41.76 ± 
9.50 cells per field of view) and 3 hours (36.10 ± 7.66 cells per field of view), although these 
findings were not statistically significant. Interestingly, however, we witnessed a significant 
reduction in the number of adherent THP-1s adherent to HUVEC treated with CGRP for 6 
hours (19.73 ± 5.38 cells per field of view). Indeed, HUVEC treated for 6 hours with CGRP 
had a significantly reduced adherent THP-1 population by the ten-minute perfusion 
timepoint (9.96 ± 3.07 cells per field of view), when compared to vehicle-treated TNFα-
activate controls (28.72 ± 4.87 cells per field of view). Thus, we conclude from these results 
that: 
1. Stimulation of quiescent HUVEC for up to 6 hours with 300nM CGRP is not sufficient 
to induce THP-1 adhesion. 
2. Stimulation of TNFα-activated HUVEC for 6 hours with 300nM CGRP is sufficient to 
significantly attenuate THP-1 adhesion from the 10-minute perfusion time point 

























Figure 41: In vitro parallel plate THP-1 adhesion assay, investigating the effect of HUVEC pre-treatment with 
300nM CGRP on adhesion to quiescent and TNFα-activated HUVEC under flow conditions for 15 minutes. Data 
expressed as adherent cells per microscopic field of view, mean ± SEM, n=3. Statistical significance was 
evaluated by repeated-measures two-way ANOVA plus Bonferroni post hoc test. ****p<0.0001; **p<0.01; 








5.4.3 Reduced THP-1 adhesion to activated HUVEC is not dependent on changes in total 
cellular VCAM-1 expression 
Following the observed phenotype that pre-treatment of TNFα-activated HUVEC with 
300nM CGRP for six hours resulted in reduced THP-1-EC interactions, we sought to identify a 
mechanism that could explain this phenomenon. We first immunoblotted total HUVEC 
protein lysates treated in a similar manner to those used in flow assay experiments for the 
expression of VCAM-1, a well-known regulator of monocyte firm-adhesion to endothelium. 
Figures 42 and 43 show that quiescent HUVEC did not express VCAM-1 and treatment of 
quiescent endothelium for up to six hours with 300nM CGRP was not sufficient to induce 
expression of this protein. 
Following stimulation of HUVEC with TNFα, we witnessed a robust induction of total cellular 
VCAM-1 protein expression that was found to be statistically significant versus quiescent 
cells. Treatment of TNFα-activated cells with 300nM CGRP for up to six hours had no effect 









Figure 42: Representative immunoblot of total cellular HUVEC lysates, probing for VCAM-1, following 














Figure 43: Densitometric analysis of immunoblotting of total cellular HUVEC lysates, probing for VCAM-1. 
Representative blots show VCAM-1 immunoreactivity at ~110 kDa and loading control β-actin at ~44 kDa Data 
expressed as arbitrary densitometric units normalised to β-actin, mean ± SEM, n=3. Statistical significance was 
evaluated by two-way ANOVA plus Bonferroni post hoc test. **p<0.01; *p<0.05 where TNFα-activated HUVEC 
were compared to their respective quiescent controls. 
 
 197 
5.4.4 Reduced THP-1 adhesion to activated HUVEC is not dependent on changes in total 
cellular PECAM-1 expression 
We next investigated changes in PECAM-1 expression by immunoblotting total HUVEC 
protein lysates treated in a similar manner to those used in flow assay experiments. PECAM-
1 is important in mediating leukocyte transmigration. Figures 44 and 45 show that PECAM-1 
expression is unchanged by treatment for up to six hours with 300nM CGRP in quiescent 
ECs. Further to this, activation of HUVEC with TNFα did not change the level of expression of 








Figure 44: Representative immunoblot of total cellular HUVEC lysates, probing for PECAM-1, following 
















Figure 45: Densitometric analysis of immunoblotting of total cellular HUVEC lysates, probing for PECAM-1. 
Representative blots show PECAM-1 immunoreactivity at ~132 kDa and loading control β-actin at ~44 kDa. 
Data expressed as arbitrary densitometric units normalised to β-actin, mean ± SEM, n=3. Statistical significance 
was evaluated by two-way ANOVA plus Bonferroni post hoc test. No significant differences were detected 
between groups. 
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5.4.5 Reduced THP-1 adhesion to activated HUVEC is not dependent on changes in total 
cellular JAM-A expression 
We next investigated changes in JAM-A expression by immunoblotting total HUVEC protein 
lysates treated in a similar manner to those used in flow assay experiments. JAM-A is 
important in the regulation of endothelial tight junctions and has a role in facilitating 
leukocyte transmigration through this axis. Figures 46 and 47 show that JAM-A expression is 
unchanged by treatment for up to six hours with 300nM CGRP in quiescent ECs. Further to 
this, activation of HUVEC with TNFα did not change the level of expression of JAM-A and 







Figure 46: Representative immunoblot of total cellular HUVEC lysates, probing for JAM-A, following 













Figure 47: Densitometric analysis of immunoblotting of total cellular HUVEC lysates, probing for JAM-A. 
Representative blots show JAM-A immunoreactivity at ~132 kDa and loading control β-actin at ~44 kDa. Data 
expressed as arbitrary densitometric units normalised to β-actin, mean ± SEM, n=3. Statistical significance was 
evaluated by two-way ANOVA plus Bonferroni post hoc test. No significant differences were detected between 
groups. 
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5.4.6 Reduced THP-1 adhesion to activated HUVEC is not dependent on changes in total 
cellular JAM-C expression 
We next investigated changes in JAM-C expression by immunoblotting total HUVEC protein 
lysates treated in a similar manner to those used in flow assay experiments. JAM-C is 
important in the regulation of endothelial tight junctions and has a role in facilitating 
leukocyte transmigration through this axis. Figures 48 and 49 shows that JAM-C expression is 
unchanged by treatment for up to six hours with 300nM CGRP in quiescent ECs. Further to 
this, activation of HUVEC with TNFα did not change the level of expression of JAM-C and 







Figure 48: Representative immunoblot of total cellular HUVEC lysates, probing for JAM-C, following stimulation 












Figure 49: Densitometric analysis of immunoblotting of total cellular HUVEC lysates, probing for JAM-C. 
Representative blots show JAM-A immunoreactivity at ~132 kDa and loading control β-actin at ~44 kDa Data 
expressed as arbitrary densitometric units normalised to β-actin, mean ± SEM, n=3. Statistical significance was 




5.4.7 Microarray analysis reveals that CGRP does not alter TNFα-induced changes in 
global endothelial gene expression 
Following the investigation of changes in whole cell protein expression of various cell 
adhesion molecules and identifying no clear candidates, we next sought to examine how 
CGRP affected the TNFα response in HUVEC at the level of the transcriptome. Here, we 
found that stimulation of HUVEC with 10 ng/mL TNFα for six hours was sufficient to induce a 
robust pro-inflammatory gene transcription network. Setting a false discovery rate (FDR) of 
q = 0.05 to decrease the chance of identifying genes that changed their expression 
artefactually, as a result of multiple-comparison testing, we identified 1351 genes whose 
expression differed following TNFα exposure versus cells treated with vehicle. Surprisingly, 
however, we found that treatment of HUVEC for six hours with 300 nM CGRP had no effect 
on HUVEC gene expression at baseline. When q = 0.05 for this data set, 0 genes had changed 
their level of expression. Furthermore, co-stimulation of TNFα-activated HUVEC with CGRP 
resulted in no change in the gene expression pattern versus TNFα treatment alone.  
For simplicity and clarity, we have shown in Table 10 the top 25 genes that downregulated 
their level of expression in HUVEC, following TNFα treatment, including their p-values and 
fold change in expression. Table 11 shows similar data for the top 25 genes that upregulated 
their level of expression under similar treatment circumstances. Tables 12 and 13 show that 
300 nM CGRP for 6 hours did not result in a change in the transcriptome induced by TNFα. 
Using GeneGo MetaCore software, we then grouped these genes into functional groupings, 
according to the signalling pathways that they belong to. As there is considerable overlap in 
these pathways owing to no single gene having one single function, we have shown the top 
10 enrichment pathways that the genes we have identified clustered into (Figure 50). 
Pathways with high levels of significance included those related to NFκB and cytokine 
signalling, particularly that related to IL-18 (gene enrichment map illustrated in Figure 51).  
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Table 10: Table illustrates top 25 genes decreasing their expression in HUVEC following six hour TNFα 
stimulation versus vehicle, thresholded by a false discovery rate of q = 0.05. 
Gene Symbol Gene Title p-value Fold change 
MAP2K6 mitogen-activated protein kinase kinase 6 0.000622073 0.205617 
DUSP4 dual specificity phosphatase 4 7.07E-06 0.299751 
DACH1 dachshund homolog 1 (Drosophila) 3.79E-06 0.306102 
OR1L8 olfactory receptor, family 1, subfamily L, member 8 0.00127583 0.318431 
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 0.000111942 0.318502 
PCDH7 protocadherin 7 8.81E-06 0.326367 
PCDH9 protocadherin 9 8.03E-06 0.327213 
TMC7 transmembrane channel-like 7 5.57E-05 0.356045 
SOX18 SRY (sex determining region Y)-box 18 8.31E-06 0.3565 
HTR1D 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 9.04E-05 0.360248 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) 1.31E-06 0.36051 
GPRIN3 GPRIN family member 3 0.001122046 0.363434 
GPR126 G protein-coupled receptor 126 6.44E-06 0.376928 
GJA5 gap junction protein, alpha 5, 40kDa 0.000221768 0.382617 
CLEC12B C-type lectin domain family 12, member B 0.000379586 0.386513 
LONRF3 LON peptidase N-terminal domain and ring finger 3 0.000678512 0.389914 
CCNE2 cyclin E2 0.000338144 0.398083 
PCDH17 protocadherin 17 9.94E-05 0.407927 
CALCRL calcitonin receptor-like 3.45E-05 0.409431 
CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 8.77E-05 0.415264 
PLAC8 placenta-specific 8 0.000148325 0.415722 
KRT80 keratin 80 0.000103213 0.41708 
MANSC4 MANSC domain containing 4 8.70E-05 0.418563 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 0.000118824 0.420874 
ALX1 ALX homeobox 1 2.67E-05 0.421508 
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Table 11: Table illustrates top 25 genes increasing their expression in HUVEC following six hour TNFα 
stimulation versus vehicle, thresholded by a false discovery rate of q = 0.05. 
Gene Symbol Gene Title p-value Fold change 
IFIH1 interferon induced with helicase C domain 1 4.77E-06 7.37101 
C2CD4B C2 calcium-dependent domain containing 4B 1.08E-06 7.66832 
IL1A interleukin 1, alpha 4.92E-07 7.78733 
ICOSLG inducible T-cell co-stimulator ligand 6.46E-06 7.83087 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 2.67E-05 8.04515 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 1.42E-06 8.67158 
CXCL11 chemokine (C-X-C motif) ligand 11 6.39E-07 8.6982 
CCL20 chemokine (C-C motif) ligand 20 3.12E-05 8.82469 
RND1 Rho family GTPase 1 2.04E-06 9.77696 
BCL2A1 BCL2-related protein A1 1.38E-06 9.85974 
GABBR1 /// UBD gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D 0.000189
399 
11.3131 
IL18R1 interleukin 18 receptor 1 5.16E-07 12.3721 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 2.04E-07 12.8676 
EBI3 Epstein-Barr virus induced 3 6.97E-06 13.0558 
ICAM1 intercellular adhesion molecule 1 0.000113
497 
14.2779 
SELE selectin E 1.74E-05 17.4448 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 2.91E-05 17.7804 
IL8 interleukin 8 3.53E-07 19.4468 
TRAF1 TNF receptor-associated factor 1 1.47E-06 19.567 
CD69 CD69 molecule 9.83E-06 22.5417 
BIRC3 baculoviral IAP repeat containing 3 9.26E-07 27.2492 
CX3CL1 chemokine (C-X3-C motif) ligand 1 3.55E-05 35.0929 
UBD ubiquitin D 4.49E-05 45.2061 
VCAM1 vascular cell adhesion molecule 1 7.37E-07 54.972 
CXCL10 chemokine (C-X-C motif) ligand 10 6.65E-07 67.5932 
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Table 12: Table illustrates top 25 genes decreasing their expression in HUVEC following six hour TNFα 
stimulation and co-stimulation with CGRP for six hours, thresholded by a false discovery rate of q = 0.05. 
Gene Symbol Gene Title p-value Fold change 
MAP2K6 mitogen-activated protein kinase kinase 6 0.000622073 0.205617 
DUSP4 dual specificity phosphatase 4 7.07E-06 0.299751 
DACH1 dachshund homolog 1 (Drosophila) 3.79E-06 0.306102 
OR1L8 olfactory receptor, family 1, subfamily L, member 8 0.00127583 0.318431 
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 0.000111942 0.318502 
PCDH7 protocadherin 7 8.81E-06 0.326367 
PCDH9 protocadherin 9 8.03E-06 0.327213 
TMC7 transmembrane channel-like 7 5.57E-05 0.356045 
SOX18 SRY (sex determining region Y)-box 18 8.31E-06 0.3565 
HTR1D 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 9.04E-05 0.360248 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) 1.31E-06 0.36051 
GPRIN3 GPRIN family member 3 0.001122046 0.363434 
GPR126 G protein-coupled receptor 126 6.44E-06 0.376928 
GJA5 gap junction protein, alpha 5, 40kDa 0.000221768 0.382617 
CLEC12B C-type lectin domain family 12, member B 0.000379586 0.386513 
LONRF3 LON peptidase N-terminal domain and ring finger 3 0.000678512 0.389914 
CCNE2 cyclin E2 0.000338144 0.398083 
PCDH17 protocadherin 17 9.94E-05 0.407927 
CALCRL calcitonin receptor-like 3.45E-05 0.409431 
CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 8.77E-05 0.415264 
PLAC8 placenta-specific 8 0.000148325 0.415722 
KRT80 keratin 80 0.000103213 0.41708 
MANSC4 MANSC domain containing 4 8.70E-05 0.418563 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 0.000118824 0.420874 
ALX1 ALX homeobox 1 2.67E-05 0.421508 
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Table 13: Table illustrates top 25 genes increasing their expression in HUVEC following six hour TNFα 
stimulation and co-stimulation with CGRP for six hours, thresholded by a false discovery rate of q = 0.05. 
  
Gene Symbol Gene Title p-value Fold change 
IFIH1 interferon induced with helicase C domain 1 4.77E-06 7.37101 
C2CD4B C2 calcium-dependent domain containing 4B 1.08E-06 7.66832 
IL1A interleukin 1, alpha 4.92E-07 7.78733 
ICOSLG inducible T-cell co-stimulator ligand 6.46E-06 7.83087 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 2.67E-05 8.04515 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 1.42E-06 8.67158 
CXCL11 chemokine (C-X-C motif) ligand 11 6.39E-07 8.6982 
CCL20 chemokine (C-C motif) ligand 20 3.12E-05 8.82469 
RND1 Rho family GTPase 1 2.04E-06 9.77696 
BCL2A1 BCL2-related protein A1 1.38E-06 9.85974 
GABBR1 /// UBD gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D 0.000189
399 
11.3131 
IL18R1 interleukin 18 receptor 1 5.16E-07 12.3721 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 2.04E-07 12.8676 
EBI3 Epstein-Barr virus induced 3 6.97E-06 13.0558 
ICAM1 intercellular adhesion molecule 1 0.000113
497 
14.2779 
SELE selectin E 1.74E-05 17.4448 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 2.91E-05 17.7804 
IL8 interleukin 8 3.53E-07 19.4468 
TRAF1 TNF receptor-associated factor 1 1.47E-06 19.567 
CD69 CD69 molecule 9.83E-06 22.5417 
BIRC3 baculoviral IAP repeat containing 3 9.26E-07 27.2492 
CX3CL1 chemokine (C-X3-C motif) ligand 1 3.55E-05 35.0929 
UBD ubiquitin D 4.49E-05 45.2061 
VCAM1 vascular cell adhesion molecule 1 7.37E-07 54.972 


















Table 14: Table illustrates top 25 genes upregulating their expression in HUVEC following six hour TNFα 












Figure 50: Enrichment of 1351 genes altering their expression in HUVEC treated for six hours with 10 ng/mL 
TNFα. Data ranked according to likelihood that genes observed appear in pre-defined gene pathways, as 



















Figure 51: Gene enrichment map pertaining to IL-18 signalling.network. 21/60 genes identified in microarray 
screen appeared in this pre-defined network, yielding a p value= 1.422e-
12
 with a FDR of q = 3.64e-
10
. B: 
binding; CM: covalent modifications; CS: complex subunit; GR: group relation; IE: influence on expression; P: 
phosphorylation; TR: transcriptional regulation Z: catalysis. Genes with a red thermometer are positively 
regulated with TNFα, where fuller thermometers indicate a strong level of expression. Genes with a blue 







In this chapter, I have shown that CGRP has the potential to act as a direct anti-inflammatory 
agent in vitro, by virtue of its ability to attenuate THP-1 monocyte-EC interactions, under 
physiological flow conditions. In Chapter Four we have shown that in the mouse, ageing to 
fifteen months is sufficient to induce infiltration of F4/80-positive mononuclear cells into the 
aortic wall. Deletion of αCGRP did not affect this process and I deemed this due to the 
mouse model of natural ageing not being harsh enough of a stimulus to provoke CGRP-
dependent vascular protection. Despite this, there is a small but mixed literature concerning 
the role of CGRP in the regulation of leukocyte trafficking, none of which has investigated 
leukocyte recruitment under flow conditions. Thus, we thought this a sensible avenue of 
research to pursue. We used THP-1 cells as a human monocyte surrogate for practical 
reasons. This monocytic cell line is well-characterised and highly-representative of primary 
monocytes (Qin, 2012) and their use circumvents the problems associated with obtaining 
high cell yields of high viability from human donors and further reduces variability in data 
from donor to donor. Monocytic cells were used in place of other innate immune cells (such 
as neutrophils), as we obtained a clear signal from the in vivo ageing study in Chapter 4 that 
F4/80-positive (i.e. monocyte/macrophage) cells infilitrated into the vascular wall with 
advancing age. Conversely, we saw no evidence of neutrophil accumulation with ageing and 
thus deemed this the best approach to take. 
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5.5.1 HUVEC activation with TNFα is absolutely required to promote leukocyte-
endothelial cell interactions via the induction of pro-inflammatory gene and 
protein expression 
In this chapter we have reproduced the data of other groups by showing that perfusion of 
inflammatory cells (such as THP-1s) over quiescent, non-activated HUVEC does not lead to 
the recruitment of these cell types to the endothelium (Gamble et al., 1985; Furie and 
McHugh, 1989). In order to achieve recruitment, we had to stimulate the endothelium with 
10 ng/mL TNFα for six hours to allow for the induction of pro-inflammatory gene expression 
and the upregulation of cell adhesion molecules at the plasma membrane. Cell adhesion 
molecules that are typically involved in leukocyte recruitment by the EC include the P- and E-
selectins, VCAM-1, ICAM-1, PECAM-1 (Golias et al., 2007) and, to some extent, JAM isoforms 
(Ostermann, 2005; Schmitt et al., 2014). This paradigm of the leukocyte adhesion cascade is 
supported by the results we obtained investigating the HUVEC transcriptome following TNFα 
treatment and through some of our protein expression studies via whole-cell 
immunoblotting. We found that VCAM-1 gene expression was upregulated almost 55-fold 
over quiescent HUVEC. Further, we showed that HUVEC do not constitutively express this 
cell adhesion molecule under non-stimulated conditions but they robustly and significantly 
induce VCAM-1 protein expression following TNFα stimulation. Furthermore, we witnessed 
an elevation of E-selectin gene expression, at around 17-fold over control cells and an 
elevation of ICAM-1 gene expression, at around 14-fold over control. Immunoblotting 
showed that quiescent HUVEC expressed similar amounts of PECAM-1, JAM-A, JAM-C that 
were unchanged by TNFα stimulation. Through microarray analysis, we also uncovered 
evidence for a high degree of increased transcript for various cytokines and chemokines, 
which may facilitate firm adhesion of the monocyte via activation of the cell to induce 
integrin engagement. We noted strong upregulation of genes encoding CXCL10, CX3CL1, IL-
8, CCL20, CXCL11, CSF2, and IL-1α. Thus, we have demonstrated our ability to activate 
canonical TNFα-induced pathways in order to recruit leukocytes to endothelium in our 
assay. 
 209 
5.5.2 Acute stimulation of THP-1 cells with 300 nM CGRP does not affect leukocyte 
adhesion to quiescent or activated HUVEC 
We have shown that acute stimulation of THP-1 cells with 100 nM CGRP for five minutes 
prior to perfusion over activated endothelium was not sufficient to alter leukocyte-EC 
interactions. This finding is in contrast with an early finding within the literature, which 
suggests CGRP can directly activate inflammatory cells such as neutrophils, albeit at high 
concentrations (Richter et al., 1992). Other studies have shown that CGRP is capable of 
inhibiting pro-inflammatory activity in pre-activated macrophages (Torii et al., 1997). Thus, it 
is conceivable that had we followed a line of investigation whereby we had pre-activated 
monocytes with TNFα and then stimulated with CGRP, we may have identified an interesting 
phenotype. Following this finding, however, we decided to abandon this line of 
investigation, mainly owing to the biological relevance of the question. It is unlikely that 
circulating CGRP directly stimulates immune cells as the concentrations found within the 
plasma are so low, around the picomolar range (Russell et al., 2014). It is more likely that the 
most relevant source of CGRP is the DRG nerve terminal that innervates the vascular wall. 
These nerves are well placed to release CGRP and in places infiltrate through the tunicae 
media to make contact with the ECs of the intimal layers of the vessel. Thus, we decided to 
instead focus on the effect of CGRP on the EC, rather than the leukocyte. 
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5.5.3 Stimulation ofHUVEC with 300 nM CGRP does not promote leukocyte adhesion in 
quiescent endothelium, but attenuates leukocyte-endothelial interactions in 
TNFα-activated endothelial cells 
Focusing on the effect of CGRP on the endothelium, we uncovered some interesting results. 
Firstly, we showed that treatment of quiescent ECs for up to six hours with 300 nM CGRP 
was not sufficient to encourage leukocyte-endothelial interactions under flow conditions. 
This indicates that CGRP likely does not induce cell adhesion molecule expression over this 
timeframe. This finding is in contrast with early studies investigating the effect of CGRP on 
endothelial biology, where treatment of endothelium with CGRP enhanced leukocyte 
adhesion under static conditions, using supraphysiological concentrations of peptide (Sung 
et al., 1992; Zimmerman et al., 1992). Further to this, cell adhesion molecule protein 
expression (VCAM-1, PECAM-1, JAM-A, JAM-C) was not significantly altered by CGRP 
stimulation for up to six hours and the transcriptome as measured by microarray was also 
unaffected. Thus, we concluded CGRP had a minimal effect on these aspects of endothelial 
biology at this concentration and within this timeframe.  
Despite this lack of activity in quiescent ECs, we identified an interesting phenotype related 
to CGRP in TNFα-activated endothelium. We showed that co-stimulation of TNFα-treated 
HUVEC with 300 nM CGRP produced a time-dependent attenuation in leukocyte adhesion 
under flow conditions, where a significant attenuation of around 50% could be observed 
when cells were treated for six hours. A trend towards a reduction in leukocyte adhesion 
could also be observed at the three-hour time point. We concluded from this that CGRP 
impinges upon TNFα activity to limit leukocyte adhesion to endothelium. This effect 
complements a study performed by Huang et al. who showed that CGRP could inhibit the 
production of chemokines from LPS-activated microvascular endothelium, resulting in a 
reduction in leukocyte trafficking (Huang et al., 2011). Whilst harder to interrogate in terms 
of mechanisms, some have shown in vivo that CGRP is capable of attenuating leukocyte 
accumulation under pro-inflammatory conditions, in models of vascular preconditioning 
(Kamada et al., 2006; Hartmann et al., 2011) and sepsis (Gomes et al., 2005). 
We were surprised at the finding that CGRP did not influence HUVEC gene transcription 
either in isolation or when combined with TNFα treatment. This is especially so because 
maximal attenuation of leukocyte recruitment occurred at six hours of treatment with CGRP, 
which would be characteristic of a process like gene transcription that takes many hours to 
complete, as opposed to a transient signalling event. TNFα treatment of HUVEC induced a 
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robust gene transcription profile, some of which was associated with typical NFκB-
dependent pathways. Given that Huang et al. have previously shown that 10 nM CGRP is 
capable of inhibiting gene transcription in human dermal microvascular ECs through a LPS-
NFκB network via the stabilisation of IκBα within the cytosol (Huang et al., 2011), we were 
surprised that we could not recapitulate this phenotype with the use of CGRP in attenuating 
TNFα transcription responses. Furthermore, more generally, increases in intracellular cAMP 
levels have been shown to inhibit NFκB-dependent gene transcription in ECs via the 
activation of PKA (Ollivier et al., 1996). Steps were taken to ensure that the CGRP used in 
this particular assay was bioactive – aliquots were used from the same batch as flow assay 
experiments and CGRP was assayed for bioactivity using a mesenteric artery preparation in 
the myograph, where it was found to produce vasodilatation at 300 nM.  
We attempted to identify specific mechanisms by which CGRP might reduce monocyte 
adhesion to activated endothelium. Initial immunoblotting for key EC adhesion molecules 
did not point to a particular molecule regulating this response. Further microarray analysis 
of endothelial gene expression revealed that whilst TNFα induced a robust and well-
characterised pattern of gene expression, CGRP did not change this response. This indicates 
that however CGRP is producing the observed phenotype, it is not by directly affecting 
TNFα-dependent gene transcription. A possibility is that CGRP is affecting intracellular 
protein trafficking – changes in total cellular adhesion molecule expression might not be 
apparent but the temporospatial distribution of adhesion molecules within the cell may be 
different. For instance, the removal of adhesion molecules (such as VCAM-1, for instance) 
from the plasma membrane and into intracellular compartments may result in a reduced 
adhesion phenotype. Indeed it is known, for instance, that molecules of the endothelial tight 
junction (including PECAM-1) can be removed from the membrane and “cycled” through the 
lateral border recycling compartment (Mamdouh et al., 2008), depending on the 
requirements of the cell to maintain its junction at a particular point in time. One way to 
interrogate this trafficking process and to build upon our cell adhesion molecule 
immunoblotting experiments would be to investigate expression of cell adhesion molecules 
within the EC membrane, perhaps by biotinylating such proteins and subsequently 
identifying them by mass spectrometry, for instance. Alternatively, in line with studies 
performed by Huang et al., it is possible that endothelial CGRP signalling is limiting 
chemokine presentation by the cell (Huang et al., 2011). Certainly, we showed that TNFα 
could induce gene expression for a range of cytokines/chemokines in HUVEC. Failure to 
secrete these factors would presumably result in lowered THP-1 activation to mediate firm 
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adhesion to the endothelium and thus a mechanism that is independent on EC adhesion 
molecule expression and dynamics might exist. 
Another surprising result was related to our findings in microarray experiments, showing 
that genes encoding proteins that comprise the CGRP receptor were less active following 
TNFα treatment versuscontrol-treated cells (CALCLR expression reduced by 0.40). This has 
been shown once before by Nagoshi et al. who found that treatment of coronary artery ECs 
with 10 ng/mL TNFα (the same concentration used in our experiments and one which is 
representative of that found within the inflamed vascular wall) was sufficient to bring about 
a ~60% reduction in CLR expression and a ~30% reduction in RAMP1 expression, which 
coincided with a loss of receptor function, as measured by cAMP assay (Nagoshi et al., 
2004). This could be a potential mechanism by which CGRP attenuates leukocyte-endothelial 
interactions, though this mode of action would point to a level of constitutive receptor 
activation by endogenously produced ligands, which is not an phenomenon that is well-
characterised of the CGRP receptor. 
Whilst we have discovered an interesting phenotype regarding the ability of CGRP to 
attenuate monocyte-EC interaction under flow conditions in vitro, there are a few limitations 
to this arm of the study and improvements with future experiments can be made. Firstly, it 
would be prudent to establish a concentration-response curve to determine the active range 
of concentration of CGRP required toproduce this phenotype. Admittedly, the concentration 
we have used in this experiment could be argued as being on the supraphysiological scale, 
especially with respect to reported circulating concentrations of peptide, thought to be 
within the picomolar range. However, we designed the experiment to obtain the best 
chance of observing a phenotype by using a relatively high concentration. Further to this, 
circulating levels of peptide probably do not represent a reservoir of biologically significant 
CGRP and may better be considered as neuronal spillover, much like circulating 
noradrenaline. At the site of release, however, local concentrations of CGRP are likely to be 
high and whilst it is not known, it is conceivable that concentrations of peptide that reach 
the endothelium in vivo are within the range that we are using. Secondly, mechanistic 
analyses would take advantage of selective CLR/RAMP1 receptor antagonists (such as 
BIBN4096BS) to probe whether the phenomenon observed is a CGRP receptor-dependent 
event or if the concentration of CGRP we have chosen is high enough to activate the AM1 
receptor for AM, comprised of CLR/RAMP2.  
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5.5.4 Conclusion 
Despite the lack of mechanism, there is some biological significance in our finding that CGRP 
can time-dependently inhibit leukocyte adhesion. We have shown in Chapter 4 that ageing is 
characterised by an enhanced infiltration of inflammatory cells into the vascular walland this 
can provide a pro-inflammatory platform for disease. A disease that is highly prevalent in the 
aged is atherosclerosis, where activation of the endothelium and trafficking of circulating 
monocytes is a hallmark early pathogenic component. Unfortunately, studies of 
atherosclerosis and CGRP are incredibly sparse, possibly owing to the difficulty of generating 
a double ApoE/CGRP KO mouse by conventional cross-breeding methods. Both ApoE and 
CGRP genes are located in close proximity to one another in the mouse genome and thus 
will usually cross over together during meiosis. Studies taking advantage of other mouse 
models of atherosclerosis (for example, in LDL receptor KO mice fed atherogenic diets) 
might reveal a protective role for CGRP in trafficking of circulating monocytes into the early 
atherosclerotic lesion. We have so far witnessed a lack of evidence supporting a protective 
role for CGRP within the ageing vasculature but we have gathered evidence for CGRP being 
protective in vitro. With the additional knowledge that previous studies from our lab 
concerning more severe CVD models reveal a degree of vascular protection afforded by 
CGRP (Smillie et al., 2014), Chapter 6 will attempt to recapitulate in vivo protection by 
challenging the ageing vasculature with ATII-induced hypertension. 
 214 
6. | Chapter Six: Investigating a role for αCGRP in a mouse model 
of geriatric hypertension 
6.1 Introduction 
In Chapter 4, I showed that aged mice lacking the gene encoding αCGRP do not suffer from 
pathological increases in baseline blood pressure and have similar vascular inflammatory 
profiles, in comparison to WT animals. We ascribed this to the lack of severity of the ageing 
model and it not being a significant enough stimulus to provoke CGRP-mediated 
cardiovascular protection. Conversely, in Chapter 5, results suggested that CGRP could act in 
an anti-inflammatory manner, by virtue of attenuating leukocyte-EC interactions. With both 
of these findings in mind, we sought to develop a new model in ageing WT and KO αCGRP 
mice that would be severe enough to generate vascular dysfunction, namely, an ageing ATII 
model of hypertension. 
There is a dense literature involving the use of the ATII model of hypertension in the mouse 
and, indeed, we have published recently on the role of αCGRP in this particular model 
(Smillie et al., 2014) (Figure 52 illustrates hypertensive data taken from this publication). 
However, there are significantly less studies related to the use of this model in ageing mice. 
Three recent publications from the Ungvari group have characterised the model and have 
apparently demonstrated its utility. Results from their laboratory have shown that infusion 
of 1.4 mg/kg/day ATII over 28 days is sufficient to induce increases in blood pressure of 
about 40-60 mmHg, in male C57/BL6 mice aged 24 months (Csiszar et al., 2013; Toth et al., 
2013a; 2013b). Hypertension in aged mice was associated with exacerbated 
cerebromicrovascular injury and upregulation of proinflammatory cytokines. However, given 
that these three publications have emerged from the same laboratory, what remains to be 
seen is whether this is a reproducible model of hypertension in aged animals. In this chapter, 
we will apply this model to male aged αCGRP WT and KO mice, in order to provoke a pro-
inflammatory vascular environment to ideally precipitate a degree of vascular protection 





































Figure 52: Figure adapted from Smillie et al. (2014) showing elevated systolic blood pressure in ATII-treated 
juvenile mice, with exacerbated hypertension in CGRP KO mice (Smillie et al., 2014). 
 216 
6.2 Hypothesis 
Infusion of 1.1 mg/kg/day ATII into aged (15 months) αCGRP WT and KO mice will produce 
hypertension and associated vascular inflammation that is exacerbated in mice lacking 
αCGRP. 
6.3 Aims 
1. To establish and characterise a new model of ATII-induced hypertension in aged 
αCGRP WT and KO mice. 
2. To investigate a potential protective role for CGRP against hypertension-induced 




6.4.1 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice does not 
clearly produce the development of hypertension 
To establish hypertension in aged αCGRP WT and KO mice, we chose to use a dose of 1.1 
mg/kg/day ATII, infused via osmotic minipump over a course of 14 days. This dosing regime 
has been previously well-characterised within our group and is known to induce 
hypertension in juvenile mice (Bodkin et al., 2014; Smillie et al., 2014). With this and the 
aforementioned studies published by Ungvari in mind, we expected to observe hypertension 
in our mice. Figure 53 shows longitudinal blood pressure responses over the course of the 
experiment that, surprisingly, did not produce a clear result. Disappointingly, we found that 
WT animals treated with vehicle trended towards a non-significant increase in systolic blood 
pressure (Figures 53, 54) from baseline to day 14 (baseline 95.89 ± 3.55 mmHg vs 110.93 ± 
7.31 mmHg). Furthermore, we discovered that WT mice infused with ATII displayed no clear 
trend towards the expected rise in systolic blood pressure (baseline 95.74 ± 8.10 mmHg vs 
96.12 ± 11.04 mmHg). Vehicle-treated KO mice displayed a trend towards a decrease in 
blood pressure at day 14 from baseline (102.68 ± 1.80 mmHg vs 90.05 ± 0.92 mmHg) and WT 
vehicle-treated mice showed a small trend towards increased blood pressure (102.90 ± 2.66 
mmHg vs 109.37 ± 8.37 mmHg). Diastolic pressure (Figure 54B) and MAP (Figure 54C) 
showed similar trends, with no significant changes detected in any of the treatment groups. 
It is worth noting that one WT ATII-treated mouse and one KO ATII-treated mouse went on 
to develop substantial renal cysts, which led to large decreases in blood pressure from 
baseline, potentially confounding some of the results from this experiment.  
As this was such a surprising result, we thought it prudent to scrutinise the data further in 
order to identify evidence of a pharmacological effect of ATII. Figure 55 illustrates changes in 
systolic (Figure 55A), diastolic (Figure 55B) and MAP (Figure 55C) blood pressure following 
Veh/ATII treatment in αCGRP WT and KO mice, with trend lines matching each animal. Here, 
we show evidence of a mix of responders and non-responders, which might be obscuring 
the final result we observed. Whilst it is clear that an unexpected result was observed in 
vehicle-treated WT animals, we see evidence for at least two WT animals within the ATII 
group responding to the infusion in the expected manner. For instance, one mouse begins 
with a baseline systolic blood pressure of 105.83 mmHg, which then rises to 147.00 mmHg 
following treatment (Figure 55A), a rise in systolic blood pressure of 41.17 mmHg. Another 
animal was found to have a lower baseline than the rest in the group, but had an increase in 
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blood pressure of 29.08 mmHg following treatment, which may be considered to be 
hypertensive relative to baseline. Strikingly, in the ATII-treated KO group of animals, we 
observed four out of six animals responding to treatment, as opposed to only two out of six 
animals in the WT ATII group. Whilst the variable responses observed in the control group 
animals confound the data somewhat, looking at responses obtained from individual 




























Figure 53: Longitudinal blood pressure responses of aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle  (Veh, saline) or angiotensin II (ATII) over 14 days. 
Results show A) systolic blood pressures of male aged αCGRP WT and KO mice following treatment; B) diastolic blood pressures of male aged αCGRP WT and KO mice following treatment; 
















Figure 54: Blood pressures of aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, saline) or angiotensin II (ATII). Results show baseline blood pressure 
(‘Before) and blood pressure at day 14 of hypertension (‘After’). Results show A) systolic blood pressures of male aged αCGRP WT and KO mice following treatment; B) diastolic blood 
pressures of male aged αCGRP WT and KO mice following treatment; C) mean arterial blood pressures of male aged αCGRP WT and KO mice following treatment. Data expressed as mm 
Hg, mean ± SEM, n=4 for vehicle-treated animals, n=6 for ATII-treated animals. Statistical significance was evaluated by repeated measures two-way ANOVA plus Bonferroni post hoc test. 
No significant differences were detected between experimental groups. 
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Owing to differences in baseline blood pressures between animals, we further sought to 
crystallise the blood pressure response from this experiment. To do so, Figure 56 illustrates 
blood pressure responses at day 14 of the experiment as a percentage change from baseline 
for each individual experimental subject. Figure 56A shows systolic blood pressure changes, 
Figure 56B diastolic and Figure 56C MAP. Indeed, when we analysed responses from 
individual animals, we uncovered evidence of groups of responders versus non-responders. 
Figure 56A shows that 2/6 WT ATII-treated animals responded in a hypertensive manner 
relative to baseline. Interestingly, 4/6 KO ATII-treated animals responded in a hypertensive 














Figure 55: Blood pressures of aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, saline) or angiotensin II (ATII). Results show baseline blood pressure 
(‘Before’) and blood pressure at day 14 of hypertension (‘After’), matched for each animal. Results show A) systolic blood pressures of male aged αCGRP WT and KO mice following 
treatment; B) diastolic blood pressures of male aged αCGRP WT and KO mice following treatment; C) mean arterial blood pressures of male aged αCGRP WT and KO mice following 
treatment. Data expressed as mmHg, mean ± SEM, n=4 for vehicle-treated animals, n=6 for ATII-treated animals. Statistical significance was evaluated by repeated measures two-way 

















Figure 56: Blood pressures of aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, saline) or angiotensin II (ATII). Results show % change from baseline 
blood pressure (‘Before’) and blood pressure at day 14 of hypertension (‘After’), matched for each animal. Results show A) systolic blood pressures of male aged αCGRP WT and KO mice 
following treatment; B) diastolic blood pressures of male aged αCGRP WT and KO mice following treatment; C) mean arterial blood pressures of male aged αCGRP WT and KO mice 
following treatment. Data expressed as %change from baseline mm Hg, mean ± SEM, n=4 for vehicle-treated animals, n=6 for ATII-treated animals. Statistical significance was evaluated by 
repeated measures two-way ANOVA plus Bonferroni post hoc test. No significant differences were detected between experimental groups. 
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6.4.2 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice does not 
promote clear cardiac hypertrophy but does induce polydipsia 
With the knowledge that ATII failed to produce a clear and consistent hypertensive response 
in this experiment, we sought to measure other markers of hypertension, which may have 
changed in the absence of an overt pressor phenotype. Figure 57 illustrates changes in 
water consumption in αCGRP WT and KO mice following vehicle or ATII infusion. Figure 57A 
shows group mean data for changes in water consumption measurements in WT and KO 
mice receiving either vehicle or ATII. Interestingly, here we found that vehicle-treated 
animals did not differ significantly in their water consumption at day 14 in comparison to 
baseline. However, both WT and KO animals that received 1.1 mg/kg/day ATII significantly 
increased their water consumption by day 14 of infusion (139.76 ± 36.34 μl/hour vs 281.42 ± 
81.07 μl/hour for WT; 112.26 ± 14.48 μl/hour vs 277.93 ± 75.36 μl/hour for KO). Thus, whilst 
significant changes in blood pressure may not have occurred, we have some evidence to 
suggest that ATII is having some pharmacological effect in these mice, with respect to water 
consumption. Figures 58A-D illustrate correlations between percentage changes in systolic 
blood pressure and water intake, in order to identify a relationship between the two 















Figure 57: Water intakes of aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, saline) or angiotensin II (ATII). Results show A) water intakes of male 
aged αCGRP WT and KO mice following treatment; B) water intakes of male aged αCGRP WT and KO mice following treatment, matched for each animal; C) % change from baseline water 
intake of male aged αCGRP WT and KO mice following treatment. Data expressed as A), B) μl/hour, mean ± SEM, n=4 for vehicle-treated animals, n=6 for ATII-treated animals; C) %change 
from baseline water intake. Statistical significance was evaluated by repeated measures two-way ANOVA plus Bonferroni post hoc test. *p<0.05 where genotype-matched treatment 















Figure 58: Correlating changes in water intake over baseline vs percentage changes in systolic blood pressure 
over baseline in aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, 
saline) or angiotensin II (ATII). Results show correlations for A) WT Veh-treated animals; B) WT ATII-treated 
animals; C) KO Veh-treated animals; D) KO ATII-treated animals. Statistical significance was evaluated by 




In conjunction with water consumption, we also investigated other parameters known to 
change following the induction of experimental hypertension. Figure 59 shows how animal 
heart weight was affected by ATII, both in terms of raw mass (Figure 59A) and heart mass 
relative to animal body size (Figure 59B). We did not observe any significant change in either 
total heart mass or heart mass relative to body size. However, we did witness an interesting 
trend towards an increase in heart mass in KO mice following ATII, though this did not reach 
statistical significance. Furthermore, data represented in Figures 60A-D show that there was 


















Figure 59: Changes in heart weight of aged (15 months) αCGRP male WT and KO mice, following infusion of 
either vehicle (Veh, saline) or angiotensin II (ATII). Results show A) changes in heart mass of male aged αCGRP 
WT and KO mice following treatment; B) changes in heart mass, relative to body weight of male aged αCGRP 
WT and KO mice following treatment. Data expressed as A) mg, mean ± SEM, n=4 for vehicle-treated animals, 
n=6 for ATII-treated animals; B) mg/mg body weight, mean ± SEM, n=4 for vehicle-treated animals, n=6 for ATII-
treated animals. Statistical significance was evaluated by repeated measures two-way ANOVA plus Bonferroni 
















Figure 60: Correlating changes in heart weight over baseline vs percentage changes in systolic blood pressure 
over baseline in aged (15 months) αCGRP male WT and KO mice, following infusion of either vehicle (Veh, 
saline) or angiotensin II (ATII). Results show correlations for A) WT Veh-treated animals; B) WT ATII-treated 
animals; C) KO Veh-treated animals; D) KO ATII-treated animals. Statistical significance was evaluated by 




6.4.3 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice does not 
induce changes in gene expression of markers of vascular dysfunction 
Whilst we did not witness significant increases in blood pressure in aged αCGRP WT and KO 
animals receiving ATII treatment, we did see some evidence for pharmacological activity of 
ATII when we measured water consumption. These data combined made us consider that 
whilst we set out to establish a more ‘severe’ model of cardiovascular stress by the infusion 
of a pressor dose of ATII, we may have perhaps generated a ‘subpressor’ ATII model instead. 
This type of model would not increase blood pressure in the mouse, but may still have the 
capacity to induce vascular dysfunction and associated inflammation. 
To investigate this, we probed total mRNA lysates from the aortae of aged αCGRP WT and 
KO mice treated with either vehicle or ATII for 14 days. We initially examined eNOS gene 
expression as an early marker of endothelial dysfunction and found no significant changes in 
the level of its expression in WT and KO mice following either vehicle or ATII administration 
(Figure 61A). We then investigated HO-1 gene expression as an early marker of oxidative 
stress and again found no significant changes in its expression (Figure 61B). Interestingly, 
however, we found that WT mice had a clear trend towards elevated HO-1 expression 
following ATII infusion, in comparison with their vehicle-treated counterparts (4015.25 ± 
483.04 copies/μl for vehicle-treated vs 12039.00 ± 3893.33 copies/μl for ATII-treated). This 
did not reach statistical significance, but points to an interesting potential action of ATII in 
promoting oxidative stress in the absence of changes in pressure. This increase was reflected 
in KO animals, but to a lesser degree. Despite potential increases in HO-1 as a response to 
oxidative stress, we observed no significant changes or clear trends in the expression of pro-















Figure 61: Gene expression analysis of vascular dysfunction markers of aortic lysates obtained from aged (15 
months) male αCGRP WT and KO mice, treated with either vehicle (Veh) or ATII. Results show A) mRNA 
expression of eNOS in aortic lysates; B) mRNA expression of HO-1 in aortic lysates; C) mRNA expression of 
NOX2; D) mRNA expression of NOX4 in aortic lysates. Data expressed as copies mRNA per microliter, mean ± 
SEM, n=3-5. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. No 
significant differences were detected between groups. 
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6.4.4 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice does not 
induce changes in gene expression markers of vascular inflammation 
Further to examination of gene expression of markers related to vascular dysfunction, we 
next studied the expression of aortic genes from aged αCGRP WT and KO animals that are 
more classically related to the development of leukocytic vasculitis. Figure 62A illustrates 
changes in aortic VCAM-1 expression in aged WT and KO mice in response to either vehicle 
or ATII. Echoing changes in HO-1 expression, we found a clear but non-significant increase in 
VCAM-1 gene expression in WT mice following ATII infusion (492.50 ± 15.74 copies/μl for 
vehicle-treated vs 1088.44 ± 325.20 copies/μl for ATII-treated). This trend was reflected in 
KO animals receiving ATII treatment, although it was less clear. We also investigated changes 
in the gene expression of another marker of vascular inflammation, MCP-1, to complement 
our VCAM-1 findings (Figure 62B). Here we did not observe as clear a signal, with expression 





















Figure 62: Gene expression analysis of vascular inflammatory markers of aortic lysates obtained from aged (15 months) 
male αCGRP WT and KO mice, treated with either vehicle (Veh) or ATII. Results show A) mRNA expression of VCAM-1 in 
aortic lysates; B) mRNA expression of MCP-1 in aortic lysates. Data expressed as copies mRNA per microliter, mean ± 
SEM, n=3-5. Statistical significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. No significant 
differences were detected between groups. 
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6.4.5 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice induces 
changes in vascular CGRP receptor gene expression 
We were also interested in investigating how aortic CGRP receptor gene expression might 
change following the induction of hypertension, in aged αCGRP WT and KO mice (Figure 63). 
Here, we have shown that the gene expression of CLR mRNA within the aorta does not 
appear to significantly change in WT and KO mice following infusion of ATII. However, we did 
note a non-significant trend towards an upregulation of CLR gene expression in WT mice 
that received ATII for 14 days (667.75 ± 35.93 copies/μl for vehicle-treated vs 904.25 ± 
186.11 copies/μl for ATII-treated). Expression of CLR in KO animals receiving ATII appeared 
comparable to controls (Figure 63A) 
Interestingly, when we interrogated aortic RAMP1 gene expression (Figure 63B), we found 
the opposite. RAMP1 appeared to be stably expressed in WT animals, with comparable 
levels of expression between vehicle- and ATII-treated groups. Vehicle-treated KO mice also 
had a very similar level of mRNA expression (335.66 ± 60.84 copies/μl). However, levels of 
RAMP1 mRNA significantly doubled in the ATII-treated KO group (770.25 ± 89.15 copies/μl) 
when compared with vehicle-treated. Levels were also significantly higher than those in the 
ATII-treated WT group. This is a striking result in comparison to RAMP2 mRNA expression, 



















Figure 63: Gene expression analysis of vascular inflammatory markers of aortic lysates obtained from aged (15 
months) male αCGRP WT and KO mice, treated with either vehicle (Veh) or ATII. Results show A) mRNA 
expression of CLR in aortic lysates; B) mRNA expression of RAMP1 in aortic lysates; C) mRNA expression of 
RAMP2 in aortic lysates. Data expressed as copies mRNA per microliter, mean ± SEM, n=3-5. Statistical 
significance was evaluated by two-way ANOVA plus Bonferroni post hoc test. **p < 0.01 where comparisons 
were made between animals of differing genotype receiving the same treatment; ##p < 0.01 where 










6.4.6 Infusion of 1.1 mg/kg/day angiotensin II in aged αCGRP WT and KO mice does not alter the 
expression of CGRP isoforms within the dorsal root ganglia 
Finally, we measured the gene expression of CGRP isoforms within the DRG of aged αCGRP WT and 
KO mice, following infusion of either vehicle or ATII (Figure 64). We found that αCGRP gene 
expression did not significantly differ between WT mice receiving either vehicle or ATII. KO mice did 
not express any transcript for αCGRP (Figure 64A). Expression of βCGRP also did not significantly 
change, although there was a small non-significant trend towards an elevation of expression in WT 
mice following ATII treatment (94.33 ± 47.16 copies/μl vs 163.25 ± 30.31 copies/μl, Figure 64B). KO 





















Figure 64: Gene expression analysis of CGRP isoforms of DRG lysates obtained from aged (15 months) male αCGRP WT 
and KO mice, treated with either vehicle (Veh) or ATII. Results show A) mRNA expression of αCGRP in DRG lysates; B) 
mRNA expression of βCGRP in DRG lysates. Data expressed as copies mRNA per microliter, mean ± SEM, n=3-4. Statistical 




6.4.7 Infusion of 1.1 mg/kg/day angiotensin II in juvenile αCGRP WT and KO mice leads to 
increased blood pressure and cardiac hypertrophy 
Due to our failure to generate hypertension following ATII infusion in aged male αCGRP WT and KO 
mice, we sought to revalidate the model in a small sample of juvenile male mice in order to exclude 
a lack of effect originating from technical reasons. We implanted juvenile αCGRP WT and KO mice 
with osmotic minipumps loaded to administer a dose of 1.1 mg/kg/day ATII or vehicle. Figure 65A 
shows that this was sufficient to induce hypertension in mice, increasing systolic blood pressure by 
approximately 30 mmHg. Vehicle-treated mice displayed no trend towards a change in blood 
pressure. 
As further validation of the model, we also investigated the degree of cardiac hypertrophy in these 
mice, as a readout of ATII activity compounded by increased blood pressure (Figure 65B). We found 
that ATII tended to increase heart mass in WT and KO animals receiving ATII treatment, but not in 





















Figure 65: Validation of the ATII model of hypertension in juvenile (3 months) male αCGRP WT and KO mice, treated 
with either vehicle (Veh) or ATII over 14 days. Results show A) systolic blood pressures of male juvenile αCGRP WT and 
KO mice following treatment; B) heart to body weight ratios of male juvenile αCGRP WT and KO mice following 
treatment. Data expressed as A) mm Hg mean ± SEM; B) heart weight to body weight ratio mean ± SEM. n=2. 
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6.5 Discussion 
In Chapter 4, we showed that ageing in mice did not promote an overt maladaptive cardiovascular 
phenotype, with respect to regulation of blood pressure. Ageing to fifteen months was sufficient to 
generate a pro-inflammatory vascular milieu, characterised by enhanced cell adhesion molecule 
expression and increased infiltration of leukocytes into the vascular wall. However, we did not find 
evidence for a role for CGRP in regulating this process – WT and KO mice appeared similar in most 
inflammatory parameters at both three and fifteen months of age. We associated this lack of 
protection with the mild nature of the ageing model, given that more overt stresses to the 
cardiovascular system can produce evidence for CGRP-mediated vascular protection (Russell et al., 
2014). Despite this, in Chapter 5 we uncovered evidence to support an intrinsic anti-inflammatory 
role for CGRP in vitro, where it acted to limit leukocyte-EC interactions in a time-dependent manner 
via its action on the endothelium. With both of these findings in mind, we sought to generate a more 
severe model of cardiovascular stress in the ageing mouse, in order to precipitate CGRP-mediated 
protection in vivo. 
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6.5.1 Infusion of 1.1 mg/kg/day ATII in aged αCGRP WT and KO mice does not lead to the 
generation of systemic hypertension 
In order to create such a model of vascular inflammation in ageing mice, we combined two existing 
models we have established in our group – that of ATII-induced hypertension and ageing itself. We 
deemed this to be an interesting experimental question that has relevance to the human condition – 
most humans tend to develop hypertension in middle age. We have already published a study 
showing that CGRP can act as a vascular protective agent in an ATII model of hypertension (Smillie et 
al., 2014) and others have shown a similar result in other models (Bowers, 2005; Sabharwal et al., 
2010). Thus, we expected that implantation of ATII-loaded osmotic minipumps would generate 
hypertension that would be compounded by the subclinical inflammation of ageing to create an 
exacerbated phenotype. We found that infusion of 1.1 mg/kg/day ATII over 14 days did not lead to a 
significant increase in systemic blood pressure in aged αCGRP WT and KO mice. This was surprising 
to us, as others have validated this model and shown it to be viable (Csiszar et al., 2013; Toth et al., 
2013a; 2013b). Additionally, upregulation of the AT1R has been observed both within the rodent 
heart (Heymes et al., 1998) and primate vasculature during ageing (Wang et al., 2003), suggesting 
that susceptibility to ATII-induced hypertension should be greater with age. It is of note that two 
mice did present with polycystic kidneys (one WT ATII-treated and one KO ATII-treated), which 
presumably led to substantial drops in blood pressure. These cysts were only observed in ATII-
treated animals and anecdotal evidence from our group has shown ATII to induce renal cysts in 
juvenile animals, in the past. Data from these mice were not excluded, as there appears to be a link 
between ATII and cyst development, meaning this phenotype is likely a facet of the model rather 
than biological anomaly (Loghman-Adham, 2004; Kaliappan et al., 2012). We further attempted to 
understand why aged mice failed to develop hypertension by reproducing some of our published 
results performed in a small sample of juvenile mice (Bodkin et al., 2014; Smillie et al., 2014) and 
found that, indeed, they did go on to develop hypertension following ATII infusion. By doing this, we 
minimised the likelihood that the absence of phenotype observed in aged mice was related to a 
failure of the experiment. Thus, we were interested in this apparent failure to respond and sought to 
scrutinize the model further, in order to understand what kind of effect, if any, was happening 
elsewhere in the mouse, with particular reference to the vasculature. 
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6.5.2 Evidence of pharmacological activity of ATII in aged αCGRP WT and KO mice by 
measurement of cardiac hypertrophy and water consumption 
It is well established that ATII can act in a dipsogenic manner to increase thirst and drinking behavior 
(McKinley and Johnson, 2004), acting to eventually increase blood volume and raise blood pressure 
as a result. Thus, we deemed that the monitoring of fluid consumption in aged αCGRP WT and KO 
mice receiving ATII infusion would be an alternative measure of ATII having a pharmacological effect 
in these animals. Indeed, we found that saline-treated animals all consumed similar volumes of 
water, regardless of genotype, but animals receiving ATII infusion significantly increased their water 
intake over vehicle-treated animals. This indicated that whilst animals were not becoming 
hypertensive, ATII was still producing a physiological response. In addition to this dipsogenic 
response, we also found evidence to suggest that animals receiving ATII treatment tended to have 
an increased heart mass, although this failed to reach statistical significance. Analysis of responses 
from each individual animal revealed that we had populations of responders versus non-responders. 
Indeed, it also appeared that CGRP KO mice had a greater population of responders to ATII with 
respect to increases in blood pressure (4/6 mice) versus WT mice (2/6 responders). Therefore, we 
investigated whether the animals that responded by increasing blood pressure also responded in a 
positive manner with respect to other markers of ATII activity, namely, water intake and cardiac 
hypertrophy. In summary, we found that there were no clear correlations between increases in 
systolic blood pressure and water intake/increased heart mass, indicating that the observed effects 
were truly independent of blood pressure and mediated by the specific activity of ATII. 
From these data combined, we concluded that ATII was inducing a pressure-independent 
cardiovascular response. Subpressor doses of ATII have been shown to influence vascular 
inflammation and dysfunction in the absence of overt changes in blood pressure (Reckelhoff et al., 
2000; Bataller et al., 2003) and thus we thought it possible that we would also observe a degree of 
inflammation in our mice, where the deletion of αCGRP might result in a worsened phenotype. 
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6.5.3 Infusion of 1.1 mg/kg/day ATII into aged αCGRP WT and KO mice does not lead to the 
generation of vascular inflammation 
Having observed clear changes in the vascular inflammatory profile of ageing aortae in Chapter 4, we 
investigated changes in pro-inflammatory gene expression within the same vessel in this model. We 
first investigated changes in eNOS mRNA expression, which may have provided an indication of 
endothelial dysfunction in mice. We did not see any significant differences or, indeed, clear trends in 
changes in mRNA expression of this enzyme across experimental groups. This was surprising, as ATII 
is a long-established inducer of early endothelial dysfunction (Schulz et al., 2011). Indeed, some have 
shown that endothelial dysfunction induced by ATII in mice can be driven by inflammatory 
monocytes, which induce expression of iNOS, generating nitro-oxidative stress sufficient to uncouple 
endothelial NOS (Kossmann et al., 2014). Of course, results shown in Chapter 4 showed that eNOS 
mRNA expression remained stable with progression in age from three to fifteen months, but the 
level of eNOS activation did differ. Thus, it would be prudent to look at eNOS protein expression and 
activity (based on phosphorylation status) within this model in order to draw better conclusions with 
respect to endothelial dysfunction. In conjunction with our eNOS mRNA finding, we witnessed no 
distinct, statistically significant pro-inflammatory signal following ATII treatment in either αCGRP WT 
or KO mice. However, we did witness some interesting trends that may point to some effect. For 
instance, WT mice receiving ATII trended towards having an elevated HO-1 mRNA expression, which 
may be indicative of a pro-oxidant environment preceding classical vascular inflammation. A similar 
result in this group was identified with respect to a non-significant elevation in aortic VCAM-1 
expression. However, we found no increase in pro-oxidant NOX enzyme expression as we did in 
Chapter 4, which would be characteristic of ATII infusion (Nguyen Dinh Cat et al., 2013). However, it 
is worth noting that this pilot study had a relatively low statistical power and increasing sample sizes 
in future experiments may reveal clearer effects. 
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6.5.4 Infusion of 1.1 mg/kg/day ATII into aged αCGRP WT and KO mice does not drastically alter 
aspects of the CGRP signalling axis but may affect vascular RAMP1 expression 
We also interrogated aspects of the CGRP signalling system, by measurement of isoform expression 
within the DRG. There is known to be a link between ATII signalling and perivascular nerve function, 
extending to alterations in CGRP-mediated vascular responses. We have previously shown that 
chronic ATII administration to mice over either a 14- or 28-day period can increase bioavailable 
CGRP, possibly in an attempt to restore cardiovascular homeostasis in the face of a strong 
vasopressor stimulus (Smillie et al., 2014). Others have shown that ATII can inhibit CGRP release 
from perivascular nerves and subsequently reduce its bioactivity (Kawasaki et al., 1998; 2000). 
Further to this, it is thought that ATII can directly remodel the sensory neuron to promote sensory 
nerve dysfunction and even denervation in the SHR; effects that are blocked by AT1R blockade and 
ameliorated by AT2R activation (Kawasaki, 2002; Kawasaki et al., 2003; Hobara et al., 2005). We 
found no strong evidence in this study for dysregulation of expression of CGRP isoforms at the mRNA 
level within DRG lysates. However, we did notice a trend towards an increase in βCGRP expression in 
the DRG of WT animals receiving ATII treatment, which may be indicative of an early response to 
cardiovascular stress. It is interesting that we see this trend with respect to βCGRP expression and 
not αCGRP. However, we have shown changes in βCGRP expression following the induction of 
hypertension (Smillie et al., 2014) and thus this isoform may represent an underappreciated area of 
CGRP research, particularly when the αCGRP KO mouse is being used. 
We further investigated CGRP signalling mechanisms by analysing the expression of CGRP receptor 
genes within the aortae of αCGRP WT and KO mice receiving ATII. We saw no change in the 
expression of CLR or RAMP2, indicating that AM receptor signalling expression remained largely 
unaffected within this model. However, we have shown a significant increase in RAMP1 mRNA 
expression only in KO mice receiving ATII treatment. RAMP1 levels were significantly raised in 
comparison to ATII-treated WTs and vehicle-treated KOs. This is an intriguing result, which may 
strengthen our long-term hypothesis of CGRP activity. This upregulation of RAMP1 may point to an 
increased sensitivity and susceptibility to a hypertensive (or, indeed, sub-hypertensive) stimulus in 
KO mice versus WT. Whilst we have shown that juvenile CGRP KO mice have a worsened 
cardiovascular phenotype in response to high-dose ATII infusion (Figure [X])(Smillie et al., 2014), in 
this chapter we provide evidence to suggest that a subpressor dose of ATII is still significant enough 
of a stimulus to provoke changes in the CGRP KO mouse. One way to think of how CGRP is acting 
might be to employ the analogy of an early braking system. In WT animals, where the ‘brake’ is 
intact, it is harder to generate pathology as a result of ATII infusion as CGRP is actively working 
against this development. However, when the brake is removed in the KO animal, the manifestation 
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of pathology is easier to see. Thus, RAMP1 may be increasing its expression in ATII-treated KO mice 
in order to amplify signal transduction through the CGRP receptor in order to counteract early 
perturbations in cardiovascular function. Changes in RAMP expression following the induction of 
hypertension have not so far been observed, although experimental manipulation of these proteins 
has yielded a level of cardiovascular protection, as previously discussed(Sabharwal et al., 2010; 
Zhang and Russo, 2010). Others have shown changes in RCP expression within the vasculature in 
order to mediate improved CGRP-dependent vascular responses in a model of subtotal nephrectomy 
salt-induced hypertension (Supowit et al., 2011). 
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6.5.5 Conclusion 
In summary, in this chapter we attempted to establish a model of vascular inflammation with the 
knowledge that ageing alone does induce inflammation but the role for CGRP within this setting is 
negligible (Chapter 4), coupled with evidence from Chapter 5 which suggests CGRP does indeed 
possess intrinsic anti-inflammatory properties. Here we have shown that infusion of 1.1 mg/kg/day 
ATII into aged αCGRP WT and KO mice did not lead to overt hypertension, as we have previously 
published in juvenile animals (Smillie et al., 2014) and shown in a small pilot study within this 
chapter. The reason for this is unclear but we have provided evidence for small groups of responders 
versus non-responders when analysing data from individual animals. Furthermore, some data from 
this chapter may suggest that whilst overt hypertension was not generated, aged CGRP KO mice may 
still be more sensitive to ATII infusion, as evidenced by a greater proportion of hypertensive 
responders within this subgroup. Furthermore, evidence of an increased propensity of these mice to 
increase aortic expression of RAMP1 mRNA may point to an early damage-limitation signal in 















7. | Chapter Seven: General Discussion 
7.1 Overview 
Ageing in humans is a complex phenotype that is governed by many biological processes that 
contribute to various extents in driving the phenomenon and, certainly, not all processes will 
contribute in each case. Furthermore, many environmental and lifestyle factors can interact with 
these endogenous biological processes to exacerbate the phenotype. Despite this apparent 
complexity, there is a great need to investigate the basic biology of ageing, owing to the increasing 
ageing population demographic in most areas of the Western world, including the UK. As ageing 
represents the single biggest independent risk factor for the development of CVD, it is evident that 
we are facing an emerging ageing epidemic that is likely to represent a substantial burden to the 
economy and public health services(Franklin, 1999). Thus, it is important that we turn to 
experimental models of ageing, both in vivo and in vitro, in order to better understand the aetiology 
of ageing such that we can develop novel therapeutics to improve healthspan. As discussed, ageing 
is often comorbid with other complications (such as hypertension) and thus it is also prudent to 
study the interactions between the ageing body and associated diseases. 
My central hypothesis was that deletion of αCGRP in mice would result in an exacerbated vascular 
inflammatory phenotype induced by ageing to fifteen months, driven in part by leukocytic processes. 
We proposed that this inflammation would impinge upon haemodynamics to generate 
hypertension. Using the evidence presented in this thesis, I am now able to address the previously 
stated aims and comment on how this evidence fits with my hypothesis. 
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7.2 Major and novel findings of this thesis 
The data from this thesis has built upon existing knowledge suggesting a protective role for CGRP 
within the cardiovascular system. However, until this thesis, no studies had been performed 
investigating how CGRP affects the ageing process, especially with respect to vascular inflammatory 
processes. Thus, with this we have contributed entirely novel findings to this field. Further to this, 
we have expanded knowledge on how CGRP acts to attenuate leukocytic vasculitis at the level of the 
leukocyte adhesion cascade. The salient findings of this thesis are as follows: 
7.2.1 Ageing to fifteen months in mice does not induce an adverse cardiovascular phenotype in 
vivo and genetic deletion of αCGRP has no effect on haemodynamic or murine growth 
parameters. 
Our initial hypothesis was that ageing to fifteen months in mice would be sufficient to precipitate a 
maladaptive cardiovascular phenotype, specifically leading to a mild, pre-hypertensive state. Data 
obtained during the on-going Framingham Heart Studyshows quite clearly that systolic blood 
pressure rises linearly with age, between the years of 30 to 84 and over. Changes in diastolic blood 
pressureoccurring with age is more complex. Data seem to suggest that diastolic pressure increases 
until around the age of 50, but then decreases as age increases. This generates a steep rise in pulse 
pressure with ageing, which is potentially dangerous (Franklin, 1999). In our studies, we used αCGRP 
WT and KO mice bred onto a C57BL/6J background at fifteen months of age. C57BL/6J mice have 
been demonstrated to live for 815 ± 16 days in laboratory conditions (Jackson Laboratories, 2008). 
Thus, from this, we deemed our mice to be “middle-aged” – a time at which humans would typically 
be expected to manifest some form of CVD, such as hypertension. 
We did not observe evidence of overt cardiovascular abnormalities in these mice, with respect to 
haemodynamic parameters and deletion of αCGRP gene had no impact on these outcomes. 
Certainly, these findings call into question the validity of using mice as models of human ageing if 
they are unable to spontaneously develop cardiovascular (or other) disease. However, I have 
discussed in Chapter 4 that mice generally only succumb to diseases related to cancer in their old 
age and the absence of other comorbidities is presumably related to the interaction between the 
mouse genome and its environment. It is known in humans that improvements in lifestyle (such as 
cessation of smoking, taking exercise and dietary improvements) can significantly improve 
cardiovascular outcome by lowering risk for hypertension, atherothrombotic disease and ultimately 
heart attack and stroke(Santos-Parker et al., 2014; Siervo et al., 2014). It is therefore likely that mice 
do not fall foul to CVD in old age presumably because they do not smoke, drink orhave poor diet. 
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Indeed, CVD can be precipitated in mice through dietary interventions, such as feeding of a high-fat 
diet (Marshall et al., 2013), hypercholesterolaemic diet (Xiangdong et al., 2011) or providing a 
hypernatraemic drinking water (Van Vliet and Montani, 2008). Thus, the interaction of the 
organism’s genome with its environment is key in producing disease and this feature is shared 
between both mice and humans (and, indeed, other mammals commonly-used in the laboratory). 
Indeed, I conjecture that were it ethical to maintain humans under standard laboratory conditions, 
the prevalence of CVD would be low. 
Despite finding little evidence to suggest overt signs of CVD were present in ageing mice, we were 
optimistic regarding the inherent stress of the ageing process in provoking cardiovascular defects in 
the αCGRP KO mouse. We have previously shown that in a short- and long-term ATII model of 
hypertension, deletion of αCGRP leads to an exacerbated hypertensive phenotype and augmented 
cardiovascular stress associated with the disease, despite WT and KO mice presenting normally 
under basal conditions (Smillie et al., 2014). This would indicate that αCGRP forms part of a stimulus-
activated network that works against acute stresses to restore homeostasis. Others using αCGRP KO 
mice (i.e. those with αCGRP deleted and calcitonin expression left intact) in other severe models of 
CVD have also shown similar results (for example, in wire-induced vascular injury and hindlimb 
ischaemia models)(Mishima et al., 2011; Yang et al., 2013). I have argued that the lack of phenotype 
in KO mice in the face of age-induced stress is probably related to the subclinical and chronic nature 
of age-associated pathologies. These pathologies are slow in onset, slow to progress and do not 
represent a serious threat to the organism at any particular point in time – there is no great upset of 
homeostasis to provoke biological systems acting to ‘regress towards the mean’, quite unlike the 
ATII model. Given the relative biological expense of synthesising, maintaining and releasing a peptide 
to counteract a subtle ‘disease’ such as ageing, it is perhaps not surprising that deletion of CGRP 
precipitates no clear phenotype – its action is simply not required in the face of an apparent ‘low 
threat’. A further confounding factor we uncovered in this study was developmental genetic 
compensation in our αCGRP KO mice. We showed that circulating plasma levels of the peptide 
remained consistent in both genotypes throughout the ageing process. Furthermore, we also 
showed that βCGRP transcript was increased in juvenile KO mice in comparison with WT animals and 
transcript of both isoforms appeared to be elevated with age. Thus, it is entirely possible that any 
potential phenotypes generated by ageing are masked by this compensation. Both isoforms of CGRP 
have high sequence homology, similar binding affinities for CGRP receptor and almost identical 
biological activity (Russell et al., 2014). Therefore, βCGRP might be compensating for a loss of αCGRP 
activity and an increase in transcript with age, if biologically active, could potentiate any level of 
cardiovascular protection stemming from these peptides. It would be interesting to see how the 
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ageing phenotype is altered in a double αCGRP/βCGRP KO mouse, though to my knowledge this 
mouse is currently unavailable. Further, the generation of a double KO by traditional cross-breeding 
methods would presumably be difficult, owing to the close proximity of both CGRP genes on 
chromosome 7 in the mouse. With these theories and issues in mind and also thinking of future 
work, I would argue that the role of αCGRP in the ageing process in absence of other comorbidities is 
likely negligible and the opportunity of extending ageing studies to a later timepoint in mice likely 
represents a risky research avenue that is perhaps best left untouched. 
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7.2.2 Ageing in mice induces changes in vascular reactivity to known pharmacological mediators 
of vasoconstriction and vasodilatation 
Despite a lack of an obvious maladaptive cardiovascular phenotype in ageing αCGRP WT and KO 
mice, we did uncover interesting evidence supporting an altered vascular reactivity phenotype in 
these animals. We have shown that aged mice display a differential contractile response in 
mesenteric arteries, depending on the agonist used. Mice aged fifteen months displayed a significant 
reduction in sensitivity to the α-adrenoceptor agonist, PE, whilst the thromboxane receptor agonist 
U46619 displayed increased potency in this experimental group. Interestingly, we also witnessed 
diminished vasodilator bioactivity to exogenous CGRP, which may point to disturbances in CGRP 
receptor signalling. This phenotype has been shown once before in ageing rats (Chan and Fiscus, 
2003), although no clear mechanism for this response was identified in this study. Despite these 
changes in vascular reactivity in this isolated preparation, we witnessed no change in in vivo 
haemodynamic parameters. Whilst initially this may seem surprising, these results are perhaps not 
so remarkable. We have studied only three physiological regulators of vascular tone and therefore 
are only examining a snapshot of what might be happening at this stage of the ageing process. 
Doubtless, other compensatory mechanisms will exist to allow the ageing organism to re-establish 
homeostasis. Changes in isolated pharmacological preparations are certainly academically 




7.2.3 αCGRP gene deletion may worsen early endothelial dysfunction in this model by increasing 
pro-oxidant damage (characterised by increased 4-HNE expression) and reducing eNOS 
activity by altering its phosphorylation status, leading to vascular inflammation. 
Despite a lack of a maladaptive cardiovascular phenotype in αCGRP WT and KO mice produced by 
ageing, we did collate some interesting preliminary evidence to support a degree of endothelial 
dysfunction in our mice. Endothelial dysfunction is typically defined as a reduction in NO 
bioavailability. This phenomenon very often presents in ageing humans and certainly in those who 
have other cardiovascular comorbidities, such as hypertension or atherosclerosis (Virdis et al., 2010). 
Multiple biological mechanisms can converge to produce endothelial dysfunction and many of these 
are associated with pro-oxidant processes. In Chapter 4, we show evidence for elevated pro-oxidant 
enzyme expression and the accumulation of oxidised macromolecules (specifically, the accumulation 
of peroxided lipid moieties). This is characteristic of the ageing process and might act as a surrogate 
marker of endothelial dysfunction. We also showed evidence for an increased level of eNOS activity 
in aged WT mice, as measured by ser1177 phosphorylation. This may be interpreted as the 
endothelium trying to boost NO signalling in face of oxidative challenges. It was interesting to 
observe that whilst WT mice had hyperphosphorylated eNOS, aged KO mice were not able to 
maintain this level of hyperphosphorylation (which was high in juvenility). Endothelial dysfunction, 
as characterised by impaired endothelial-dependent vasodilatation exists both in aged laboratory 
animals and in humans free from other known comorbidities thought to contribute towards this 
phenotype, suggesting a primary role for ageing alone in driving this response (Küng and Lüscher, 
1995; Taddei et al., 1995; Gerhard et al., 1996; Lesniewski et al., 2009). The primary mechanism by 
which endothelial dysfunction manifests is through the induction of oxidative stress. However, other 
mechanisms may contribute, such as the enhanced production of vasoconstrictor autacoids with 
age. This is quite common with respect to the shift in the balance of vasodilator prostanoids in 
juvenility to more vasoconstrictor eicosanoids with age (Tang and Vanhoutte, 2008; Seals et al., 
2011). Indeed, as previously discussed, in Chapter 3 we witnessed an enhanced sensitivity of isolated 
mesenteric arteries from aged mice to the thromboxane receptor agonist, U46619, which may be an 
additional marker of endothelial dysfunction. We observed an induction in pro-oxidant enzyme gene 
expression and also an induction in anti-oxidant enzyme gene expression, potentially induced as a 
response to elevated oxidative stress. This was accompanied by elevated peroxidised lipid 
bioavailability in aged mouse aorta, which has been shown to be a hallmark of vascular ageing by 
other laboratories (Sin et al., 2014). Surprisingly, we did not find evidence for increases in 
nitrosylated tyrosine residues, which is consistently seen with ageing (Hemmeryckx et al., 2013). 
However, this may be a reflection of a reduction in NO generation, meaning less NO is available to 
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react with superoxide to form peroxynitrite, the molecule responsible for the nitration of 
macromolecules. In order to gain a more concrete understanding of what is happening at the level of 
the endothelium in juvenile and aged αCGRP WT and KO mice, it would be essential to investigate 
endothelial-dependent NO production directly, as our markers may only be considered surrogates at 
this stage. Experiments may take advantage of isolating aortic ECs from juvenile and aged αCGRP WT 
and KO mice and measuring NO liberation from these cells following exposure to a pharmacological 
agonist, such as acetylcholine.  
In conjunction with evidence for endothelial dysfunction occurring with ageing, that perhaps 
manifested more clearly in αCGRP KO mice, we also observed the appearance of vascular 
inflammatory markers within the aortae of aged mice. This, to my mind, validates the use of mice to 
study the fundamental processes of ageing – both mice and humans appear to share features of 
vascular inflammation as part of this biological process. We witnessed significant elevations in the 
mRNA expression of pro-inflammatory vascular markers, including VCAM-1 and F4/80, a marker of 
macrophage infiltration. Increases in expression of these types of molecules associated with 
leukocyte trafficking have been shown in the mouse aorta before (Hemmeryckx et al., 2013). Indeed, 
elevations in cell adhesion molecule expression and infiltration of inflammatory cells into the 
vascular wall are strongly associated with the ageing process, especially in patients who have early 
atherosclerotic lesion development subsequent to early endothelial dysfunction (Woollard and 
Geissmann, 2010). 
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7.2.4 Co-treatment of TNFα-activated endothelial cells with CGRP results in the attenuation of 
leukocyte adhesion through an unknown mechanism that appears to be independent of 
regulation of gene transcription. 
In Chapter Five we showed some evidence to support an anti-inflammatory role for CGRP, owing to 
its ability to reduce THP-1 monocyte recruitment to inflamed endothelium under physiological flow 
conditions in vitro, by virtue of its activity on the EC itself. Furthermore, treatment of endothelium 
for up to six hours with CGRP in the absence of TNFα did not induce leukocyte recruitment. These 
findings combined suggest that CGRP possesses a neutral property at the level of the 
endothelium.Our finding is consistent with a recent study by Huang et al. who showed that CGRP 
could inhibit mononuclear cell transmigration by inhibiting EC NF-κB activity (Huang et al., 2011). 
The phenotype we observed appeared to be independent in changes of whole cell expression of the 
cell adhesion molecules VCAM-1, PECAM-1, JAM-A and JAM-C. Further to this, microarray 
experiments showed that CGRP did not alter the pro-inflammatory endothelial transcriptome 
induced by TNFα. This was surprising to us, given that CGRP is known to induce transcriptional 
activity in some cell types (Walker et al., 2010a). 
With respect to understanding the mechanisms regulating CGRP-mediated attenuations in leukocyte 
adhesion, there is work yet to be done. Initial experiments should be classically pharmacological in 
nature, and attempt to understand the relationship between concentration of CGRP and its ability to 
alter the leukocyte adhesion response. Thus, one would be able to determine the minimal 
concentration required to produce attenuations in adhesion and at which point this process 
becomes saturated. CGRP receptor experts may argue that the concentration of CGRP that we have 
used in this thesis is high with respect to affinity for other receptors for other peptides of the CGRP 
family (i.e. the AM1 receptor) and therefore lower concentrations of peptide that still give a 
response may tell us something about the nature of the mechanism involved. Indeed, to further 
expand on this, experiments using selective antagonists for the CGRP receptor (such as BIBN4096BS) 
would definitively uncover whether or not the observed phenomenon is related to the CGRP 
receptor, or others. Finally, whilst it is generally accepted that CGRP can induce cAMP synthesis in 
ECs and many of the cellular mechanisms induced by CGRP are related to the cAMP-PKA axis, other 
signalling pathways may also be involved. I conjecture that CGRP may be increasing NO 
bioavailability and liberation from the EC and this may, in part, be driving the anti-inflammatory 
response. Thus, it would be exciting to investigate the relative contribution of this pathway to the 
phenotype, perhaps by making use of pharmacological NOS inhibitors and seeing if this alters the 
response in any way. Results from Chapter Four add credence to this hypothesis, where we showed 
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that eNOS activity was drastically altered in αCGRP WT and KO mice from juvenility through to 
middle-age. 
With regards to unraveling molecular mechanisms, we have already shown that CGRP does not 
appear to influence gene transcription, despite taking six hours to achieve full effect. Thus, I believe 
that future experiments here should be carefully examining temporospatial protein dynamics within 
the EC. For instance, experiments should investigate the expression of cell adhesion molecules 
within the plasma membrane over time; perhaps by biotinylating membrane-bound proteins under 
control conditions and seeing if the expression profile of proteins within the membrane changes 
within this period. If any key proteins are uncovered, it may be useful to employ microscopy 
techniques to image the trafficking of these proteins to understand their fate. Indeed, it is known 
that some endothelial adhesion molecules are constantly being recycled from the plasma 
membrane, through endosomal compartments and back into the membrane again (Mamdouh et al., 
2008), which may contribute towards part of the phenotype that we are observing. 
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7.2.5 Infusion of 1.1 mg/kg/day ATII into fifteen month-old αCGRP WT and KO mice did not 
result in the generation of a hypertensive phenotype, despite evidence of pharmacological 
activity by ATII. 
Throughout our earlier in vivo studies, we appreciated that ageing in mice was sufficient to induce a 
degree of subclinical vascular inflammation that was largely unaffected by αCGRP gene deletion. This 
was valuable information that helped us understand some of the key biological processes 
underpinning vascular ageing. We then hypothesised that the addition of a more acute and 
inflammatory stress into aged mice might push the cardiovascular system further in order to 
precipitate an exacerbated phenotype that was regulated by αCGRP. Thus, we combined our ageing 
model with our existing ATII model of murine hypertension. We thought that this model would be 
more representative of the human condition, owing to the fact that most humans living in 
developed nations become hypertensive in middle-age(Franklin, 1999). We were surprised to learn, 
however, that aged mice did not develop hypertension following the infusion of 1.1mg/kg/day ATII. 
We went on to validate that ATII was being infused into these animals by analysing other known 
markers of ATII activity, specifically water consumption and cardiac hypertrophy. Following these 
analyses, we concluded that ATII was having a level of pharmacological activity in the absence of 
increasing blood pressure. Thus, we may have inadvertently generated a ‘subpressor’ model of 
cardiovascular stress, though our limited early studies did not see much evidence for aberrant 
vascular inflammation in these mice. Interestingly, studies from other laboratories have shown that 
aged mice develop a worsened hypertensive phenotype, in comparison to younger animals (Csiszar 
et al., 2013; Toth et al., 2013a; 2013b). With these and our results in mind, coupled with the relative 
dearth of publications associated with this new model, I would suggest that a repeat of this study 
with an increased sample size would be justifiable in order to evaluate the reproducibility of the 




7.3 Summary & Conclusions 
In summary, the results of this thesis are novel in that they for the first time show that CGRP is not 
protective of the cardiovascular system in a mouse model of ageing. However, CGRP may possess 
intrinsic anti-inflammatory properties when acting on the endothelium, which may work to limit 
vascular inflammation induced by aberrant leukocyte activity. Further work is required to elucidate 
the mechanisms by which CGRP might be able to afford this level of protection and, indeed, it will be 
important to see whether this protection can be translated back into in vivo models of CVD. 
However, it is hoped that the results presented in this thesis have advanced our knowledge of CGRP 
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